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Abstract
The ability to engineer mice which carry exogenous genes targeted for 
expression in specific tissues, or have an endogenous gene functionally switched off 
has allowed us to examine the role of particular proteins in an in vivo model. This 
technology, in combination with a well-characterised model of chemically-induced 
skin carcinogenesis in the mouse, has allowed us to start dissecting the changes that 
occur during a particular pathway of tumorigenesis. TGppi has been shown to act as 
an inhibitor of both normal cellular proliferation and tumour formation. However, it 
can also accelerate malignant conversion at later stages of carcinogenesis.
Previously in this laboratory, mice were generated that overexpressed Tgfpi in 
suprabasal layers of skin epidermis under the control of a KIO promoter. These 
transgenic mice showed an increased proliferation rate in the basal compartment of 
their epidermis compared to wild-type controls. In this study, it is shown that the 
change in proliferative index is not dependent on p53, a molecule central to growth 
control and apoptosis. The K10-7g/pl mice were crossed on to a Tgfp 1-null 
background and the proliferative phenotype of the transgene was examined. An 
increased basal cell proliferative index was observed whether the background was 
Tgfp 1-null or wild-type.
TGPpi has been shown to induce apoptosis and a line of transgenic mice 
overexpressing BCL-2 in the epidermis became available, providing an opportunity to 
investigate the role of an apoptotic pathway in the skin. These KlO-BCL-2 mice were 
shown to express the transgene at both mRNA and protein levels in suprabasal cells of 
the epidermis. Normal skin homeostasis, however, was not disrupted by the exogenous 
BCL-2 and expression of other apoptotic markers was not altered in these mice. 
Furthermore, KlO-BCL-2 mice responded to chemical insult by a skin tumour 
promoter in the same way as wild-type littermates.
KlO-Tg/pl mice had demonstrated resistance to papilloma formation during 
chemical carcinogenesis and tumours on the transgenic mice had also shown a higher 
rate of malignant conversion in the same experiment. In this study, the effects of 
epidermally-targeted Tgfpi during tumorigenesis were investigated further by crossing 
the KlO-Tg/pl mice to a tumour-developing K5-7?A5 transgenic line. Mice carrying 
both the K5-RAS and K10-7g/pl transgenes showed no difference in tumour formation 
compared to those harbouring just the K5-/M5 transgene.
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Chapter 1 
INTRODUCTION 
1.1 The Mouse in Cancer Research
1.1.1 Transgenic and Knockout Mice
Transgenic technology, used to stably introduce foreign DNA into the germ line of 
mice, has had a profound impact on the course, progress and scope of cancer research. 
Transgenic animals provide a valuable tool for investigation of the complex biological 
processes which control development of normal and neoplastic cells. The capability to 
target gene expression to a specific tissue and developmental stage, along with the 
ability to inactivate genes by homologous recombination, has allowed the development 
of mouse models for many types of cancer. Neoplasms arising in transgenic mice are 
heritable, demonstrate reproducible, and therefore predictable, patterns of growth and 
development, and can be specifically induced in a large variety of tissue types.
The introduction of an exogenous gene driven by a promoter which restricts 
expression of the transgene to a specific tissue compartment is an approach which 
particularly lends itself to the analysis of the tumour promoting functions of dominant 
acting oncogenes. Many mouse cancer models have been developed via this approach 
(Hanahan, 1989; Bedell et al, 1997). Furthermore, the development of gene targeting 
techniques using mouse embryonic stem cells has allowed the inactivation of one or 
both alleles of endogenous tumour suppressor genes in order to study their role in 
cancer promotion. This gene inactivation technology has been applied to study 
virtually every known tumour suppressor gene originally identified in humans (Bedell 
et al, 1997). There are many advantages to such “knockout” mice. First, the 
heterozygous version of a tumour suppressor knockout may provide a useful animal 
model for the corresponding human cancer predisposition syndrome. A second 
advantage, provided by the homozygous knockout mice, is the insight into the role of 
these genes in embryonic development. In many cases, mice completely null for a
13
given tumour suppressor exhibit embryonic lethality and a distinct pattern of organ 
malformations. Analysis of the biological and molecular bases of the observed defects 
helps elucidate the function of particular genes in organogenesis, regulation of cell 
cycle control, differentiation, and apoptosis.
The availability of numerous transgenic and knockout lines has assisted in the 
analysis of genetic interactions among oncogenes and tumour suppressor genes. 
Intercrossing of two different gene knockout mice to generate doubly deficient mice, or 
a gene knockout and a conventional transgenic mouse, can reveal different levels of 
cooperation or antagonism between the two genes. In some cases embryonic lethality 
in doubly deficient mice can be accelerated or delayed. One of the most striking 
examples of this is the rescue of the embryonic lethality of Mdm-2 null mice when 
crossed on to a p53-null background (Jones et al, 1995). This reflected the tight 
regulation that occurs between these two genes. In other situations, tumour incidence 
rates can be accelerated and tumour spectra altered by the combined effects of the 
transgenic and/or knockout alleles.
Another important technology for gene ablation in mice is cell-type specific gene- 
inactivation. The Cre-lox system is one such technique that has been used to knockout 
genes in specific tissues (Gu et al, 1994; Chambers, 1994). One mouse carrying the 
Cre recombinase enzyme driven by a tissue specific promoter is crossed with a mouse 
carrying the piece of DNA to be removed between two short loxP sites. Offspring of 
these mice then produce Cre recombinase in the designated tissue which recognises the 
loxP sequences and excises the intervening DNA.
1.1.2 Multistage Skin Carcinogenesis
The mouse skin model is an ideal system in which to study the multistage nature of 
cancer pathogenesis: it has been well characterised and the target organ is easily 
accessed and monitored. The majority of human cancers are epithelial in origin with
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skin cancer of the epidennis being one of the most prevalent. There are two main types 
of skin cancer in humans: basal cell carcinoma, in which cells appear as 
undifferentiated or basal-like cells, and squamous cell carcinoma, in which cells 
keratinise in an aberrant fashion. Melanoma is also increasingly becoming a major 
killer. A clearer understanding of the genetic and epigenetic changes which are 
involved in the process of epithelial carcinogenesis is necessary if significant advances 
in treatment are to be made. The mouse model is, of course, only a model. Most human 
skin cancer is UV-induced whereas this model is created by chemical induction. 
Nevertheless, most genetic changes are very similar in mouse skin and other tumour 
systems.
1.1.2.1 Biology of the Skin
The skin is the largest organ in the body and consists of two major components. The 
outer epidermis is a stratified squamous epithelium which forms a protective barrier 
against ultraviolet radiation and other chemical and biological injury. It is composed of 
several layers of kératinocytes undergoing terminal differentiation, with the outer cells 
being constantly shed and replaced. Underlying the epidermis, separated from it by a 
basement membrane, is the dermis. Whereas the epithelial region is composed of 
densely packed epithelial cells with relatively little inter-epithelial space, the dermis 
consists mainly of an intercellular matrix, within which are occasional scattered cells 
of various types and through which runs a network of both blood vessels and nerve 
fibres. This matrix contains rich networks of minute fibres of elastin, collagen and 
reticulin, all produced by fibroblasts. Together the fibres provide the mechanical 
strength of the skin and give it some elasticity.
Throughout the dermis specialised regions of skin can be seen. These include the 
hair follicles, which consist of infolds of the epidermis. There are also various glands 
in the skin including the sebaceous glands, which secrete sebum into the hair follicle 
canal, and sweat glands. Other cell types found in the skin include melanocytes (which 
produce melanin, the pigment involved in protection from ultraviolet radiation), 
adipocytes (involved in the regulation of temperature), and other cells involved in 
immune and inflammatory responses such as Langerhans’ cells and granulocytes.
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All the superficial cell layers and the functional integrity of the epidermis are 
ultimately dependent on the proliferative compartment, the basal layer. It is this layer 
which replaces the cells lost through surface desquamation or through damage. The 
basal cells in human epidermis are cuboidal or columnar cells with their long axis 
perpindicular to the surface plane of the skin. In mouse the basal cells are similar in 
many areas but in epidermis on the back of the mouse they tend to be much thinner, 
flatter cells. Lying above the basal layer is the suprabasal of cells which consist of the 
spinous and granular layers. The number of spinous cell layers is variable, depending 
on the site, but may be as little as a single layer, as in the mouse. In comparison with 
the basal cells the suprabasal cells tend to be thinner and have a higher cytoplasmic- 
nuclear ratio. The outermost layer is the stratum comeum consisting of comeocytes or 
squames. All internal organs have disappeared and the cells are metabolically dead. 
These therefore represent the final, mature, terminally differentiated cells.
The epidermis is under a constant state of proliferation, commitment, 
differentiation, and elimination so that the functional integrity of the tissue is 
maintained. The intact epidermis has the ability to respond to diverse environmental 
stimuli by continuous turnover to maintain its normal homeostasis throughout an 
organism's life. This is achieved by a tightly regulated balance between stem cell self­
renewal and the generation of a population of cells that undergo a limited number of 
more rapid (amplifying) transit divisions before giving rise to nonproliferative, 
terminally differentiating cells. Normal human stratified epidermis has a temporally 
and spatially coordinated programme of proliferation and differentiation which is 
characterised by sequential changes in gene expression. One class of genes which 
shows such changes is the cytokeratin gene family encoding the major cytoskeletal 
proteins present in kératinocytes. The actively proliferating kératinocytes of the basal 
layer co-express cytokeratins K5 and K14. As basal cells commit to terminally 
differentiate, they exit the cell cycle, and begin to move outward towards the surface of 
the skin, in conjunction with a loss of contact with the basement membrane. As the 
cells migrate upwards into the suprabasal or spinous layers, proliferative capacity is 
lost, K5 and K14 expression is suppressed and the synthesis of K1 and KIO is induced. 
The kératinocytes change morphology, flatten out and change the nature of contacts 
between neighbouring cells. As the next stage of differentiation occurs and
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kératinocytes move into the granular layer, K1 and KIO expression is downregulated 
and involucrin, loricrin and keratinocyte transglutaminase are upregulated. This is 
associated with synthesis of filaggrin which aggregates with keratins 1 and 10 to form 
large, complex bundles of fibres thus adding more strength to the epidermis. Involucrin 
and loricrin are crosslinked by transglutaminase. At this stage nuclei and cytoplasmic 
organelles are lost and in cells of the comified layer a permeable inner membrane 
envelope of highly crosslinked proteins replaces the nuclear membrane. Mature 
squames that reach the surface and are sloughed off, consist merely of keratin 
macrofibrils in a filaggrin matrix within the comified envelope.
Other proteins of the epidermis that are important for epidermal architecture and 
intercellular signalling include integrins and desmosomes. Desmosomes consist of a 
variety of proteins which serve, amongst other things, as adhesion molecules keeping 
cells tightly bound and organised (reviewed in Garrod, 1995). They are essential for 
cell architecture as they provide the anchoring point for the keratin intermediate 
filament network of the kératinocytes. Integrins are a family of adhesion molecules 
(Varner and Cheresh, 1996) which mediate cell-extracellular matrix and cell-cell 
interactions. They are potent signalling molecules and are thought to regulate cell 
growth and differentiation (Dedhar, 1995) and differences in integrin expression and 
function can be used to differentiate epidermal stem cells from transit amplifying cells 
(Jones and Watt, 1993).
1.1.2.2 Mouse Model of Skin Carcinogenesis
Application of carcinogens and tumour promoting agents to mouse skin showed that 
the development of fully malignant tumour cells involves several stable intermediate 
stages (Yuspa, 1994). In this mouse skin model the development of malignant 
squamous cell carcinomas can be divided into distinct stages: initiation, promotion, 
premalignant progression, malignant conversion, malignant progression, invasion and 
metastasis. The development of each stage is accompanied by a variety of 
morphological, biochemical and genetic changes. These changes come about due to 
quantitative and qualitative alterations in certain cellular genes including changes in 
gene structure and/or loss of normal expression. An attraction of this carcinogenesis
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model is that mouse keratinocyte cell cultures which represent each of the intermediate 
stages have been well characterised in vivo. The genetic changes occurring during 
multistage carcinogenesis have thus been studied by a combination of both in vivo (i.e. 
mouse skin) and in vitro (cultured cell lines) approaches.
Initiation
In the mouse skin carcinogenesis model used in our lab initiation occurs as a result of a 
single topical application of a mutagen such as dimethylbenzanthracene (DMBA) to 
the dorsal skin of the mouse. Initiated cells can remain dormant in the skin for a 
considerable period of time until activated by tumour promotion (Loehrke et al, 1983). 
Initiated kératinocytes display a very subtle change in phenotype. For example, in 
culture, they have an altered response to signals for terminal differentiation such as 
calcium (Yuspa and Morgan, 1981). In vivo, initiated kératinocytes are 
indistinguishable from normal ones. The target of DMBA initiation is the activation of 
the Ha-/?ût.y gene by specific point mutations (Balmain et al, 1984; Bizub et al, 1986; 
Harper et al, 1987). These mutations are associated with papilloma formation and can 
be found in initiated skin before the appearance of tumours (Nelson et al, 1992). The 
nature and amino acid position of Ras mutations depends on the carcinogen (Brown et 
al, 1990). In human cancer, RAS gene mutations, which have presumably been induced 
by UV light, have been found in both benign and malignant skin tumours although at a 
much lower frequency than that obseved in DMBA-initiated mouse skin tumours 
(Leon et al, 1988; Ananthaswamy et al, 1989). When the w~Ras^^ oncogene is 
introduced into normal mouse kératinocytes, the recipient cells form papillomas when 
grafted to nude mice (Roop et al, 1986), and transgenic mice expressing a Ras 
oncogene in the epidermis develop papillomas (Bailleul et al, 1990), showing that this 
single genetic change is sufficient to produce the initiated phenotype. In vitro, mouse 
kératinocytes expressing v-Ras^^ have a high proliferation rate and fail to terminally 
differentiate (Cheng et al, 1990). Hyperproliferation is caused by overexpression and 
autocrine response to transforming growth factor ot (Tgfa) (Click et al, 1991).
Promotion
Repeated treatment of initiated mouse skin with a tumour promoter causes the 
selective clonal expansion of initiated cells to produce benign squamous cell
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papillomas (lannaccone et al, 1987). These papillomas are characterised by an increase 
in the number of proliferating cells along with a decrease in the rate of differentiation 
and cell death. The most potent exogenous skin promoters are the phorbol esters such 
as tetradecanoylphorbol acetate (TPA) which activates protein kinase C (PKC). This 
enzyme activity accelerates epidermal terminal differentiation (Dlugosz and Yuspa,
1993). Initiated cells are relatively resistant to this signal and so proliferation of the 
initiated subpopulation is favoured. There is some dispute as to whether exogenous 
promotion directly produces genetic alterations that lead to tumour progression. Yuspa 
(1994) argues that exogenous promotion is likely to be epigenetic since papillomas are 
diploid when they first emerge, a single genetic change in normal kératinocytes is 
sufficient to produce a papilloma phenotype, and most promoting agents are not 
mutagens. Yet, the observed chromosomal aberrations (see below) could potentially be 
due to the genotoxic activity of TPA (Kinsella et al, 1978; Petrusevska et al, 1988) and 
would argue against a purely epigenetic mechanism for promotion in this model 
system.
Premalignant progression.
Whether exogenous promotion is a purely epigenetic process or not, sequential, non- 
random chromosomal aberrations correlate with premalignant progression of mouse 
skin papillomas (Aldaz et al, 1987) and this stage is the main time-dependent 
component of cancer pathogenesis. Molecular (Kemp et al, 1993a) and cytogenetic 
(Aldaz et al, 1989) studies have demonstrated frequent trisomy of chromosomes 6 and 
7 in papillomas. Trisomy of chromosome 7 involves the duplication of the 
chromosome which carries the mutant Ras allele, suggesting that an increase in mutant 
Ras level may be required for early selection of initiated cells.
Malignant conversion.
5-10% of papillomas spontaneously convert to cancers (Aldaz et al, 1987) and so 
malignant conversion of benign tumours is relatively rare. This conversion, although 
spontaneous, is not thought to be random as not all papillomas have an equal chance of 
conversion. Subpopulations of papillomas with a high risk for malignant conversion 
have been identified (Hennings et al, 1990) and the crucial events in the conversion 
process appear to be genetic since the conversion frequency can be significantly
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increased by exposing animals bearing benign tumours to mutagens (Aldaz et al, 
1987). The subclass of high-risk papillomas is also more sensitive to mutagen-induced 
conversion and so the factors that determine the risk of conversion must increase 
susceptibility to the induced or spontaneous genetic changes. Differences in phenotypic 
markers such as TgfP, a6P4 integrin, keratin 13 and Rara expression levels have been 
used to distinguish between high and low risk papillomas at an early stage (Glick et al, 
1993; Cui et al, 1994; Tennenbaum et al, 1993, Nischt et al, 1988; Darwiche et al, 
1996).
Several genetic alterations have been associated with malignant conversion. 
Frequent loss of the remaining wild-type Ha-Æaj allele is often observed (Bremner et 
al, 1990). Furthermore, mutations in the Tp53 gene, while rarely found in papillomas, 
are frequently detected in carcinomas (Bums et al, 1991; Kemp et al 1993a). Those 
carcinomas that showed loss of heterozygosity on chromosome 11 (where the Tp53 
gene resides) also had mutations in the remaining allele of Tp53 (Bums et al, 1991). 
Kemp et al (1993b) found that papillomas produced on p53 null mice by chemical 
carcinogenesis underwent much more rapid malignant progression than those on wild- 
type mice. Progression rate was also greater in heterozygous mice and was associated 
with loss of the remaining wild-type allele.
Spindle Conversion
A further stage in mouse skin carcinogenesis is the progression from squamous 
carcinoma to the more aggressive spindle cell tumour, in which the markers of 
differentiation such as E-cadherin are lost (Navarro et al, 1991; Diaz-Guerra et al, 
1992). This conversion is also associated with a further increase in the ratio of mutant 
to normal Ha-/?^^ genes (Buchmann et al, 1991). Deletion or altered regulation of 
pl6Ink4a and pl5Ink4b has also been shown to occur in tandem with the loss of 
differentiation associated with this stage (Linardopoulos et al, 1995). In this lab, Cui et 
al (1996) have shown that overexpression of Tgfp 1 in the epidermis of transgenic mice 
can accelerate spindle tumour formation during mouse skin carcinogenesis and, more 
recently, that the conversion event is mediated directly via the Tgfp signalling pathway 
of the tumour cell (Portella et al, 1998).
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1.1.3 Effects of Genetic Background on Tumour Susceptibility and 
Transgenic Phenotype
Similar to the human situation, phenotypic variability is seen in mice when 
particular spontaneous or induced mutations of interest have been placed on different 
strain backgrounds. Several recent examples illustrate the importance of strain-specific 
modifier genes on the phenotype of mutations in mice. Tumour models provide a good 
example of a genetic background effect. Although unusual and unique neoplasms may 
arise that are specific for the genetic alteration, the overall tumour spectra in 
genetically altered mice tends to follow that of the strain background. For example, 
Tp53 knockout mice on a 129/Sv background develop tumours sooner on average than 
do their counterparts of predominantly C57B1/6 backround (Donehower et al, 1995b). 
Moreover, in C57B1/6 Tp53 null mice, the predominant tumour type is lymphoma, 
whereas in the null 129/Sv strain, testicular teratomas are as common as lymphomas.
Strain background effects have also produced variability in phenotypes other than 
neoplasia. One example is that found with epidermal growth factor receptor (Egfr) 
knockouts in which the time of lethality for one mutation ranged from peri- 
implantation to post-partum depending on the strain background (Threadgill et al, 
1995). Post-natal disease severity is another phenotype that may be modified by 
genetic background. Examples such as the cystic fibrosis transmembrane conductance 
regulator (Cftr) knockout mouse model of cystic fibrosis (Rozmahel et al, 1996) 
demonstrate how modulation of the phenotype of induced mouse mutations by 
modifier genes can more closely mimic the polygenic or multifactorial nature of 
important human disease.
Usually the modifying loci of the genetic background are undefined. Increasingly, 
however, modifier loci are being mapped (Balmain and Nagase, 1998). In Tgjfil 
knockout mice (which will be discussed later), Bonyadi et al (1997) were able to map a 
major genetic modifier of embryonic lethality using the difference in survival rates
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between C57B1/6 and NIH strains. Similarly, in a line of Apc-deficient mice called Min 
(Multiple intestinal neoplasms) mapping studies identified a modifier locus Moml 
(Modifier of Min 1) (Dietrich et al, 1993). These genetic approaches to the mapping 
and eventual cloning of genetic modifiers add another dimension to the analysis of 
disease resistance and susceptibility.
1.2 TRANSFORMING GROWTH FACTOR p
In many cases tumour cells develop when normal progenitor cells lose control of 
signalling pathways that regulate responses to soluble growth regulatory factors. The 
transforming growth factors beta (TGFps) constitute one such family of negative 
growth regulators that play an important role in carcinogenesis.
1.2.1 TGFP Family and Biochemistry
The TGFPs are part of a large superfamily of growth factors, which play pivotal 
roles in regulating broad aspects of cell behaviour, including regulation of cell 
division, survival, differentiation and specification of developmental fate, in a variety 
of organisms (Roberts and Spom, 1990; Cui and Akhurst, 1996). The TGFP 
superfamily comprises more than thirty distinct members that are grouped in several 
subfamilies, including the TGFP family, the activin/inhibin family, bone 
morphogenetic proteins (BMPs) and the Drosophila decapentaplegic (Dpp) gene 
product, Mullerian inhibiting substance, and the Xenopus laevis Vg-1 and Vgr-1.
Three mammalian TGFP isoforms exist termed TGFpl, p2 and p3. In vitro, all three 
isoforms have similar qualitative effects on cells, though the sensitivity of certain cell 
types to different isoforms is remarkably different (Cheifetz et al, 1990). TGFpi is a 
25kDa homodimeric peptide. It is synthesised as a 390 amino acid precursor (pre-pro- 
TGFp) with an N-terminal short-signal peptide but undergoes post-translational 
processing leaving a peptide of 112 amino acids. Processed TGPp is secreted as a
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biologically inactive or latent form in a non-covalent complex with the latency 
associated peptide (PLAP).
As previously mentioned, TGFp is a multifunctional growth factor, but the nature of 
its action on a particular target cell is critically dependent on many parameters 
including the cell type and its state of differentiation. The most studied property of 
TGFP is as a regulator of cell growth and this will be discussed in more detail later. 
Other functions include stimulation or inhibition of differentiation, regulation of 
extracellular matrix, and contol of the immune response.
TGFp is an important regulator of extracellular matrix (ECM) deposition, 
composition, and cell-substratum interactions. The ECM can affect cell proliferation, 
differentiation, morphology, adhesion, migration, and interaction between cells and so 
TGFP may indirectly affect cell proliferation and differentiation through modulation of 
ECM. TGFp promotes ECM formation in general, by stimulating fibroblastic cells to 
synthesise and secrete various ECM ligands and receptors such as numerous collagens, 
proteoglycans and fibronectin, as well as several members of the integrin class of ECM 
receptor and cell adhesion molecules (for review see Roberts and Spom, 1990). In 
addition, TGFP inhibits ECM degradation by stimulating the expression of some ECM 
pro tease inhibitors, like the tissue inhibitor of metalloproteinase (TIMP) and 
plasminogen activator inhibitor type I (PAI-I), and by down-regulating the expression 
of the ECM proteases themselves (Roberts and Spom, 1990).
TGFp is also a potent regulator of the immune system and inflammatory responses, 
generally functioning as an immunosuppressor (Wahl, 1992). It can inhibit 
proliferation of thymocytes (Ristow, 1986) and lymphocytes (Kehrl et al, 1986), and 
can suppress B cell proliferation and immunoglobulin secretion (Kehrl et al, 1991). 
TGPP can also suppress the synthesis and activity of some cytokines, such as 
interleukins (Wahl et al, 1988), interferon-y (Czamiecki et al, 1988) and tumour 
necrosis factor a  (TNFa). Early in the inflammatory response, TGFp acts as a potent 
chemoattractant, stimulating monocyte migration and macrophage production (Wahl et
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al, 1987). However, later in the response, it exhibits anti-inflammatory effects such as 
down-regulation of macrophages and antagonism of TNFa function.
1.2.2 Regulation of Cell Growth
TGFP is a pluripotent hormone that can positively or negatively regulate 
proliferation of a variety of target cells. Although TGFp was originally identified by its 
ability to induce a transformed phenotype in normal rat kidney fibroblast cells (Moses 
et al, 1981; Roberts et al, 1981) consequent studies have shown that the predominant 
action of TGFP on cell proliferation is inhibitory. All three TGFP isoforms possess 
reversible growth inhibitory activities on cell types including epithelial, endothelial, 
haematopoietic, fibroblastic, lymphoid, and neuronal cells (for review see Roberts and 
Spom, 1990; Massague, 1990). TGFp can also display some apparently conflicting 
growth stimulatory effects. For example, TGFpl stimulates the growth of NRK cells in 
the presence of EGF in soft agar, but both inhibits the growth and antagonises the 
mitogenic action of EGF on the same cells in monolayer culture (Roberts et al, 1985). 
The growth promoting effect may be indirect, due to the enhanced expression of the 
extracellular matrix (ECM) proteins, fibronectin, type I collagen and proteoglycans, 
and increased integrin-mediated adhesion to these molecules (Ignotz and Massague,
1986). Others have proposed that TGFP may act more directly to modulate the 
components of the cell cycle as part of its mitogenic activity
TGFP is a potent growth inhibitor of keratinocyte cell lines (Reiss and Sartorelli,
1987), and the inhibition of MvlLu epithelial cells and HaCaT kératinocytes has been 
linked to the suppression of RB phosphorylation and to the inhibition of c-MYC 
transcription (Pietenpol et al, 1990; Laiho et al, 1990). This suggests that the 
antiproliferative activity of TGFP might be mediated by inhibition of c-MYC activity 
and/or down-regulation of specific CDK components. Indeed, TGFP has been shown 
to down-regulate CDK4 protein expression in MvlLu cells (Ewen et al, 1993) and 
cyclin E and CDK2 protein levels in kératinocytes (Geng and Weinberg, 1993). 
Furthermore, it was initially proposed that the CDK inhibitor might mediate
TGpp-dependent growth inhibition of epithelial cells (Polyak et al, 1994). However, 
cell lines derived from knock-out mice are still growth-arrested by TGFP
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(Nakayama et al, 1996) indicating that is not absolutely essential for the
antiproliferative action of TGFp in vivo, although it is possible that other CDK 
inhibitors such as p57^^^compensate for the loss of p27^‘^  ^ in the knockout mice.
1.2.3 TGFp Receptors and Signalling
TGFp signals by contacting two distinct but related transmembrane serine/threonine 
kinases called receptors I and n. It binds directly to receptor U which is a constitutively 
phosphorylated kinase. It seems that bound TGFp is then recognised by receptor I 
which is recruited into the complex and becomes phosphorylated by receptor II at the 
GS domain (a region highly conserved in type I receptors across species). This allows 
receptor I to generate a phosphorylation signal for the first step of a signalling cascade. 
It is generally accepted that both receptors are essential in order to signal (Wrana et al,
1994).
Much progress in identifying signalling events downstream of the type I receptor has 
been made with the discovery of the SMAD family of proteins as TGFP signal 
transducers. The first known member of this family, Mad, was identified by genetic 
analysis of a Drosophila BMP-like signalling pathway, the Dpp pathway (Sekelsky et 
al, 1995). Mad (Mothers against decapentaplegic)-related genes, called Sma2, Sma3, 
and Sma4, were identified by genetic analysis of the related Daf4 pathway in 
Caenorhabditis elegans (Savage et al, 1996). Vertebrate homologues, called SMADs 
(for Sma and Mad homolgue) were identified shortly thereafter (see Kretzschmar and 
Massague, 1998 and references therein).
Based on the most recent studies on the SMAD family of proteins (see Kretzschmar 
and Massague, 1998 for review), a model of TGFp/SMAD signalling can be 
suggested, TGFp binds to and activates type I and type II receptor serine threonine 
kinases leading to transient association with specific receptor-activatable SMADs 
(SMAD2, SMADS). These SMADs become phosphorylated by the activated type I 
receptor, then associate with a co-SMAD (e.g. SMAD4) and move into the nucleus. In 
the nucleus the SMAD complexes associate with a whole variety of different DNA-
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binding transcription factors such as FAST-1 (Liu et al, 1997) leading to active 
transcriptional complexes and stimulation of target gene expression.
1.2.4 Tgf^ Knockout and Transgenic Mice
1.2.4.1 TGFp in Development and Tgf^l Knockout Mice
The widespread expression of the TGFp genes and protein throughout mammalian 
development suggests that TGFp plays an important role during post-implantation 
embryogenesis (Heine et al, 1987; Lehnert and Akhurst, 1988; Gatherer et al, 1990). 
Using in situ hybridisation Tg/pl mRNA can be detected by 7.5 days post-coitum in 
blood islands of the yolk sac, the allantois and in the precardiac mesoderm of the 
embryo (Akhurst etal, 1990).
As previously mentioned, the ability to generate knockout mice has become a very 
powerful tool for investigating the function of a gene in vivo. Tg/pl knockout mice 
were generated by two independent groups (Shull et al, 1992; Kulkami et al, 1993) and 
have been used to determine TGFP Us role during embryogenesis. Over 50% of mice, 
null for Tgfpl, reached birth. However, these animals developed a fatal wasting 
syndrome, beginning at about 2 weeks of age, caused by multifocal inflammation. The 
Tgfpl null mice died by around 3-4 weeks and the massive inflammation was 
attributed to an autoimmune-like disorder brought about by the immunosuppressing 
actions of Tgfpi. More detailed examination has shown that death in these mice was 
usually due to cardiopulmonary failure following severe inflammation of the heart and 
lungs (Kulkami et al, 1995).
Of the 30-40% of Tgfpl null mice that did not make it through to parturition, it was 
thought that either there was an under-representation of Tgfpi null gametes (due to 
reproductive abnormalities in heterozygous animals) (Shull and Doetchman, 1994), or 
that Tgfpl null conceptuses were dying in utero (Dickson et al, 1995). On a mixed 
genetic background, Dickson et al (1995) showed that, although normal Mendelian 
genotype ratios of wild-type, heterozygous, and null conceptuses were present at 9.5
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days of gestation, the number of viable Tgfpi null embryos was reduced to 50% of 
expected levels by 11.5 days of gestation. It was found in the Tgfpl null conceptuses 
that the vascular network, which develops from yolk sac blood islands, had failed to 
form properly. More specifically, there was lack of endothelial tube formation and the 
establishment of weak endothelial connections probably due to inadequate endothelial 
differentiation. The other phenotype of the Tgfpl null yolk sac was severe anaemia, 
which is perhaps surprising since Tgfpi has been reported to be an inhibitor of 
haematopoiesis. However, both these facts probably point towards the primary 
function of Tgfpl in early embryogenesis as a modulator of cellular differentiation and 
phenotype, and not as a negative growth regulator.
TgfP2 and Tgfps have also been knocked out in transgenic mice. Tgfp3 null 
animals reach parturition with no intrauterine death but they all die within hours of 
birth due to posterior clefting of the secondary palate. The cellular defect is one of 
epithelial cell migration out of the midline seam (Proetzel et al, 1995).
It became clear during studies on 7g/pl knockout mice in this lab that the 
percentage of 7g/pl null prenatal lethality depends on the genetic background of the 
mice. Similarly, the severity of the 7g/p3 null phenotype depends on the genetic 
background of the mice (Proetzel et al, 1995). Bonyadi et al (1997) used the 
differences between survival of TgfÇtl nulls on a NIH genetic background (70-80% 
survival) and survival on a C57/B16 background (0% survival) to map a potential 
genetic modifier of the 7g/pl knockout phenotype. A major codominant modifier 
locus of embryo lethality was identified on proximal mouse chromosome 5. This gene 
accounted for approximately three-quarters of the genetic effect between strains.
1.2.4.2 TgfP Transgenic Mice
There have been numerous attempts to make transgenic mice which overexpress 
Tgfp but many of these have failed due to absence of transgene expression or 
embryonic lethality (Spom and Roberts, 1992). However, several laboratories have 
generated Tgfpl-expressing transgenic mice, using tissue-specific gene promoters to
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restrict the expression of Tgfpi to specialised organ systems. Mice which overexpress 
Tgfpi, or related proteins, in skin will be discussed in section 1.2.5. Here, the effect of 
ectopic expression of Tgfpi in mammary gland and pancreas are summarised.
The mammary gland is attractive as a model system to study since the development 
of this tissue takes place mostly postnatally and is therefore readily accessible. 
Silberstein and Daniel (1987) had originally shown the reversible inhibitory effects of 
Tgfp on mouse mammary gland development by implanting slow-release pellets 
containing TgfP next to developing epithelial end buds. Two groups subsequently 
made transgenic mice ectopically expressing Tgfpi in the mammary gland. Jhappan et 
al (1993) used the whey-acidic protein {WAF) gene promoter to direct expression to 
the alveoli, while Pierce et al (1993) targeted Tgfpl expression to the mammary ductal 
epithelial cells using the mouse mammary tumour virus (MMTV) promoter. WAP- 
7g/pl transgenic females displayed significant inhibition of lubuloalveolar formation 
and therefore defective lactation. These mice were shown to have increased rates of 
apoptosis in the mammary epithelium at all stages of mammary development (Kordon 
et al, 1995). The MMTV-Tgf^l mice however exhibited hypoplasia of the mammary 
ductal tree during mammary development, with no effect on alveolar outgrowths 
during pregnancy. The different phenotypes of these two transgenic lines highlight the 
difference of using two different promoters directed at the same tissue.
More recently, Bottinger et al (1997a) overexpressed a dominant-negative mutant 
Tgfp type n  receptor (DN-TpRU) in the mammary gland with the MMTV promoter. 
They showed that older virgin transgenic mice had an increased incidence and degree 
of lobulo-alveolar side-branching in the mammary gland when compared with their 
wild-type littermates. All this evidence suggests that endogenous TgfPs are important 
in maintaining normal mammary epithelial homeostasis. Another report by the same 
group highlighted the importance of Tgfp in the pancreas (Bottinger et al, 1997b). 
Targeting of a dominant-negative TpRII to the exocrine pancreas caused increased 
proliferation of pancreatic acinar cells and also showed perturbed acinar 
differentiation.
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1.2.5 TGFp in Skin and Multistage Carcinogenesis
1.2.5.1 Expression and Role of TGFP in Skin Homeostasis
As discussed in section 1.2,2 TGpp has a profound inhibitory effect on keratinocyte 
proliferation in culture (Reiss and Sartorelli, 1987). In vivo, the phorbol ester TPA was 
shown to induce high levels of Tgfpl mRNA in mouse epidermis (Akhurst et al,
1988). This appeared surprising in view of the fact that initated keratinocyes and early 
papillomas responded to Tgfp by growth arrest, but nevertheless underwent clonal 
expansion in response to treatment with TPA. To elucidate this apparent inconsistency, 
an investigation of Tgfp mRNA and protein synthesis was carried out by a combination 
of in situ hybridisation and immunocytochemistry using isoform specific antibodies to 
Tgfpl (Fowlis et al, 1992). TPA treatment of adult mouse skin induced Tgfpi protein 
in suprabasal kératinocytes i.e. that sub-population of epidermal cells which had 
previously been shown to produce the highest levels of Tgfpl mRNA. The 
extracellular or processed form of Tgfpl was located mainly in the dermis suggesting 
that it may be involved in a paracrine mechanism of regulatory comunication between 
epidermal and mesodermal tissues. More recently, Glick et al reported basal cell 
hyperproliferation in the normal epidermis of Tgfpl knockout mice with the 
observation of a 3- to 5-fold increase in the BrdU labelling index without evidence of 
suprabasal proliferation or hyperplasia (Glick et al, 1993).
To further investigate the role of Tgfpi in the epidermis, two different laboratories 
generated transgenic mice which use keratin promoters to drive Tgfpi expression 
mainly in the suprabasal layer of the epidermis (Sellheyer et al, 1993; Gui et al, 1995; 
Fowlis et al, 1996). Sellheyer et al (1993) targetted expression using a human keratin 1 
(Kl) promoter driving a porcine TgfPl cDNA. Ail of the founder mice died within 24 
hours of birth due to complete inhibition of epidermal development. There was 
complete inhibition of DNA synthesis in the epidermis and a reduced number of hair 
follicles. Cui et al (1995) generated viable lines of transgenic mice using the KIO 
promoter constitutively expressing bioactive simian Tgfpl in suprabasal cells.
29
Surprisingly, these mice had a two- to threefold increase in epidermal DNA labelling 
index over control mice, in the absence of hyperplasia. The marked difference in 
phenotype between the mice of Cui et al (1995)and Sellheyer et al (1993) is probably 
due to the level of transgene expression. The K1 promoter is a stronger promoter than 
that of the KIO gene. This suggested that Tgfpl not only increased keratinocyte 
proliferation in vivo, but also increased keratinocyte turnover in a compensatory 
manner. In these same transgenic mice however, the transgene acted as expected, as a 
negative regulator of cell growth, when hyperplasia was induced by treatment with the 
phorbol ester TPA. Analysis of expression of the TgfP type II receptor (TPRII) was 
consistent with these observations. In quiescent epidermis, TPRII expression was 
barely detectable, but increased rapidly in response to TPA treatment (Cui et al, 1995). 
Taken together, all this data suggests that Tgfpi and TpRII act in concert to regulate 
epidermal homeostasis in vivo.
A similar result was seen when Tgfpi was expressed in suprabasal cells under the 
control of an inducible promoter, K6 (Fowlis et al, 1996). On treatment of these 
transgenic mice with topical TPA, the transgene was “switched on” and, as with KIO- 
Tgfp mice (Cui et al, 1995), epidermal BrdU labelling index was higher in transgenics 
than control mice.
TgfP’s role in maintenance of skin homeostasis was confirmed when a dominant- 
negative TpRH was expressed in the epidermis of transgenic mice (Wang et al, 1997). 
Targeting expression with a loricrin promoter produced mice with a thickened and 
wrinkled skin showing hyperplasia and hyperkeratosis. In vivo labelling with BrdU 
showed a 2.5-fold increase in labelling index over controls, with labelled cells 
occurring in both basal and suprabasal cells of transgenic epidermis. However, a 
similar transgenic line using the K5 promoter produced mice with undisturbed normal 
skin (Amendt et al, 1998). The K5 promoter targets only basal and follicular cells 
while the loricrin promoter drives expression in both basal and suprabasal cells. 
Therefore the different phenotypes of these two mice may indicate a more significant 
role for Tgfp signalling in suprabasal kératinocytes than basal cells for maintaining
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skin homeostasis. Alternatively, it may be a case of different levels of expression: the 
weaker K5 promoter may not be a complete knockout of functional TpRII.
1.2.5.2 TGFP and Tumour Suppression
TGpp is a potent inhibitor of epithelial proliferation, can affect epithelial 
differentiation, and can induce apoptosis. These properties suggest that disruption of 
TGpp metabolism might play an important role in multistage carcinogenesis. 
Conflicting findings from various studies have promoted the idea that TGFp might 
have biphasic effects during epithelial carcinogenesis. In this section, TGFp’s tumour- 
suppressing properties will be discussed, and in the following section its activities as a 
potential promoter of carcinogenesis will be summarised.
TGpp can inhibit proliferation of several human and rodent transformed and 
carcinoma cell lines in vitro (Manning et al, 1991; Arteaga et al, 1990; Haddow et al, 
1991) and it has been shown that the growth inhibitory effect can be reversed using 
anti-TGFp antibodies (Arteaga et al, 1990). Many transformed kératinocytes and cell 
lines derived from skin tumours have lost their response to TGpp (Haddow et al, 
1991). Using a panel of cell lines derived from benign and malignant mouse skin 
tumours, it was shown that the loss of growth control by TGpp occurs at a relatively 
late stage of carcinogenesis and furthermore, that it is independent of Ras gene 
activation. The question of how this ties in with the action of endogenous TGpp during 
tumour progression has been tackled in a number of in vivo studies.
Wu et al (1992) showed that transfection of a TGFp-responsive colon carcinoma 
cell line with a TGFpl antisense-expression vector enhanced its tumorigenicity in vivo. 
More direct evidence that TGpp expression can suppress tumour growth in vivo has 
come from studies on transgenic mice. Pierce et al (1995) demonstrated mammary 
tumour suppression by transgenically targeted Tgfpi. In our own lab, tumour 
formation was investigated using mice which express recombinant Tgfpl in the 
epidermis (Cui et al, 1996). Several transgenic lines of mice, which expressed active 
Tgfpi in suprabasal kératinocytes either constitutively (Cui et al, 1996) or in response
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to hyperplasia (Fowlis et al, 1996) were subjected to chemical carcinogenesis, 
involving initiation with dimethylbenzanthracene (DMBA), followed by repeated 
application of the tumour promoter, TPA, to the skin. The transgenics were more 
resistant to induction of benign skin tumours than controls due to a prolonged latency 
and significantly reduced tumour number per mouse.
In accordance with TgfP’s tumour suppressing activities, loss of TgfP expression in 
benign tumours is correlated with a high risk for malignant conversion (Glick et al, 
1993; Cui et al, 1994). As mentioned earlier, populations of benign papillomas have 
different rates of premalignant progression and malignant conversion. Glick et al 
(1993) demonstrated an association between the loss of expression of TgfP proteins 
within tumour cells and a high risk of conversion to the malignant state, and Cui et al 
showed that, in benign tumours from p53 null mice, Tgfpi protein staining is 
prognostic for a low probability of malignant conversion (Cui et al, 1994). The 
importance of Tgfp loss in progression was further demonstrated by reconstituting 
papillomas in a skin-grafting model system using combinations of v-Faa'^^-initiated 
kératinocytes and dermal fibroblasts from Tgfp knockout mice or the wild-type 
littermates (Glick et al, 1994). The v-Fa^^'^-transduced wild-type kératinocytes 
produced benign papillomas in grafts whereas the transduced TgfP-null kératinocytes 
formed either very dysplastic papillomas or squamous cell carcinomas.
1.2.5.3 TGFp as a Stimulator of Malignant Progression
Tgfp has also been shown to have positive effects on malignancy during multistage 
carcinogenesis (Arteaga et al, 1993; Glick et al, 1994; Cui et al, 1996). When tumour 
cells become TGFp-resistant, TGFP production may be increased because there is no 
longer a selection for down-regulating its production. For example, malignant skin 
carcinomas, which are no longer responsive to TgfP had increased Tgfpl mRNA 
expression (Krieg et al, 1991). Using transgenic mice which overexpress Tgfpi in the 
epidermis, Cui et al (1996) found that Tgfpl has apparently biphasic effects during 
multistage carcinogenesis, working in an inhibitory manner at early stages, when
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normal growth responses to Tgfp are active, but accelerating the conversion to 
malignancy and increasing the incidence of spindle cell carcinomas at later stages.
As previously discussed, TGPp actively promotes angiogenesis and endothelial cell 
spreading, wound healing and immunosuppression. These properties could all serve a 
role to enhance tumour growth. Welch et al (1990) showed that TGpp increased 
surface lung métastasés following inoculation of a TGpp-resistant mammary 
adenocarcinoma clone into syngeneic rats. A 6-fold increase in collagenolytic activity 
and a rise in heparanase activity accompanied this increased invasive potential. Portella 
et al (1998) demonstrated that Tgfpl can act directly on kératinocytes in vivo to induce 
the epithelial-to-mesenchymal conversion of a malignant invasive cell line. Further 
evidence of the importance of the Tgfp signalling pathway for induction and 
maintenance of invasiveness and metastasis was demonstrated by Oft et al (1998). 
Expression of a dominant-negative type H TgfpR in Ha-Ra.y transformed mammary 
epithelial cells blocked the epithelial-to-mesenchymal transition. Furthermore, the 
same TgfPRII dominant-negative, when expressed in a highly metastatic colon 
carcinoma cell line, inhibited their in vitro invasiveness and completely abolished 
metastasis formation (Oft et al, 1998). Recently, Hojo et al (1999) showed that TGFp 
induced by cyclosporine could enhance metastasis in vivo and the effect was 
independent of the host's immune cells.
1.3 P53 and Tp53 Knockout Mice
1.3.1 The P53 Tumour Suppressor
More than 50% of human primary tumours contain TP53 mutations (Hollstein et al, 
1991) and it is well accepted that inactivation of P53 is one of the central events 
leading to malignant transformation. It has been described as the “guardian of the 
genome” (Lane, 1992) because of its crucial role in the cell’s response to genotoxic 
stress. In normal cells under physiological conditions the P53 protein is expressed at 
low levels and has a short half-life due to rapid turnover mediated by ubiquitination 
and proteolysis. The protein becomes stabilised and activated in response to stressful 
stimuli including exposure of cells to DNA damaging agents, hypoxia, nucleotide
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depletion, or oncogene activation. The response to these insults takes the form of either 
cell-cycle arrest or apoptosis and it is thought that the tumour suppressing function of 
P53 is to preserve genomic integrity (Lane, 1992). Cell cycle arrest at the G1 stage 
allows cells time to repair DNA damage instead of fixation as mutations, whilst 
apoptosis serves to eliminate potentially oncogenic cells which are mutated.
The P53 protein is a DNA-binding transcription factor that enhances the rate of 
transcription of several known genes that carry out, at least in part, the P53-dependent 
functions of a cell. Through analysis of the degeneracy of the P53 DNA binding site, it 
has been suggested that there may be as many as 200-400 P53 target genes (El-Deiry et 
al, 1992). These include mediators of cell cycle arrest such as (El-Deiry et al,
1993) and GADD45 (Zhan et al, 1998) and mediators of apoptosis like BAX (Miyashita 
and Reed, 1995) and FAS/APOl (Owen-Schaub et al, 1995). Some targets of P53 
appear to negatively regulate its function through regulation of the half-life of P53. The 
MDM2 gene encodes a P53-binding protein that conceals the P53 transactivation 
domain thereby inhibiting its function as a transcriptional activator. MDM2 plays a 
crucial role in targeting P53 for degradation via ubiquitination and proteolysis (Haupt 
et al, 1997; Kubbutat et al, 1997).
1.3.2 Tp53 Knockout Mice
Knockout mouse studies have provided invaluable insight into the role of p53 in 
tumorigenesis. p53 null mice were generated by several groups, all resulting in similar 
conclusions (Donehower et al, 1992; Clarke et al, 1993; Jacks et al, 1994). The 
majority of mice deficient in p53 develop normally, however, these animals are prone 
to the spontaneous development of a variety of neoplasms. The two major tumour 
types that develop are lymphomas and sarcomas. Other rare tumour types observed 
include mammary and lung adenocarcinomas, medullablastoma, glioblastoma, 
testicular tumours, and hepatomas. The majority of mice lacking p53 die by 6 months 
of age with a mean time to tumour onset of only 20 weeks. Tp53 heterozygous mice 
also succumb to tumour development but with a delayed onset and a difference in 
tumour spectrum compared to p53-null mice (Harvey et al, 1995). By 12 months of 
age only 8% of the heterozygote mice develop tumours, but from 12 months onwards
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the rate of tumour development accelerates such that by 18 months of age, 50% of 
Tp53 heterozygote mice acquire tumours. Heterozygous mice develop more sarcomas 
than lymphomas. Thus it is clear that loss of one or both copies of Tp53 can facilitate 
tumour development.
Differences in tumour phenotype have been observed in p53 null mice of different 
genetic backgrounds. For example, 35% of the pure 129/Sv strain null for p53 develop 
testicular tumours as compared to 9% in p53 null mice on the 129/Sv-C57Bl/6 hybrid 
strain (Harvey et al, 1993). As mentioned above, most p53 null mice are viable and 
fertile but some developmental abnormalities became visible upon closer inspection 
(Sah et al, 1995). In crosses between Tp53 heterozygote animals, 25% of the offspring 
should be null for p53 but this ratio is reduced. Some female embryos were found to 
display defects in neural tube closure resulting in exencephaly. The increased 
proliferative potential of the neural ectoderm in mice lacking p53 is in keeping with 
p53 functioning as a growth suppressor.
Kemp et al (1994) showed that p53 null mice were susceptible to radiation-induced 
tumourigenesis. The irradiated null mice showed a much decreased latency for 
tumorigenesis compared to irradiated wild-type controls. Another finding was that 
during chemically-induced carcinogenesis of the skin in Tp53 knockout mice, loss of 
p53 did not increase the initiation rate or number of papillomas, but had a marked 
effect on enhancing malignant conversion to carcinomas.
The Tp53 knockout mice have been very useful in analysing cooperating effects with 
other genes during tumorigenesis due to the ability to generate mice with two distinct 
genetic alterations by breeding. A line of mice that carries a truncated form of SV40 
large T antigen, which can bind and inactivate Rb (retinoblastoma gene product) but 
not p53 (Symonds et al, 1994), slowly develop choroid plexus tumours. On breeding 
these mice to a p53 null genetic background, the animals developed tumours more 
rapidly. There was also a significant decrease in survival of mice, with a focal 
emergence of aggressive tumour nodules. The aggressive phenotype corresponded to a 
decrease in the levels of apoptosis (Symonds et al, 1994). Other transgenic and 
knockout lines in which crossing on to a p53-null background caused a change in
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tumour phenotype or latency include Rb knockout (Williams et al, 1994), Apc 
knockout (Clarke et al, 1995), Atm knockout (Westphal et al, 1997), MMTV-WhG 
transgenics (Donehower et al, 1995b) and transgenics (Hundley et al,
1997). All these lines showed a reduction in tumour latency on a p53 null background 
compared to a wild-type p53 background.
Recently, the importance of one of the key negative regulators of p53, Mdm2, was 
demonstrated in a cross between mice carrying null alleles for these two genes (Montes 
de Oca Luna et al, 1995; Jones et al, 1995). Mice null for Mdm2 are not viable and die 
shortly after implantation at 5.5 days of development. Surprisingly, when crossed on to 
a p53 null background, the early embryonic lethal phenotype was completely rescued. 
This data supported two important concepts: (1) the dividing cells of the early embryo 
make functional p53 and, (2) p53 must be down-modulated by Mdm2 for cell division 
to proceed.
1.3.3 P53 and TGFP
TGF(3 can inhibit cell proliferation by causing growth arrest in the G1 phase of the 
cell cycle (Massague, 1990). Progression through G1 is dependent on the sequential 
formation, activation and subsequent inactivation of the G1 cyclin-CDK complexes, 
primarily cyclin D-CDK4 and cyclin E-CDK2 complexes (Sherr, 1993). TGFP has 
been shown to down-regulate the synthesis of CDK4 and inhibit the activity of cyclin 
E-CDK2 (Ewen et al, 1993; Koff et al, 1993). As mentioned above, the activity of the 
CDKs is negatively regulated by a number of small proteins including p21^^\ p 2 7 ^ \  
pl5^K4b p]^ i^NK4a p)atto et al (1995) showed that in the HaCaT keratinocyte cell 
line TGFP could induce p21^^\ p21 °^*  ^ is mediator of P53-induced cell cycle arrest 
and TGFp’s effects on these CDK inhibitors has raised the possibility of P53 being a 
mediator of TGFP signalling.
The involvement of P53 as a potential mediator of TGFP response seems to depend 
very much on the cell line being analysed. Blaydes et al (1995) found that introduction 
of a dominant negative P53 mutant into TGFp-responsive thyroid epithelial cells
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containing wild-type P53 did not reduce responsiveness, demonstrating that P53 
function is not necessary for TGpp response. However, expression of a temperature- 
sensitive TP53 gene in a partially responsive rat line demonstrated a significant 
modulation of TGFp response (Blaydes et al, 1995). Datto et al (1995) showed that 
p21^^^ induction by TGFp in HaCaT cells was p53-independent while in MvlLu mink 
lung epithelial cells, Ewen et al (1995) demonstrated that TGFP down-regulated 
CDK4 translation in a P53-dependent manner. Analysis of apoptotic pathways in the 
M l myeloid leukaemia cell line suggested that P53-induced apoptosis and that induced 
by TGFp were working through different pathways (Selvakumaran, 1994). Ectopic 
expression of BCL-2 blocked TGFP-induced apoptosis but only delayed P53-induced 
apoptosis. Thus, the role, if any, of P53 in a TGFP-induced arrest or apoptotic pathway 
is dependent on the tissue or cell line being analysed.
1.3.4 P53 and Skin
Mutations of the TP53 tumour suppressor gene have been observed in over 90% of 
non-melanoma skin cancers (Brash et al, 1996), including human cutaneous squamous 
cell carcinoma (SCC) (Bums et al, 1993), UVB-induced mouse SCC (Kanjilal et al, 
1993) and human basal cell carcinomas (Rady et al, 1992). These observations suggest 
that P53 plays an important role in the pathology of skin tumorigenesis and a number 
of groups have investigated the role of P53 in normal skin and its carcinogenesis. In 
normal quiescent skin, functional P53 is not a vital component of growth control as 
demonstrated by the fact that the skin of p53-deficient mice (Donehower et al, 1992) 
does not display any abnormalities. Hall et al (1993) found that no P53 antibody 
staining was seen in normal human skin but it appeared within 2 hours of UV exposure 
and peaked at 24 hours. The role of p53 in UV-induced apoptosis in the skin was 
demonstrated by Ziegler et al (1994) that the apoptosis rate was significantly lower in 
p53 null mice than the wild-type controls. This result differed from the findings of Li 
et al (1996) who reported that skins of transgenic mice carrying a Tp53 mutant allele 
had a slight increase in apoptosis rates following UV irradiation. This may be due to 
the presence of functional wild-type p53 in these mice. Interestingly, the Tp53 mutant-
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carrying mice showed a reduction in repair of UV-induced DNA damage (Li et al, 
1996).
In terms of skin tumorigenesis it appears that p53 plays different roles in the 
development of UV-induced and chemical-induced skin cancers. Li et al (1995; 1997) 
used two different mouse models to look at skin tumour induction by UV irradiation. 
In a Tp53 transgenic line that carries both wild-type and mutant Tp53 alleles, they 
found that these mice developed more tumours and more multiple tumours than control 
mice, but the latent period for skin tumour development was similar in Tp53 transgenic 
and control groups (Li et al, 1995). In the second experiment, again using UV 
irradiation, Tp53 knockout mice were analysed: they noted that p53 null mice had a 
higher incidence and a shortened latent period for UV-induced skin tumours compared 
to wild-type controls. In contrast to this, the tumour incidence of chemically-induced 
skin tumours was similar in wild-type and heterozygous Tp53 knockout mice and 
decreased in Tp53 null mice (Kemp et al, 1993b). The latency of chemically-induced 
tumours was also similar in wild-type, heterozygous, and homozygous p53-deficient 
mice; however, the tumours induced in p53 null mice were more malignant, and the 
loss of Tp53 alleles enhanced the rate of malignant progression (Kemp et al, 1993b).
Thus, it is likely that loss of p53 function is an important step in the initiation of 
UV-induced skin cancers, but is a rate-limiting causal step in malignant progression of 
chemical-induced tumours. More recently, under a chemical carcinogenesis regimen, a 
transgenic line expressing a mutant Tp53 in the epidermis (Kl-7p53'”) was shown to 
undergo accelerated papilloma formation, malignant conversion, and metastasis 
compared to wild-type mice (Wang et al, 1998a). In a follow-up study, cells of 
papillomas from the Kl-7p55'” line were shown to have a significantly higher number 
of centrosomes than those from p53 null mice, suggesting a gain of function for this 
mutant Tp53 (Wang et al, 1998b).
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1.4 BCL-2
1.4.1 BCL-2 Functions and Biochemistry
One of the most prominent regulators of apoptosis is the proto-oncogene BCL-2 (B- 
cell lymphoma 2). As implied by its name this gene was discovered because of its 
involvement in B-cell malignancies, where chromosomal translocations activate the 
gene in the majority of follicular non-Hodgkin’s B-cell lymphomas (Tsujimoto et al, 
1985). BCL-2 is now known to belong to a growing family of apoptosis-regulatory 
gene products, which may be either death antagonists including BCL-2, BCL-Xl, 
BCL-w, MCL-1, and A1 and death agonists BAX, BAK, BCL-Xs, BAD, BID, BOK, 
BIK, BIM, KRK, and MTD (Kroemer, 1997).
The members of this BCL-2 family differ in their tissue- and activation-dependent 
expression patterns, as well as in structural features. Most members possess a carboxy- 
terminal transmembrane region but some, for example BID and BAD, do not, thereby 
influencing their subcellular distribution. In addition, they possess variable amounts of 
BCL-2 homology (BH) regions (BHl to BH4), which determine their capacity to 
interact with each other or with other unrelated proteins. The BHl and BH2 domains 
are required for BCL-2 and BCL-Xl to interact with BAX and to suppress apoptosis. 
However, mutations in BCL-Xl can prevent hetero-dimerisation with BAX or BAK 
but still maintain anti-apoptotic activity, suggesting that the anti-apoptotic proteins can 
also function independently to regulate cell survival (Cheng et al, 1996). Furthermore, 
using Bax- and Bcl-2-deficient mice, Knudson and Korsmeyer (1997) showed that 
these molecules could also function independently of each other.
The BH3 domain of proapoptotic proteins such as BAX, BAK or BAD is sufficient 
but not required for their binding to BCL-2 or BCL-XL and to promote apoptosis 
(Chittenden et al, 1995). In fact, this domain probably plays a dominant role since 
introduction of the BH3 domain of BAX in BCL-2 is sufficient to convert BCL-2 to a 
killer protein (Hunter et al, 1996). In addition there are proteins such as BID, BIK, and
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BIM that have BH3 domains but lack identifiable BHl and BH2 domains and which 
are nevertheless efficient proapoptotic proteins, confirming the key role of the BH3 
domain in triggering apoptosis.
A fourth domain, BH4, is found in the N-terminal region of antiapoptotic proteins 
only (apart from the proapoptotic BCL-Xs that also contains a BH4 domain). This 
domain has been shown to bind to several proteins including RAF-1 (Wang et al,
1996) and CED-4 (Wu et al, 1997a). Mutants of BCL-2 lacking the BH4 domain not 
only lose their antiapoptotic activity but behave like killer proteins (Cheng et al, 1997). 
Proteolytically modified forms of BCL-2 lacking the BH4 domain have been shown to 
be produced through caspase cleavage during apoptosis and were found to accelerate 
the apoptotic process (Grandgirard et al, 1998).
BCL-2 family proteins can undergo posttranscriptional changes. Two modifications, 
phosphorylation and proteolysis, have been described and shown to have regulatory 
function on the activity of some family members. BCL-2 has been shown to be 
phosphorylated following exposure of cells to Taxol or paclitaxel and this may be via a 
Jun N-terminal kinase (INK) pathway (Yamamoto et al, 1999). The proapoptotic 
protein BID has been shown to be a substrate for caspase 8 (Li et al, 1998). Activation 
of FAS leads to the activation of caspase 8 which cleaves BID generating a C-terminal 
fragment of the protein. This fragment can trigger cytochrome c release leading to cell 
death.
The BCL-2 family members have been shown to be both membrane associated and 
cytosolic. BCL-2, which appears to be exclusively localised to membranes, has been 
reported to be associated with ER, mitochondrial membranes, and the nuclear envelope 
(Krajewski et al, 1993). In contrast, BAX and BCL-Xl are found in the cytosol. It is 
thought that the protein localisation changes during apoptosis. For example, BAX was 
found to move from the cytosol to the mitochondria when apoptosis was induced (Hsu 
et al, 1997). Insertion of BCL-2 family members such as BAX into the mitochondrial 
membrane can trigger cytochrome c release (Jurgensmeier et al, 1998) leading to 
downstream apoptotic events.
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1.4.2 Bcl-2 Knockout and Transgenic Mice
Mice deficient in Bcl-2 were created by gene targeting in embryonic stem cells (Veis 
et al, 1993; Nakayama et al, 1994). Mice homozygous for the Bcl-2 mutation complete 
embryonic development and appear normal during the first week after birth. After this 
however, the mice begin to show growth retardation and many die young. These mice 
have massive apoptosis in the embryonic kidney and hypoplastic renal development, 
which progresses to severe polycystic kidney disease. Initially, Bcl-2 mutant mice have 
normal hair pigmentation but, at five to six weeks, with the second hair follicle cycle, 
the hair turns grey. This is a result, at least in part, of the loss of melanocytes. Over 
time, Bcl-2-deficient mice develop fulminant apoptosis of the thymus and spleen, and 
an almost complete loss of lymphocytes (Veis et al, 1993). Thus, Bcl-2 may have its 
most dramatic role in maintaining homeostasis in adult tissues.
A number of transgenic mouse lines have enabled researchers to investigate which 
processes rely on a Bcl-2-sensitive death programme. Targeted expression of Bcl-2 to 
lymphoid cells leads to an increase in the numbers of mature resting B cells and 
potentiates their longevity (McDonnell et al, 1989). Affected T cells are markedly 
resistant to the cytocidal effects of radiation, glucocorticoids and anti-CD3, but thymic 
censorship appears normal. These Bcl-2 transgenic mice go on to develop a low 
incidence of malignant lymphoma. Lymphoid-specific expression of Bcl-2 transgenes 
allowed a novel subset of pre-B cells to accumulate in severe combined 
immunodeficiency (Scid) mutant mice and in mice lacking recombination activating 
genes Rag-1, Rag-2, or immunoglobulin ji heavy chain (Strasser et al, 1994; Young et 
al, 1997), and this has implications for signalling via the pre-B cell receptor and the B 
cell receptor. The physiological significance of apoptosis during spermatogenesis has 
also been established because ectopic expression of Bcl-2 or Bc1-Xl in mouse testis 
results in male sterility (Furuchi et al, 1996; Rodriguez et al, 1997a).
The Bcl-2 protein has been shown to be capable of preventing apoptosis in a number 
of other cell types through overexpression in transgenic mice. These include neurons
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of the central nervous system (Martinou et al, 1994), hépatocytes (Lacronique et al,
1996), retinal photoreceptors (Chen et al, 1996) and oocytes (Morita et al, 1999). 
Apoptotic cell death was also prevented in the mammary gland by expression of Bcl-2 
under the control of the whey acidic protein (WAP) promoter (Humphreys et al, 1996; 
Jager et al, 1997). Jager et al (1997) also showed that Bcl-2 could contribute to 
mammary carcinogenesis by inhibiting apoptosis. When these mice were crossed to 
MMTV-Myc transgenic mice, the Bcl-2 overexpression led to an accelerated 
development of Myc-induced mammary tumours.
1.5 Growth Control and Apoptosis
1.5.1 Tissue Homeostasis
Tissue homeostasis is regulated by a balance between proliferation, growth arrest 
and programmed cell death (or apoptosis) (Korsmeyer, 1995). Up until relatively 
recently, studies of tumorigenesis tended to concentrate on the regulation of cell 
proliferation. It is now clear that negative growth control (including apoptosis) must 
also be understood to elucidate how appropriate cell numbers within a tissue are 
maintained, and how changes to the equilibrium can contribute to malignancy.
One way in which a tissue maintains negative growth control is through terminal 
differentiation. During this conversion of proliferating undifferentiated cells into non­
proliferating, highly differentiated cells, two interrelated cellular processes are 
invoked; the regulated progression of cells through successive stages of cell 
differentiation, and growth inhibition which leads to growth arrest. In tissues where 
there is a rapid turnover of cells, terminal differentiation may culminate in apoptosis of 
the cell. Therefore, differentiation-inducing cytokines can be considered as a type of 
negative regulator of cell growth. TGF(3 is a strong inhibitor of proliferation of most 
epithelial, endothelial, and haematopoietic cells as has been discussed previously. It 
has also been shown to induce apoptosis (Oberhammer et al, 1992) and differentiation 
(Zentella and Massague, 1992) in various cell types.
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Cell cycle regulatory genes, proto-oncogenes and tumour suppressor genes are being 
shown to play major roles in processes such as positive and negative regulation of cell 
growth, differentiation and survival. Progression through the cell cycle is governed by 
the cyclin-dependent kinases (CDKs) and their associated subunits, the cyclins (Sherr, 
1993; Sherr, 1994). One way in which the CDKs are known to exert positive control 
on the cell cycle is by hyperphosphorylation of and inactivation of negative cell cycle 
regulators such as RB (retinoblastoma gene product) (Sherr, 1994). CDK inhibitors 
such as p21^^\ p27^^\ p]^ i^NK4b ^^ i^NK4a been implicated in negative growth
control (Elledge and Harper, 1994). The tumour suppressor P53 is also closely 
involved in cell cycle regulation, mediating delay or arrest at checkpoints along the cell 
cycle following DNA damage (Lane, 1992). It has also been shown to play a vital role 
in the induction or mediation of various apoptotic pathways (Oren, 1994). The product 
of the proto-oncogene BCL-2 is known to play a role in promoting cell survival and 
inhibiting apoptosis (Oltavai and Korsmeyer, 1994) and its connection to the cell cycle 
is now being elucidated.
1.5.2 Apoptosis
Apoptosis is a physiological form of cell death that plays a critical role in 
development, tissue homeostasis, and immune defence in multicellular organisms 
(Wyllie et al, 1980; Vaux et al, 1994). During apoptosis, a cell activates an intrinsic 
suicide mechanism that systematically destroys the cell. Its surface membrane begins 
to bleb and express pro-phagocytotic signals, the cell shrinks and severs contact with 
its neighbours, chromatin becomes condensed and cleaved, and eventually the whole 
cell fragments into membrane-bound vesicles that are rapidly ingested by neighbouring 
cells (Fraser and Evan, 1996; Korsmeyer, 1995). This cell suicide is programmed by 
genetically controlled pathways (Wyllie et al, 1980). Defects of genes that control this 
pathway that save cells normally destined for destruction may underlie both cancer and 
autoimmune diseases, while defects that promote excessive cell death may contribute 
to neurodegenerative disease and immunodeficiency.
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1.5.3 TGFP and Induction of Apoptosis
Initiation of apoptosis can be induced by the absence of incoming survival signals 
from the environment or signalled directly as a result of cell damage or through 
cytokine-mediated pathways. Several studies have provided evidence that TGFP might 
act as an inducer of apoptosis in some cell types. Levels of TGppi mRNA were 
increased during castration-induced regression of the prostate, a process where 
apoptosis is of major importance (Kyprianou and Isaacs, 1989). In cultures of primary 
rat hepatocytes and human Hep 3B hepatoma cells, TGFpl appeared to induce cell 
death with apoptotic features, including DNA fragmentation, condensation of 
chromatin, cellular rounding and fragmentation, and phagocytosis by neighbouring 
cells (Oberhammer et al, 1991; 1992; Lin and Chou, 1992). Similar events have also 
been observed in cultures of primary rabbit uterine epithelial cells and endometrial 
stromal cells treated with TGFP (Rotello et al, 1991; Moulton, 1994). Jurgensmeier et 
al (1994) cocultured transformed fibroblasts with normal fibroblasts and found that, in 
synergy with TGFP, normal fibroblasts were able to eliminate transformed cells by 
induction of apoptosis.
The mechanisms by which TGFp exerts its apoptotic effect are still poorly 
understood but recently some studies have been addressing this question. Bies and 
Wolff (1995) found that overexpression of B-MYB accelerated apoptosis in TGFpi- 
treated M l myeloid leukaemia cells, and overexpression of SMAD4, a signal 
transducer of the TGFP family, caused MDCK cells to undergo apoptosis (Atfi et al,
1997). Caspase family proteases were activated in response to TGFp treatment of the 
Hep3B hepatoma cell line (Chen and Chang, 1997) and, in the same cell line, the PI3- 
kinase/AKT pathway was shown to protect against TGFP-induced apoptosis by 
inhibiting a step downstream of SMAD but upstream of caspase-3 (Chen et al, 1998).
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1.5.4 P53 and Apoptosis
It is believed that P53-dependent apoptosis is one of the central pathways of somatic 
cells to secure the elimination of cells with abundant DNA damage. Under 
circumstances where DNA damage is irreparable, survival factors for the cells are 
limiting, or an activated oncogene is forcing the cell into a replicative cycle, P53- 
mediated apoptosis prevails over growth arrest. P53’s involvement in apoptosis was 
realised when it was noted that over-expression of wild-type P53 could result in rapid 
loss of cell viability, in a manner characteristic of apoptosis (Yonish-Rouach et al, 
1991). Indisputable evidence for the role of P53 in apoptotic processes was provided 
by the study of Tp53 knockout mice. Tp53-/~ thymocytes (Lowe et al, 1993; Clarke et 
al, 1993), and Tp53-I- stem cells of the small and large intestine (Clarke et al, 1994) 
are much more resistant to radiation-induced apoptosis than the corresponding wild- 
type cells. However, these studies also made clear that only a subset of apoptosis- 
inducing events are P53-dependent. For example, immature thymocytes lacking p53 
die normally when exposed to glucocorticoids or to components that mimic T-cell 
receptor engagement (Lowe et al, 1993; Clarke et al, 1993).
The mechanism by which P53 stimulates apoptosis is still relatively unknown. 
Studies of p21^^^-deficient fibroblasts revealed the significant contribution of p21 
induction to p53-mediated G1 arrest; however, the same studies also showed clearly 
that p21 was not required for p53-mediated apoptosis (Deng et al, 1995; Brugarolas et 
al, 1995). The first P53 target gene identified to encode a candidate effector of P53- 
mediated apoptosis was BAX (Miyashita and Reed, 1995). The relative contribution of 
BAX to p53-mediated apoptosis appears to be cell type-dependent; bax is not required 
for radiation-induced, p53-dependent apoptosis of thymocytes (Knudson et al, 1995). 
However, it does contribute to apoptosis of oncogene-expressing mouse fibroblasts, as 
shown by the attenuated apoptosis of such cells when derived from bax-deficient mice 
(McCurrach et al, 1997). Furthermore, in a transgenic mouse tumour model, it was 
shown that p53-induced bax expression is necessary for efficient inhibition of tumour 
growth, attributed to apoptotic elimination of the tumour cells (Yin et al, 1997). Other 
p53 target genes implicated in apoptosis include FAS/APOl (Owen-Schaub et al, 
1995) and more recently DR5/KILLER (Wu et al, 1997b), p53-induced genes {PIGs)
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(Polyak et al, 1997) and the IGF binding protein 3 {IGF-BP3) (Buckbinder et al, 
1995).
1.5.5 BCL-2, Apoptosis and Skin
As discussed in section 1.1.2.1, the skin is a layered organ in which a differentiation 
programme exists that initiates within the basal layer, continues upward through the 
spinous layer, and terminates within the granular layer. Despite the constant generation 
of basal kératinocytes, the cellularity within each differentiation layer remains stable. 
Thus, the rate of cell loss or death in the differentiating suprabasal layers is in 
equilibrium with the rate of proliferation observed in the basal layer. Studies of the 
skin reveal that the morphological features seen in the granular and comeal layers are 
similar to the cellular changes described for apoptosis (Gavrieli et al, 1992). 
Furthermore, constant exposure to environmental hazards such as UV light 
dramatically increases the probability that an epidermal stem cell may acquire a 
harmful mutation. To protect the organism from accumulating damaged or abemant 
cells, basal kératinocytes in vivo seem to be susceptible to apoptosis in response to 
genotoxic damage (Kraemer, 1997). In this way, apoptosis helps maintain homeostasis 
within the skin.
The identification of proteins from the BCL-2 family in skin suggests that these 
proteins may play a regulatory role in epithelial cell homeostasis (Rodriguez- 
Villanueva et al, 1995, Krajewski et al, 1994). There is some controversy as to which 
layer of the epidermis the protein is expressed in. A number of studies located BCL-2 
expression exclusively in the basal layer of the epidermis (Hockenbery et al, 1991; 
Cerroni and Kerl, 1994; Verhaegh et al, 1995) while others found expression also in 
the spinous and granular layers (Krajewski et al, 1994; Stenn et al, 1994). Plettenberg 
et al (1995) on the other hand found that, within normal human epidermis, 
melanocytes were the only cells that expressed BCL-2 constitutively. In skin tumours, 
two different studies have revealed that basal cell carcinomas and malignant 
melanomas express BCL-2 while squamous cell carcinomas do not (Verhaegh et al, 
1995; Morales-Ducret et al, 1995).
46
Recently, transgenic studies have investigated a role for Bcl-2 in skin and skin 
tumorigenesis. Rodriguez et al (1997b) found that overexpression of Bcl-2 in female 
mice could prevent vaginal opening by blocking apoptosis in this tissue. Targeting of 
human BCL-2 to the epidermis under control of a human keratin-1 (Kl) promoter 
caused aberrant expression of keratin 6 (K6), regions of multifocal hyperplasia, and an 
increased susceptibility to skin tumour formation by chemical carcinogenesis 
(Rodriguez-Villanueva et al, 1998). Transgenic mice expressing Bc1-Xl or Bcl-Xs 
under control of the human keratin 14 (K14) promoter were also generated (Pena et al,
1 9 9 7 ) BcI-Xl transgenics showed an increased resistance to UV-irradiation, 
whereas the Bcl-Xs transgenic mice showed an increased sensitivity. These studies 
suggest that BCL-2 and related proteins may play a role in influencing cell survival in 
the epidermis.
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Chapter 2 
MATERIALS AND METHODS
2.1 Mouse Procedures
2.1.1 Animal Husbandry
All mice were housed under a 14-hour light to 10-hour dark cycle. Animal technicians 
handled food, water and bedding requirements. All mouse procedures were conducted 
in accordance with Home Office Regulations and as detailed in the covering project 
licence. Unless otherwise stated, I conducted the procedures as covered by my Home 
Office personal licence.
2.1.2 Observation and Monitoring of Mice
In accordance with procedures as described in the Home Office project licence, all 
animals susceptible to the development of neoplasia were monitored at least twice a 
week for signs of ill-health and discomfort. Any animal suffering or deviating from a 
normal health status was sacrificed without delay. Mice which developed tumours 
were observed more closely and the position of the tumours, size of tumours and speed 
of growth of the tumours were recorded. If a single tumour reached 10mm in diameter 
or if 10% of the mouse body surface was affected by neoplasia, the mouse was 
sacrificed and relevant tissues were collected.
2.1.3 Identification and Tail Biopsy of Transgenic Mice
At 19-21 days of age mice were weaned and males and females were separated. The 
mice were given a number in consecutive sequence and identified by ear punching. 
They were put under brief anaesthesia with a halothane/oxygen mixture in an
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anesthesia chamber. A small tail-tip biopsy (0.5-1.0cm) was taken using a hot, sterile 
scalpel blade to ensure cauterisation.
2.1.4 Collection of Tissues from Mice
When skin was to be collected, mice were shaved 48 hours before collection to check 
that the mouse was in the resting telogen phase of the hair cycle. Mice that exhibited 
signs of hair growth at the time of tissue collection were excluded from the 
experiment. If whole skin was being collected for histological analysis mice were 
injected with BrdU as described in Section 2.2.5. Animals were sacrificed by cervical 
dislocation. A strip of skin was cut from the shaved area, part of which was put in 4% 
paraformaldehyde (Sigma), and the rest snap frozen in liquid nitrogen for -70°C 
storage.
When only epidermal cells were required for RNA or protein extraction, the skin was 
treated with a hair-removing agent (Immac™) prior to sacrifice. The strip of skin was 
then immersed in water at 60°C for 30 seconds followed by immersion in ice-cold 
water for 30 seconds so that the epidermal cells could be scraped off using a scalpel 
blade. These cells were snap frozen in liquid nitrogen.
For collection of tumour samples, the mouse was injected with BrdU one hour before 
sacrifice. Tumour samples were split in two with one half being fixed in 4% 
paraformaldehyde and the other frozen in liquid nitrogen and stored at -70°C. A piece 
of adjacent dorsal skin was also taken from those affected mice for comparison.
2.1.5 Injection of Bromodeoxyuridine (BrdU) into Mice
BrdU is a potent carcinogen and so all procedures were carried out in a fume hood. 
Bromodeoxyuridine (Sigma) was dissolved at a concentration of 125mg/ml in water by 
heating the solution to 60°C. This was stored as a stock solution at 4‘^ C and from this a 
working solution of 25mg/ml in sterile saline (0.85% NaCl) was made. Each mouse 
was weighed and injected intraperitoneally with the equivalent of 2jil BrdU solution
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per gram of mouse (i.e. 50|ag BrdU per g mouse). Exactly one hour later the mouse 
was sacrificed and the appropriate tissues fixed in 4% paraformaldehyde.
2.1.6 Chemical Carcinogenesis Treatment of Mice
All handling of TEA (12-0-tetradecanoylphorbol-13 acetate) was conducted in a fume 
hood. Animals were aged between 10 and 14 weeks at time of treatment and any 
animal found to be in the telogen phase of the hair cycle was excluded. TP A was made 
up as a stock solution using acetone as a solvent and stored at -20°C. From this, a 
working solution of 5x10'^ M was prepared and each application consisted of 200)11 of 
this TPA solution being dropped on to a shaved area of dorsal skin. 200|il of acetone 
alone was used as a negative control. After treatment, mice remained in the fume hood 
for a minimum of 1 hour to ensure the chemicals had completely dried. Exactly one 
hour before skins were due to be harvested, mice were injected with BrdU as described 
above.
Mice were treated with TPA under two different regimes -  a multi-application chronic 
treatment and a single-application acute treatment. Three mice of each genotype were 
treated for each timepoint. Under the acute treatment, mice received one application of 
TPA and skin was harvested at 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 4 days 7 
days, and 10 days after the application. Chronic TPA treatment consisted of 4 
applications of TPA to the dorsal skin: an initial one followed by applications at 3 
days, 6 days and 9 days after the first. Skins were harvested at 12 days into the 
treatment.
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2.2 Different Transgenic Mouse Lines Utilised
2.2.1 Tg/pl knockout mice
Mice carrying a disrupted non-functional Tgfftl gene were initially provided by 
Kulkami et al (1993). Targeted deletion of some of the first exon and first intron was 
carried out by insertion of a neomycin-resistance gene to render the Tgf^l gene non­
functional (figure 2.1 A). The mice were analysed on both the original mixed genetic 
background (50% NIH, 37.5%C57B16, 12.5%129SV) and also, after breeding through 
four generations with NIH mice, on a 93% NIH background.
These mice were genotyped, following a tail-tip biopsy, by polymerase chain reaction 
(PCR) - see below. Wild-type alleles were identified with nested primers from the first 
exon and intron of the mouse Tg/pl gene (95,96,97,98). Null alleles with a primer 
from exon 1 (TGF) and from the phosphoglycerate kinase 1 (PGKI) promoter of the 
neomycin resistance cassette (PGK). Table 2.1 lists sequences of primers with 
annealing temperatures used.
2.2.2 Tgfpi transgenic mice
Transgenic mice engineered to overexpress a constitutively active simian Tgfpl 
protein were utilised. The two lines used in this investigation were the H-line (Cui et 
al, 1995) and the M2-line (Fowlis et al 1996) as shown in figure 2.IB. The H-line 
transgene consists of the bovine cytokeratin VI (KIO) promoter driving the activated 
simian Tg/pl cDNA with the SV40 small t intron and polyadenylation signal from 
SY40. This targets transgene expression to the suprabasal layer of skin epidermis. The 
M2-line transgene consists of the inducible bovine K IV (K6) promoter driving the 
same activated simian Tgf^l and with the same SV40 polyA tail. Again, this targetted 
expression to the suprabal layer of epidermis, but only in response to a promoter such 
as TPA. Both lines of mice were on a 93% NIH genetic background.
Both these lines of mice were screened to detect the presence of the transgene either by 
PCR and/or by Southern Blotting. The PCR reaction was carried out using primers
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from the SV40 polyA region of the transgene (SVl and SV2, see Table 2.1). The cycle 
was as described in section 2.4.2 with an annealing temperature of 50“C. Southern blot 
analysis used a SV40-specific hybridisation probe to detect the transgene and a mouse 
cystic fibrosis transmembrane conductance regulator gene probe (mCftr, Tata et al 
1991) as an internal DNA loading control was used to estimate hemi- or homozygosity 
of the transgene.
2.2.3 Tp53 knockout mice
Mice carrying a disrupted, non-functional Tp53 gene were initially provided by 
Donehower et al (1992). They had been derived by homologous recombination in an 
ES cell line of 129/Sv genetic background rendering the Tp53 gene non-functional as 
shown in figure 2.1C. In this lab, they were bred by crossing them to NIH mice through 
4 generations or transgenic mice with a NIH background.
The mice were genotyped by PCR. Wild-type alleles were identified with primers 
around the locus of exon 5 (P53W1 and P53W2) and null alleles with a primer from a 
Tp53 intron (P53MI) and a primer from the inserted cassette (P53M2). The PCR was 
carried out as described in section 2.4.2 with an annealing temperature of 55°C.
2.2.4 Ras transgenic mice
K5-RAS mice were generated at the Beatson Institute for Cancer Research by K. 
Brown et al which consisted of the keratin 5 (K5) mini-gene driving a constitutively 
active human Ha-i?AS cDNA as shown in figure 2. ID (Brown et al, 1998).
The mice were bred through 3 generations onto at least a 82% NIH genetic 
background. Genotyping was carried out by PCR either using the SV40 polyA PCR 
(described above for the 7g/p transgenic mice) or using primers specific for the 
mutated RAS gene itself (tcrl and tcr2). When carrying out this PCR an internal control 
was also used by amplification of the thyroxine stimulating hormone beta (Ts'/ip) gene
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(primers TSHl and TSH2). The PCR reaction was carried out as described in section
2.4.2 and an annealing temperature of 55°C was used.
2.3 Genotyping of Transgenic Mouse DNA
2.3.1 Genomic DNA Extraction from Tail Tip Biopsy
The mouse tail tip was placed in 700|l i 1 of tail lysis buffer ( lOOmM Tris-HCl pH8.5, 
5mM EDTA, 0.2% SDS, 200mM NaCl ) containing 0.1 mg/ml proteinase K (Sigma) 
and was incubated at 55°C until the tissue was fully digested (usually overnight). 
Following lysis, the mixture was shaken and centrifuged in a bench top Eppendorf 
microcentrifuge at 13,000rpm for 10 mins to pellet the tail debris. The supernatant was 
decanted into a fresh 1.5ml eppendorf, and an equal volume of isopropanol was added. 
This mixture was shaken until precipitation was complete; the precipitate was removed 
with a sterile pipette tip, dried in a fresh eppendorf tube and the DNA was dissolved in 
lOOp.1 IxTE buffer.
2.3.2 Genotyping by PCR
Oligonucleotides were synthesised on an Applied Biosystems 391 DNA synthesiser. 1 
|il of the genomic DNA preparation was mixed with 10-25pmol sense and anti sense 
primers, 200p.M each of dCTP, dATP, dTTP and dGTP (Boehringer Mannheim), 1 
unit of Taq polymerase (Cambio) and Ix PCR reaction buffer (Cambio) in a total 
volume of 30jil. The reaction was overlaid with mineral oil (Sigma) to prevent 
evaporation and the PCR was carried out using a DNA Thermocycler (Perkin Elmer 
Cetus). 30 - 35 cycles of amplification were carried out, each cycle consisting of 3 
sequential steps; dénaturation (95°C for 1 min), annealing (50 - 62^C, 1 min), and 
elongation (72°C, 2 mins). PCR products were stored at 4°C until analysed by agarose 
gel electrophoresis on a 1.2 -1.5% gel.
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2.3.3 Genotyping by Southern Blotting
The concentration of genomic DNA was determined by measuring OD at 260nm. l|il 
of the DNA solution was dissolved in 999pil dHzO. A solution containing 50p,g/ml 
double-stranded DNA has an absorbance of 1 at 260nm.
lOjLig genomic DNA was digested by an appropriate restriction enzyme. 4 units of 
enzyme (Gibco BRL) per jig DNA were used in a total volume of 40|il containing the 
appropriate reaction buffer (Gibco BRL) and the digestion was carried out at 37°C 
overnight. The digested DNA was separated in a 0.8% agarose gel at 80V for 4-5 
hours. The gel was then denatured in 0.5M NaOH, 1.5M NaCl for 30 mins followed 
by neutralisation in IM Tris-HCl pH8.0, 1.5M NaCl for 30 mins.
The gel was placed on a sheet of 3MM Whatman paper which was soaked in 
lOxSSC and which acted as a wick in a tray containing a reservoir of lOxSSC. A piece 
of hybridisation membrane (Hybond-N, Amersham) cut to the size of the gel was 
placed on top of the gel followed by two pieces of 3MM Whatman paper. Finally, a 
stack of paper towels was laid flat on the top and covered with a glass plate and a light 
weight (1kg). The transfer took place overnight at room temperature. The Hybond-N 
membrane was removed, dried and the DNAs were fixed by placing it on a UV 
transilluminator for 4 minutes.
The Hybond-N membrane was pre-soaked with 2xSSC then rolled up with a mesh and 
placed in a hybridisation bottle containing pre-hybridisation solution (6xSSC, 
5xDenharts, 100]ug/ml salmon sperm DNA, 0.5%SDS). The membrane was pre­
hybridised by incubation at 65°C for 4 hours. The radioactive probe (see section 2.5.4) 
was denatured, added to the hybridisation mix (as pre-hybridisation mix + 10% 
Dextran Sulphate) at 2 x 10*" cpm per ml and hybridisation was carried out overnight at 
65°C.
Membranes were washed in the bottle at 65°C for 10 mins with 2xSSC, 0.1%SDS and 
in a sandwich box at 65°C with shaking for 15 minutes with 0.2xSSC, 0.1%SDS. The 
membrane was wrapped in clingfilm and exposed to Kodak X-Omat autoradiographic 
film overnight before being developed in a Fuji X-ray film processor RGB.
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2.4 DNA Analysis
2.4.1 Agarose Gel Electrophoresis
A 0.8-2.0% agarose solution was made up in 1 x TAB buffer (0.04M Tris-acetate, 
ImM EDTA pH8.0) and dissolved in a microwave; ethidium bromide (Sigma) was 
added to a final concentration of 0.5jig/ml. The agarose mixture was poured into a 
horizontal gel mould and allowed to set at room temperature. DNA samples were 
mixed with 10% volume of gel-loading buffer (50% glycerol, 1% bromophenol blue, 
lOmM sodium phosphate pH7.0) and loaded into wells. Gels were run at 
approximately 7V/cm inter-electrode distance in TAB buffer. An appropriate size 
marker (Gibco BRL) was run alongside the PCR samples, the bands were visualised on 
a UV transilluminator and photographed.
2.4.2 Preparation of Plasmid DNA
All preparations were performed under sterile conditions. 20-50ng of plasmid DNA 
containing the required insert was added to lOOjal of E. Coli DH5a competent cells on 
ice before heat-shocking at 56°C for 1.5 minutes. Incubation on ice for 2 minutes was 
followed by addition of 0.5ml of sterile L-broth (1% bacto-tryptone, 0.5% yeast 
extract, 1% sodium chloride, pH 7.0). The cells were shaken for one hour at 37°C in an 
orbital incubator (x 225rpm), before plating out at 200, 100, and 50|al volumes onto 
agar plates (L-broth plus 1.5% bacto-agar and 50mg/ml ampicillin), and incubated at 
37°C overnight in an inverted position.
The following day, a single bacterial colony was picked and used to inoculate 5ml of 
L-broth containing 50mg/ml ampicillin. This was cultured overnight at 37°C in an 
orbital shaker at 225rpm. 1.5ml of the overnight culture was microcentrifuged for 5 
minutes, the supernatant discarded and the pellet resuspended in 100|il of Solution 1
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(50mM glucose, 25mM Tris-HCl, lOmM EDTA pH8.0). 200|il of fresh Solution 2 
(0.4M NaOH, 1%SDS) was added and inverted gently until the mixture cleared. The 
lysed cells were incubated on ice for 5 minutes. The solution was neutralised by the 
addition of 150|il Solution 3 (3M KG Ac pH4.8), the tubes mixed gently, and then 
placed on ice for 30 minutes to precipitate the protein. The samples were 
microcentrifuged for 2-3 minutes before removing and retaining the supernatant. An 
equal volume of isopropanol was added to the solution and the tubes vortexed, then 
centrifuged at 14000rpm to precipitate and pellet the DNA. The supernatant was 
removed and the pellet resuspended in 50|il TE plus 50p,g/ml RNase A. This was 
incubated at 37°C. After 30 minutes an equal volume of phenol/chloroform (50/50) 
was added to the sample, mixed thoroughly and centrifuged for 5 minutes in a 
microcentrifuge. The aqueous phase was retained, a 1/10th volume of 3M sodium 
acetate and an equal volume of isopropanol were added, and DNA was precipitated at - 
20°C for 1 hour. Microcentrifugation at 14000rpm for 15 minutes pelleted the DNA 
which was washed 2x in 70% ethanol, air-dried, then resuspended in 30fxl TE.
2.4.3 Generation of DNA Fragments for Probes
To isolate a DNA insert, approximately 20|ig of plasmid DNA was incubated with the 
appropriate restriction enzyme(s) (Gibco BRL), at a concentration of 2-3 units/pg 
DNA, in a total volume of lOOpl with buffer (Gibco BRL), at 37^0 for at least 1 hour. 
An aliquot of the digest was analysed with respect to an uncut sample by agarose gel 
electrophoresis, to confirm complete digestion. Ipg/ml Ikb DNA ladder (Gibco BRL) 
was run alongside the samples to confirm band sizes.
To isolate the excised DNA fragment, the remaining volume of the digestion was run 
in a 1% low melting-point agarose gel (Metaphor). The agarose gel was visualised by a 
UV transilluminator and the band of the correct size was cut from the gel with a sterile 
scalpel blade and weighed. To extract the DNA from the gel a GeneClean 11 kit (Bio 
101 Inc.) was used. Three volumes of 6M sodium iodide per volume of agarose gel 
were mixed together and incubated at 50°C for 5 minutes to solubilise the gel. 5pi of 
glassmilk (silica matrix) per 5pg DNA was added, followed by vortexing, and
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incubating on ice for 5 minutes with occasional mixing. The glassmilk/DNA was then 
pelleted by microcentrifugation at 14000rpm for 5 seconds before washing in 10-50 
volumes of NEW Wash™ (sodium chloride, Tris, EDTA, ethanol mixture in kit). The 
glassmilk/DNA was pelleted again, supernatant removed, and the washing step was 
repeated twice. The pellet was resuspended in an equal volume of distilled water and 
incubated at 50°C for 2-3 minutes to release the DNA from the glassmilk. The 
glassmilk was pelleted, and the water containing the DNA was removed to a fresh 
eppendorf. Ipl of the DNA sample was run in a 1% agarose gel to check integrity and 
estimate the concentration.
2.4.4 Preparation of ^^P-labelled Probes
DNA inserts to be used as probes were labelled with a-^^P dCTP (Amersham) using a 
random primed labelling kit (Boehringer Mannheim). lOOng DNA was resuspended in 
23pl H2 O, denatured at 100°C for 10 minutes and quenched on ice. lOOmM of each 
dNTP (except dCTP), 4pl reaction buffer (Boehringer Mannheim), 1 unit of Klenow 
enzyme and 0.5pCi a-^^PdCTP was added to DNA for a final volume of 40pl and the 
reaction incubated at 37*^ C for 60 minutes. The labelled probe was collected by passing 
the sample through a Nick column™ (Pharmacia), followed by two 400pl aliquots of 
TE buffer. The second 400pl aliquot, containing radiolabelled DNA, was collected. 
The specific activity of the probe was determined using a Texas Instuments 
scintillation counter.
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2.5 RNA Analysis
2.5.1 Extraction of RNA from Frozen Tissue
All glassware, tips, eppendorfs, and solutions (except those containing Tris or organic 
solvents) were treated with 0.01% diethylpyrocarbonate (DEPC) (Sigma) before 
sterilisation to prevent the degradation of the RNA by RNAses. A commercial 
solution, TRIzol™ (Biogenesis Ltd, based on the method described by Chomczynski 
and Sacchi 1987), was used to extract RNA from frozen tumours, skin and other 
tissues. If necessary, tissues were partially ground using a mortar and pestle then 
transferred to a glass homogeniser. 2ml TRIzol™ per lOOmg tissue was added to the 
homogeniser. The tissue was disaggregated and incubated at room temperature for 5 
minutes. 0.2ml chloroform / ml TRIzol™ was added, the sample shaken and incubated 
for a further 3 minutes at room temperature. Samples were then centrifuged at 
10,500rpm in a refrigerated Sorvall centrifuge (SM24 rotor) for 15 minutes at 4°C. The 
aqueous layer was removed to a fresh tube and the RNA was precipitated by addition 
of 0.5ml isopropanol per ml TRIzol™ and incubated at room temperature for 10 
minutes. Samples were re-centrifuged and the supernatant discarded. The RNA pellet 
was washed once with 75% ethanol and resuspended in 30-50pl DEPC water.
2.5.2 Northern Blotting
RNA was run in a 1.5% denaturing agarose gel containing 16.6% formaldehyde and Ix 
MOPS buffer (200mM MOPS Sodium salt, 50mM sodium acetate, lOmM EDTA 
pH7.0). 50% formamide, 2.2M formaldehyde, and Ix MOPS was added to 5pi of RNA 
to a total volume of lOpl, and incubated at 55-60°C for 10 minutes before quenching 
on ice. 1/6^ *^  volume of lOx loading buffer (50% glycerol, ImM EDTA pH8.0, 0.25% 
bromophenol blue, 0.25% xylene cyanol) was added, and the samples loaded into 
wells. E.coli RNA ran alongside the samples and was used as size markers. 
Electrophoresis occurred at 50-100V for 4-8 hours in circulating Ix MOPS to prevent 
depletion of ions at the anode.
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After electrophoresis, the gel was washed for 20-30 minutes 2-3 times in Milli-Q water 
to get rid of formaldehyde. Marker lanes were cut off and stained for 10 minutes in 
1.5pg/ml ethidium bromide before destaining in water. The rest of the gel was placed 
on a piece of lOx SSC soaked 3MM Whatman paper, acting as a wick in a reservoir of 
lOx SSC. The RNA was blotted overnight onto Hybond-N membrane (Amersham) as 
described above for Southern Blotting.
2.5.3 Reverse-Transcription of RNA to cDNA
7pi of RNA (0.5 - Ipg) was incubated at 90°C for 5 minutes before quenching on ice. 
Ipl (50ng) of oligo d(T) was added, followed by incubation at 65^C for 10 minutes. 
After quenching on ice, 4pl of 5x RT buffer (250mM Tris HCl pH8.3, 375mM 
potassium chloride, 15mM magnesium chloride), 5pi of 2.5mM dNTPs, Ipl O.lmM 
DTT, 1.2pl Moloney Leukemia Virus Reverse Transcriptase (MMLV RT) (Gibco 
BRL), and 0.8pl of RNA Guard (RNAse inhibitor) were added and the reaction 
incubated at 37°C for 1 hour. The reaction was stopped by heating at 95°C for 5 
minutes, then quenched on ice. The mixture was stored at -20°C until required.
2.5.4 Reverse-Transcription PCR
Ipl of the 20pl cDNA mixture resulting from reverse transcription was combined with 
15mM magnesium chloride, Ix buffer (Cambio), 50pmol of primers BCl and BC2 
(see Table2.1), 200mM dNTPs, and 1 unit of Taq polymerase (Cambio) in a total 
volume of 50pl. The reaction was overlaid with mineral oil (Sigma) to prevent 
evaporation and the PCR was carried out using a DNA Thermocycler (Perkin Elmer 
Cetus). 35 cycles of amplification were carried out, each cycle consisting of 3 
sequential steps: dénaturation (95°C for 1 min), annealing (55°C, 1 min), and 
elongation (72°C, 2 mins). PCR products were cleaned using a ‘Wizard’ Clean-up kit 
(Promega) and the DNA was redissolved in 30pl TE buffer. Digestion of the PCR 
products was carried out as described above.
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2.5.5 Radioactive In Situ Hybridisation
2.5.5.1 Radioactive Riboprobe Synthesis
In order to generate a -labelled riboprobe, the plasmid containing the insert of 
choice (see Table 2.2) was linearised using appropriate restriction enzymes with 
respect to the T7 and T3 promoter, ethanol precipitated and resuspended in clean Ix 
TE at a known concentration. Ipg DNA template in Ipl TE was incubated at 37°C for
1.5 hours with the appropriate polymerase in reaction buffer (0.04M Tris-HCl pHS.O, 
8 mM MgCE, ImM spermidine, 0.025M NaCl) (Gibco BRL) containing O.lmM DTT, 
ImM ATP, CTP and GTP, 7.5mM UTP-S, 0.3mg/ml BSA (RNase and DNase free) 
(all Pharmacia), 75pCi ^^S-UTP (Amersham) (dried into a RNase-free 1.5ml eppendorf 
tube), and 30 units RNAguard (Pharmacia) in a total volume of lOpl. The reaction was 
terminated by incubation with 0.15 units DNasel dissolved in Ix DNase buffer (O.IM 
NaOAc pH5.0, 5mM MgCL, lOmM DTT (added fresh)), 50 units RNAguard and 
0.05mg polyA. The reaction mix was separated through a G50 sephadex Nick™ 
column (Pharmacia). The column was first equilibrated with 3ml column buffer (0.3M 
NaOAc pH5.0, lOmM Tris-HCl pH7.5, ImM EDTA pH8.0, 0.1% SDS, lOmM DTT. 
The probe mixture was eluted through the column with 2 volumes column buffer and 
the final fraction retained. An equal volume of phenol pH5.0 was added, mixed and 
microcentrifuged for 10 minutes. The aqueous phase was retained and extracted with 
an equal volume of chloroform : isoamyl alcohol (24 : 1). 2.5 volumes of ethanol were 
added to precipitate the riboprobe by incubating on dry ice for 30 minutes. The RNA 
was pelleted by microcentrifugation for 2 0  minutes, the pellet air-dried and 
resuspended in lOpl DEPC-treated water. 73pl alkali digestion buffer (40mM NaHCOg 
pHlO.2, 60mM NaaCOs, lOmM DTT) was added and the riboprobe was alkali- 
digested for a predetermined time at 60“C.
The length of alkali-digestion was determined by the following equation (Cox et al, 
1984);
Incubation time (minutes) = (Lo -  Li) / (0.11 x Lo x Li)
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where Lo = original length of riboprobe (kb) 
and Li = required length of riboprobe (kb)
The alkali-digested probe was quenched on ice and lOpl O.IM NaOAc pH6.0, 0.05mg 
PolyA added before the sample was separated using a G50 sephadex Nick™ column 
(Pharmacia). The eluted sample was extracted with phenol and chloroform : isoamyl 
alcohol before ethanol precipitation, as described above.
The pellet was resuspended in an appropriate volume of 50mM DTT calculated so that 
a 1 in 10 final dilution would result in a solution at 3 x 10"^  cpm/|uil. The lOx stock 
solution of riboprobe was stored at -20°C for up to 14 days before use.
2.5.5.2 Pretreatment of Tissue Sections
All pre- and post-hybridisation washes were performed using 250ml glass troughs 
(Solmedia). Slides were held in a glass microscope slide carrier. All washes took place 
at room temperature unless otherwise stated.
Slides were dewaxed twice in Histoclear™ for 10 minutes then rehydrated in 3x 2 
minute washes of 1 0 0 % ethanol, followed by 2  minute immersions in an ethanol series 
comprising 90%, 80%, 70%, 50% then 30% ethanol in Milli-Q water. The slides were 
equilibrated in 0.85% saline for 5 minutes and then immersed in PBS for 5 minutes. 
The tissue was refixed in fresh 4% PFA/PBS for 20 minutess then washed twice in 
PBS for 5 minutes. The sections were incubated with 40pg/ml proteinase K in PKB 
(50mM Tris-HCl pH7.5, 5mM EDTA pH8.0) for 7.5 minutes then washed for 3 
minutes in PBS. This was followed by further fixation in 4% PF A/PBS for 5 minutes. 
The tissue was acetylated in O.IM triethanolamine with freshly added 0.2% acetic 
anhydride for 10 minutes then washed for 5 minutes in PBS followed by 0.85% NaCl. 
The sections were dehydrated by 2 minute washes in an ascending etanol series (30%, 
50%, 70%, 80%, 90%, 100%). The slides were left to air-dry under cover at room 
temperature.
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2.5.5.3 Hybridisation of Probe to Sections
The riboprobe was applied to selected tissue sections at a 1 in 10 dilution (3 x 10"^  
cpm/ml) in a freshly made hybridisation mix comprising 0.3M NaCl, lOmM Tris-HCl 
pH8.0, 5mM EDTA, lOmM NaP0 4  pH6 .8 , 10% dextran sulphate, Ix Denhardts, 
0.5mg/ml tRNA, 0.5mg/ml PolyA, 50mM DTT. The hybridisation mixture and probe 
were mixed and denatured at 80“C for 3 minutes and quenched on ice. 3-7 |li1 of the 
riboprobe mixture was carefully pipetted onto individual tissue sections then covered 
with a coverslip. Coverslips were cut using a diamond pen in order to fit individual 
tissue sections. They were placed carefully onto the sections to prevent air bubble 
formation and to protect the tissue. The slides were placed in a humid chamber 
containing a tissue soaked in 4x SSC, 50% formamide and sealed with tape for 
hybridistion overnight at 55°C.
2.5.5.4 Post-hybridisation Washes
Slides were transferred quickly to a glass slide holder, then washed sequentially in the 
following: 5x SSC, 0.1% |3-mercaptoethanol for 15 minutes at 50°C; 2x SSC, 50% 
formamide, 1% (I-mercaptoethanol for 20 minutes at 65“C; 4x 10 minute washes at 
37°C in RNase buffer (lOmM Tris-HCl pH8.0, 5mM EDTA, 0.5M NaCl) followed by 
a 30 minute incubation in RNase buffer plus 20pg/ml RNase A at 3TC, then a 15 
minute wash in RNase buffer; 2x SSC, 50% formamide, 1% P-mercaptoethanol at 
65°C for 20 minutes; 2x SSC at 50°C for 15 minutes; O.lx SSC at 50°C for 15 minutes. 
The sections were dehydrated in an ethanol series in Milli-Q water (50%, 70%, 90%, 
and 100%) for 2 minutes each. The slides were allowed to dry in a dust-free 
environment then dipped for 1 0  seconds in a 0 .1 % gelatin, 0 .0 1 % chrome alum 
solutionand allowed to dry before emulsion (Ilford) was applied.
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2.5.5.5 Autoradiography
All autoradiographic procedures were carried out in darkroom conditions illuminated 
with Kodak 904 filtered light. Slides were dipped in a 45°C, 50% solution of Ilford K5 
emulsion / 1% glycerol. The emulsion was allowed to dry for 1.5-2 hours in a light­
tight environment. Dry slides were stored in light-tight boxes with dessicant at 4°C 
prior to developing. The period of storage (7-14 days) was governed by the expression 
levels of the mRNA under investigation.
After the sections had been exposed for an appropriate period of time they were 
developed at room temperature by agitation in 20% Phenisol (Ilford) for 3 minutes, 
followed by 30 seconds in 1% acetic acid, then 30 seconds in Milli-Q water and fixed 
in a fresh 30% solution of sodium thiosulphate for 5 minutes. The developed slides 
were washed in cold running water for a minimum of 1 hour before staining.
2.5.5.6 Staining Radioactive In Situ Slides
Slides were stained in filtered Harris’ haematoxylin (Gurr) for 30 seconds and rinsed in 
running tap water for 1 minute. The stain was fixed in Scott’s Tap Water (20g MgS0 4 , 
2 0 gNaHCO3/ litre of water) and the slides rinsed in running tap water for 1 minute. 
The slides were then prepared for mounting in Gurr’s DePeX Neutral Mounting 
medium (BDH).
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2.6 Protein Analysis
2.6.1 Extraction of Protein from Frozen Tissue
Protein was extracted from tissues which had been snap frozen in liquid nitrogen and 
stored at -70°C. Tissue was first ground with a mortar and pestle, then transferred to a 
15ml (Falcon 2059) tube containing 1ml lysis buffer (25mM Tris pH7.4, 150mM 
NaCl, 1% Nonidet P40(Sigma), ImM EDTA, 2mM EGTA, lOmM NaF, ImM DTT 
plus the protease inhibitors leupeptin, aprotinin, and PMSF, all 50|ig/ml (Sigma)). The 
tissue was incubated in lysis buffer on ice for 30 minutes. Lysis mixture was 
transferred to eppendorfs and centrifuged in a benchtop microfuge at 14000rpm for 10 
minutes. Supernatant was collected and stored at -20°C until needed.
Protein concentration was determined using the Lowry method. A series of bovine 
serum albumin (BSA, Sigma) standards were made up in water (0 -  500p,g/ml). 80pl 
of protein sample (diluted 1:25 in water) or BSA standard was added to 800 |li1 Solution 
A (2% NazCOs in O.IM NaOH, 1% CUSO4  in water, 2% NaK tartrate in water, 
combined freshly in a ratio of 98:1:1 respectively) and incubated at room temperature 
for 10 minutes. 80|il Folin’s reagent (freshly diluted 1:1 with water) was added, 
samples were mixed and incubated in the dark at room temperature for 45 minutes. 
Samples and BSA standards were measured spectrophotometrically at O D 7 5 0  and 
protein concentration was deteimined from the ensuing standard curve.
2.6.2 SDS-PAGE Separation of Proteins
SDS-PAGE separation of proteins was carried out using a 10% separating gel and a 
5% stacking gel. The separating gel consisted of 6.5ml 30% acrylamide/bisacrylamide 
(Sigma), 5.1ml solution A (1.5M Tris, 0.4% SDS, pH8 .8 ), 7.7ml sterile water, 195pl 
fresh 10% ammonium persulphate (APS), 19.5|l i 1 TEMED (Sigma). Stacking gel 
contained 1.9ml 30%acrylamide/bisacrylamide, 3.2ml solution B (0.5M Tris, 0.4%
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SDS, pH6.8), 6.8ml water, 60pl 10% APS, 12pl TEMED. A Imm-thick gel was 
poured and allowed to set for at least 1 hour. 40-50jig total protein in a total volume of 
60 |li1 was added to the 2 x  sample buffer (160mM Tris-HCl pH6.8, 4% SDS, 20% 
glycerol, 0.02% bromophenol blue, freshly added lOOmM DTT) and heated at 85°C for 
5 minutes. Samples were loaded on to the gel alongside a Rainbow molecular weight 
marker (Amersham) and electrophoresed in running buffer (0.025M Tris, 0.2M 
glycine, 0.1% SDS, pH8.3) at 125V until the samples had stacked at the stacking gel / 
separating gel interface. The voltage was then increased to 200-250V until bands had 
separated as desired.
2.6.3 Western Blotting
The separated proteins in the SDS-PAGE gel were transferred onto a membrane 
(Hybond ECL, Amersham) in transfer buffer (0.025M Tris, 0.192M glycine, 20% 
methanol). A Biorad electroblot apparatus was used to transfer at 30V overnight in the 
cold room followed by 1-2 hours at 60V the following morning. The membrane was 
then rinsed in Tris-buffered saline (25mM Tris, 125mM NaCl, pH8.0) before probing.
The membrane was incubated in blocking buffer (O.OIM Tris pH7.5, O.IM NaCl, 0.1% 
Tween 20 (Sigma), 2% BSA) for 2 hours at room temperature on a rocking platform. 
Primary antibody at the required dilution was added to dilution buffer (O.OIM Tris 
pH7.5. O.IM NaCl, 0.1% Tween 20, 1% BSA) (see table 2.3) which was incubated 
with the membrane for 1 hour at room temperature. The membrane was given three 
sets of washes: 2x 5minutes in wash 1 (O.OIM Tris, O.IM NaCl, 0.1% Tween 20), 2x 5 
minutes in wash 2 (O.OIM Tris, 0.5M NaCl, 0.1% Tween 20) and 2x 5 moinutes in 
wash 1 again. The secondary horseradish peroxidase (HRP)-conjugated antibody was 
diluted in dilution buffer (ususally 1:5000) and applied to the membrane for 1 hour. 
Washes were repeated as before and the labelled proteins were detected using an 
Amersham ECL kit where the HRP-catalysed oxidation of luminol results in emission 
of light. Membranes were wrapped in clingfilm and exposed to Amersham Hyperfilm 
ECL for between 10 seconds and 1 hour before being developed in a Fuji X-ray film 
processor RGII.
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2,7 Histochemistry
2.7.1 Preparation of Slides
Microscope slides were dipped in a 2% 3-Aminopropyl-triethoxysilane (TESPA, 
Sigma) in acetone solution for 5 seconds followed by two washes in acetone and two 
in Milli-Q water. The slides were baked dry at 42°C before storing in boxes at room 
temperature.
2.7.2 Preparation and Sectioning of Paraffin-Embedded Tissues
Tissues were fixed overnight in 4% PEA at 4°C with continuous rotation. The 
following day, the sample was washed in PBS (30 mins), ethanol : 0.85% saline mix (1 
: 1) (2 X 15mins) and 70% ethanol (2 x 15mins). The tissue could be stored at this 
stage for an indefinite period. Processing of the tissues was done through a Shandon 
Citadel Automatic Processor which consisted of 3 washes in methanol, 1 wash in 
100% ethanol, 3 washes in xylene and 2 washes in paraffin wax. The tissues were 
embedded in paraffin wax in a suitable orientation and stored at 4°C.
Tissues embedded in paraffin wax blocks were placed on a microtome and 6pm serial 
sections cut. These were floated onto Milli-Q water at 42°C. TESPA-coated slides 
were placed under the floating sections and used to pick them up. The slides were then 
covered and left to dry at 42°C. Sections were stored at 4“C.
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2.7.3 Pretreatment of Sections before Staining
Dewaxing and rehydration of the sections was performed before any staining 
procedure. Slides were placed in microscope slide holders, and soaked in Histoclear™ 
for two 7 minute periods. This was followed by two 2 minute immersions in 100% 
ethanol, then a single immersion for 2 minutes in each of 90%, 80%, 70%, and 50% 
ethanol dilutions. The sections were then ready for staining.
2.7.4 Dehydration and Mounting of Sections
Following staining, the slides were dehydrated through an ethanol series (30%, 50%, 
70%, 90%, 100% and 100%) for 2 minutes each, followed by two soaks in 
Histoclear™ the first 2 minutes, then 7 minutes. Coverslips were mounted onto the 
sections using Gurr’s DePeX Neutral Mounting medium (BDH) in a fume hood, and 
left to dry overnight.
2.7.5 Haematoxylin and Eosin Staining
Following dewaxing and rehydrating, sections were stained in filtered Harris’ 
haematoxylin (Gurr, BDH) for 10-30 seconds, then rinsed in running tap water for 1 
minute. The stain was fixed in Scott’s Tap Water (20g MgSO^, 20gNaHCO3/ litre of 
water). Following a further rinse in running water, sections were stained in filtered 
eosin (5g eosin (Gurr), 50ml saturated acetic picric acid, 400ml water, 2.5g potassium 
dichromate, 50ml ethanol, added in that order / 500ml stock; the stock was diluted 1 in
4.5 with water for a working concentration) for 30 seconds, then rinsed briefly in 
running water. Sections were then rehydrated and mounted as described above.
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2.7.6 Antibody Staining
Sections were dewaxed and rehydrated as described above. The sections were washed 
three times in PBS, 5 mins each wash, before blocking endogenous peroxidase by 
incubation with 1.2% hydrogen peroxide in methanol for 20 mins. Three 5 minute 
washes in PBS were followed by incubation with proteinase K (20 pg/ml) in 50mM 
Tris pH 8.0 for 15 minutes. After three 5 minute washes in PBS, 20-50 pi blocking 
solution was applied to the sections for 30 mins (0.1% gelatin, 0.1% BSA and sheep 
serum in PBS). Most of the blocking solution was removed and primary antibody was 
applied. If dilution of the antibody was required, dilution was done in blocking 
solution (as above) at the dilutions shown in table 2.3. Slides were incubated in a 
humidified chamber for either 2 hours at room temperature or overnight at 4°C. Small 
pieces of coverslips were laid on top of the sections to spread antibody uniformly over 
the section and to prevent the section from drying out.
Coverslips and antibody were removed by washing three times with PBS containing 
0.1% sheep serum and 0.1% BSA (5 minutes per wash). A biotinylated secondary 
antibody was diluted in blocking solution (see above) and applied to the sections for 60 
minutes at room temperature. The sections were washed 3 times as before and 
incubated with an avidin-biotin complex (ABC kit, Dako) for 30 minutes. After 
washing, 3,3’-diaminobenzidine tetrahydrochloride (DAB, Sigma) was applied for 1-6 
minutes until the brown signal appeared. The sections were then placed in water, and 
rinsed under a running tap. Sections were counterstained with Harris’ haemotoxylin 
(Gurr) for 30 seconds and after washing in tap water they were dehydrated and 
mounted as described above.
2.8 Statistical Methods
When it was impossible to determine whether the data being analysed followed a 
Gaussian (or normal) distribution, non-parametric statistical tests were carried out. The
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Mann-Whitney rank sum test was employed when comparing two data groups and, for 
three or more data groups, the Kruskal-Wallis test was performed.
In comparing tumour formation in two different K5-RAS transgenic lines, the data 
was plotted as a Kaplan-Meier survival curve with the endpoint being age at onset of 
tumour (as opposed to death). A log-rank test was performed to compare the sastistical 
significance of difference between the two ‘survival curves’.
Statistical tests were carried out using GraphPad Prism version 3.0a for Macintosh.
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Table 2.1 Sequences of primers used in polymerase chain reactions
Allele Primer
Name
Primer Sequence 
5’ to 3’
Annealing
temperature
T g f^ l WT 95
96
97
98
GCGGACTACTATGCTAAAG
GGTCACCCGCGTGCTAATGG
CGTGCGCCTGTCGCTTTCTG
GAGAGTAAGCCCACTAGAG
58°C
rg /p iK O TGF
PGK
AGGGAGCTGGTGAAACGGAA
TCCATCTGCACGAGACTAGT
5 8T
SV40 polyA SVl
SV2
GGACAAACTACCTACCTACAGAGATTTA
ATTCATTTTATGTTTCAGGTTCAG
58°C
Tp53 WT P53W1
P53W2
GTGTTTCATTAGTTCCCCACCTTGAC
CTGTCTTCCAGATACTCGGGATAC
5 5 T
Tp53 KO P53M1
P53M2
GGGACAGCCAAGTCTGTTATGTGC
TTTACGGAGCCCTGGCGCTCGATGT
5 5 T
K5-/ÎA5 tcrl
tcr2
ATGGGGAGACGTGCCTGTTG
GTCCTGAGCCTGCCGAGATTC
55°C
K10-BCL2 KIO
Bcl-K
TTGGGGCTGGTGATTACTTA
CCGCATCCCACTCGTAGC
60"C
BCl
BC2
GCCTCTGTTTGATTTCTCCTG
CTGATTCGACGTTTTGCC
54°C
Tsh^ TSHl
TSH2
TCCTCAAAGATGCTCATTAG
GTAACTCACTCATGCAAAGT
55“C
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Table 2.2 Templates and probes used for radioactive in situ hybridisation
cDNA Plasmid Linearised
By:
RNA
Polymerase
Probe
length
Reference
Human BCL-2 pBluescript
SK+
X bal
(antisense)
T7 600bp Allsopp et al, 
1993
Human BCLr2 pBluescript
SK+
Kpn I 
(sense)
T3 600bp Allsopp et al, 
1993
SV40 polyA pBluescript
SK-
Kpn I 
(antisense)
T3 900bp Mulligan et al, 
1979
SV40 polyA pBluescript
SK-
Sac I 
(sense)
T7 900bp Mulligan et al, 
1979
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Table 2.3 Antibodies used in Western Blotting and Immunohistchemistry
Antibody Catalogue
no.
Specificity Western blotting 
dilution
Immunohistochemistry
dilution
BrdU
(Amersham)
RPN 202 - - No dilution
BAX
(Pharmingen)
Human and 
mouse
1 :750 1 : 500
BCL-2 (100) 
(Santa Cruz 
Biotechnology)
SC-509 Human only 1: 1000 -
BCL-2 (N-19) 
(Santa Cruz 
Biotechnology)
SC-492 Human and 
mouse
- 1:400
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Chapter 3 
RESULTS
3.1 Introduction
TGppi is an inhibitor of epithelial cell growth and can alter the differentiative 
properties of kératinocytes. It has also been shown to be an inducer of apoptosis in 
some cell types (Oberhammer et al, 1991; Rotello et al, 1991; Lin and Chou, 1992). 
Our lab showed that Tgf^l mRNA and protein is induced in suprabasal kératinocytes 
in vivo in response to hyperplasia (Akhurst et al, 1988; Fowlis et al, 1992) which 
suggests that it plays a role in the regulation of epidermal homeostasis. To investigate 
this phenomenon, transgenic mice had been generated using a keratin 10 (KIO) 
promoter to drive expression of Tgjf>\ in the suprabasal keratinocyte compartment. 
Surprisingly, these mice showed a two- to three-fold increase in epidermal DNA 
labelling index over control mice (Cui et al, 1995). Possible explanations for this include 
firstly, that at a low concentration, Tgf]3 can directly elevate mitosis, perhaps via 
effects on the extracellular matrix. Secondly, Tgfp may be inducing the migration of 
basal kératinocytes into the suprabasal compartment (i.e. induction of differentiation). 
Finally, there may be an induction of apoptosis by Tgfp which leads to a 
compensatory increase in proliferating cells in order to maintain epidermal 
homeostasis.
3.2 Increased proliferative index in K10-7g/pl mouse skin is not mediated via 
p53
One of the molecules most commonly associated with apoptosis (or programmed 
cell death) is the tumour suppressor p53, and many apoptotic pathways have been 
shown to occur via a p53-dependent mechanism (Lowe et al, 1993; Clarke et al, 1994; 
Lin et al, 1995). Also, p53 has been implicated in the control of grovyth of various 
systems (Cajot et al, 1992; Finlay, 1992). In order to test whether p53 was involved in 
the elevated proliferation index of K10-7g/pl mouse epidermis, the K10-7g/pl
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transgenic mice were crossed with a Tp53 knockout line which was available in the lab 
at the time.
The Tp53 knockout mice were bred onto a NIH genetic background (from a FVB 
background) so as to reduce variation due to strain background since the K10-7g/pl 
line (H-line) was already on the NIH background. The H-line transgenic mice were then 
crossed with the 7)?55-knockout mice to generate H-line mice either wild-type, 
heterozygous or homozygous null for Tp53. Two generations of transgenic breeding 
were necessary to achieve the desired transgenic genotypes. The breeding protocol is 
outlined in figure 3.1 A. Mice were genotyped by PCR. To determine Tp53 status, two 
separate PCRs were carried out as shown in figure 3.IB. One set of primers detected 
the presence of the endogenous Tp53 gene giving a band of 385bp. The other reaction 
used primers which amplified a 512bp fragment indicating the presence of the 
disrupting knockout cassette (see figure 3.IB). The presence of the H-line transgene 
KlO-Tg/pl was detected using primers which amplified a 580bp fragment of the SV40 
polyA fragment of the transgene as in figure 3.1C.
Female mice that were either wild-type {Tp53^ '^ )^ or homozygous null (Tp53'^') with 
respect to their Tp53 genotype were chosen for analysis. At 11-12 weeks of age, the 
mice were injected with BrdU, 1 hour later the mice were culled and a strip of dorsal 
skin was taken for paraffin histology. Skin sections were labelled with an anti-BrdU 
antibody (see figure 3.2), counterstained with haematoxylin and the number of BrdU- 
positive cells present in the interfollicular epidermis were counted.
The results are presented in Table 3.1 and in graph form in figure 3.3. Firstly, the 
results show an increased BrdU labelling index when the K10-7g/pl transgene is 
present (compare p53+/+, H-ve column with p53+/+, H+ve column) which is as 
expected from previous experiments (Cui et al, 1995). The difference reported 
previously was a two- to three-fold increase when H-line homozygote mice were 
compared to NIH controls. In this experiment, the H-line mice are a mixtui’e of 
heterozygotes and homozygotes (in fact, a 2:1 heterozygote:homozygote ratio) which 
explains why the difference is not so pronounced.
This experiment suggests, however, that p53 does not play a pivotal role in the 
mechanism by which increased Tgfp leads to increased cellular proliferation in these 
transgenic mice. Comparison with the other two columns in figure 3.3 (H-ve and H+ve 
on a p53-null background) shows that mice with no functional p53 behave no
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Figure 3,1
Breeding scheme and genotyping of Tp53 and KlO-Tgf^l knockout mice
A. Breeding scheme for crossing Tp53 knockout mice with H (KlO-Jg/pl) line 
mice
p53’^ ' represents a mouse which is homozygous for the Tp53 knockout allele 
p53* '^ represents a mouse which is heterozygous for the Tp53 knockout allele 
p53+^ represents a mouse which is wild-type with respect to its Tp53 status
H/H represents a mouse which is homozygous for the K10-7g/pi transgene 
H/+ represents a mouse which is heterozygous for the K lO -7 ^ 1  transgene 
+/+ represents a mouse with no K10-7g/pl transgene.
Fractions represent the expected Mendelian ratio of each genotype from the cross shown.
B. Determination of Tp53 knockout genotypes by PCR
M (marker): Ikb DNA ladder (Gibco BRL)
Two separate PCR reactions were can ied out on each DNA preparation. 
The first reaction detected the Tp53 wild-type allele.
The second reaction detected the Tp53 knockout allele.
Therefore, in the gel shown above, 
mice 1 and 2 are Tp53 null: p53‘^’ 
mice 3 and 5 are Tp53 heterozygous: p53^' 
mouse 4 is Tp53 wild-type: p53^ ^^
C. Determination of the presence of the KlO-Jg/pl transgene by PCR
Primers SVP2 and SVP3 were used to amplify a region of the SV40 poly A fragment of the KlO-Tg/pl 
transgene.
M (marker): Ikb DNA ladder (Gibco BRL)
Lanes 1,2,3,6: K lO -T ^ l positive: H/+ or H/H 
Lanes 4,5: K10-7g/pl negative: +/+
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pS3T" X H/H
+/+p53
H/+
p53+'- X p53 
H/+ I H/+
+ /- +/+p53
H/+
,+/+p5T
H/H H/+ +/+
,+/-p53
H/H H/+ +/+
p53
H/H H/+ +/+
1/16 1/8 1/16 1/8 1/4 1/8 1/16 1/8 1/16
B
512bp {Tp53 null allele) 
385bp {Tp53 WT allele)
-580bp (K lO -rg/p l allele)
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Figure 3.2
Labelling of mouse skin with bromodeoxyuridine (BrdU)
D
#
BrdU staining showing a cell of the interfoliicular epidermis and a cell of the hair follicle in S-phase. 
Mice had their dorsal skin shaved 24 hours before administraton of BrdU and only those animals 
showing no hair regrowth selected, to ensure that the skin was not in a hair-growing cycle (anagen). 
Mice were injected with 50pg BrdU/g body weight one hour before sacrifice. On sacrifice a strip of 
dorsal skin was taken and fixed in 4% paraformaldehyde and subjected to immunohistochemistry with 
an anti-BrdU antibody (Amersham).
Arrows indicate BrdU+ve cells - one in the interfoliicular epidermis and the other in the hair follicle. 
E: epidermis 
D: dermis 
H: hair follicle
Bar, 100pm
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Table 3.1
BrdU labelling indices of interfoliicular cells of skin epidermis from mice 
produced by crossing KlO-Tg/pl transgenics with Tp53 knockout mice
GENOTYPE P53+/+, H-ve P53+/+, H+ve P53-/-, H-ve P53-/- ,H+ve
0.65 1.23 0.64 0.44
1.46 1.44 0.35 1.57
0.76 1.19 0.94 1.3
0.67 2.1 1.19 3.1
BRDU 1.07 1.78 0.51 1.82
Labelling 1.07 2.61 0.57 1.68
Index 0.87 2.85 2.06 1.95
0.32 1.1 1.92 2.48
0.5 1.36 0.62 2.39
1.44 1.53 0.74
1.51 1.2 1.1
0.2 0.78 0.58
0.98 0.69 0.95
0.47 0.69
MEAN 0.855 1.45 0.92 1.54
+/-SD +/- 0.40 +/- 0.64 +/- 0.59 +/- 0.77
MEDIAN 0.82 1.78 0.64 1.57
H+ve denotes mice that carry the KlO-Tg/pi transgene in either the heterozyous or homozygous state.
Each number represents the labelling index of a single mouse. Labelling index shown is the number of 
BrdU-positive cells per 100 basal cells of interfoliicular epidermis. A minimum of 1000 cells was 
counted for each skin section and two sections were assayed from each mouse.
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Figure 3.3
Loss of p53 does not affect the increased BrdU labelling index in the epidermis of 
H-line (K10-7g/pl) mice
2.5
1.5
BrdU
L a b e l l in g
In d ex
0.5
p53+/+,H-ve p53+/+,H+ve p53-/-,H-ve
G e n o t y p e
p53-/-,H+ve
The BrdU labelling indices represent the mean of the scores for each genotype shown in Table 3.2 i.e. 
the labelling index is the mean number of BrdU+ve cells per 100 basal cells of the interfoliicular 
epidermis.
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differently than those wild-type for p53 function in terms of cellular proliferation in 
the epidermis. In the presence of elevated cellular proliferation, yet no hyperplasia, one 
must postulate an increase in apoptosis or differentiation whereby cells slough off 
more rapidly from the skin surface. Whether or not Tgfpl induces apoptosis directly 
or indirectly, this process must be p53-independent.
3.3 Neither increased suprabasal Tgf|3l nor loss of p53 affects Bax expression
Another important player in many apoptotic pathways is the Bcl-2 family member 
Bax. Bax has been shown to promote apoptosis in certain cell types (Oltvai et al, 
1993). Some work suggests that Bax might act downstream of p53 (Selvakumaran et al, 
1994; Miyashita and Reed, 1995; Yin et al, 1997). Similarly, there have been studies 
which have found that Bax is up-regulated during TGF(31-induced apoptosis 
(Teramoto et al, 1998). Therefore, epidermal skin sections from the KlO-Tg/p 1/2)755 
knockout cross were stained with an anti-Bax antibody to assess protein expression in 
the various ZpJi/KlO-Jg/pl genotypes.
Bax staining was observed throughout the epidermis, in both basal and suprabasal 
cells, as shown in figure 3.4. However, no difference in Bax levels was found between 
genotypes, whether Tp53 null or KlO-Tg/pl positive. This shows that firstly, 7g/pl 
overexpression in skin epidermis does not lead to an increase in Bax levels and 
secondly, absence of p53 does not affect Bax production in the skin as determined by 
immunohi stochemistry.
3.4 Nullizygosity for Ig/pl does not alter epidermal proliferative index
Previous work in the lab had shown that a line of mice overexpressing Tg/p 1 in the 
suprabasal layer of the epidermis had an increased BrdU labelling index in the 
suprabasal layer of the epidermis. Glick et al (1993) had shown that the Tg/pl 
knockout mice also had an increased BrdU labelling index, which contrasts with the 
data of Cui et al (1995). The results of Glick et al could be due to indirect effects of 
loss of Tgj^l since the Tgfpl null animals have neither epidermally nor dermally- 
derived Tgfpl. However, their data were obtained from only four mice which were of 
disparate ages between 2 and 5 weeks post-partum. In this type of experiment, with 
potentially large biological variation, we felt that this was inadequate, especially as the 
skin undergoes such profound changes in the first 3 to 4 weeks of life. We therefore
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Figure 3.4
Immunohistochemical Bax expression in mouse epidermis is affected neither by 
loss of p53 or overexpression of 7g/pl
f
B
Skin was fixed in 4%PFA, embedded in wax, cut into 6|o,m sections and stained with mouse anti-Bax 
antibody (A) as described in Materials and Methods, bax protein staining is cytoplasmic and is present 
throughout all layers of the epidermis. There were no qualitative or obvious quantitative differences in 
staining. (B) shows a no primary antibody control.
Bar: SO^m
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decided to examine this issue by re-assessing BrdU labelling index in the colony of 
Tgfpl null mice.
An initial study was carried out assessing how many Tgfpl "^ ' mice survived to birth 
and to what age they survived. Heterozygous 7g/pl knockout mice were intercrossed 
as in figure 3.5A. Pups were genotyped by PCR on death if before 3 weeks of age, or 
after tail-tipping at weaning as shown in figure 3.5B. It was found that approximately 
60% of the expected 7g/pl null mice were born and the spread of age at death is 
illustrated in figure 3.6.
It had become clear from concurrent studies in our lab that 2g/pi knockout mice 
have a variable penetrance of prenatal lethal phenotype which depends on mouse 
strain. For example, on a C57/B16 background, no 7g/pl null mice survive to birth, 
whereas on aNIH background, 70-80% of null mice are born (see Bonyadi et al, 1997 
for details). The mice we had were on a mixed genetic background (50% NIH, 37.5% 
C57B1/6J, 12.5% 129SV). Some of these mixed background mice were therefore bred 
through at least 3 generations with NIH stock until the 7g/pl knockout allele was on a 
93% NIH background and both mixed and inbred NIH backgrounds were analysed.
Four litters from the mixed genetic background and three litters with the NIH 
background were injected with BrdU at 21 days of age and dorsal skin was harvested 
one hour later. A piece of tail was taken for genotyping and BrdU-positive cells in the 
dorsal interfoliicular epidermis were counted.
This experiment showed no significant difference in the number of epidermal cells in 
S phase between 7g/pl knockout mice and either heterozygote or wild-type littermates 
(see Table 3.2 and figure 3.7), unlike Glick et al (1993), who found a 3- to 5-fold 
increase in BrdU labelling in skins of 7g/pl null animals compared to heterozgote and 
wild-type animals.
One possible reason for the discrepancy between these results and the results of 
Glick et al is the difference in genetic background of the two TgfÇ>\ knockout lines. On 
a mixed genetic background there appeared to be greater variation among BrdU labelling 
indices compared to mice on a NIH genetic background. The genetic background of the 
mice analysed by Glick et al is not defined but appears to be a mixed background. Even 
among the two wild-type and four heterozygote Tgf^l knockout mice in their study, 
labelling index varied between 1.7 +/- 0.4 and 8.2 +/- 2.6 BrdU-positive cells per total 
basal nuclei. A further difference between the two studies is that, of the three litters
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Figure 3.5
Breeding scheme and genotyping of Tgf^l knockout mice
A. Breeding protoeol used to generate Tgffil null mice
tgfbl'^' represents a mouse which is homozygous null for Tgf^l 
tgfbU^' represents a mouse which is heterozygous null for Tg/pl 
tgfbr'' represents a mouse which is wild-type at the Tgj^l locus
Fractions represent the expected Mendelian ratio of each genotype bom assuming no 
prenatal loss.
B. Wild-type and knockout Tg/pl alleles and PCR reaction used to genotype the 
mice
Two separate PCR reactions were carried out on each DNA preparation.
The first reaction, using primers 95-98, detected the TgJ^l wild-type allele.
The second reaction, using primers TGF and PGK, detected the knockout allele.
M (marker): Ikb DNA ladder (Gibco BRL)
In the gel shown opposite:
mouse 1 is heterozygous tgfbl^^ 
mouse 2 is wild-type tgfbl^^^ 
mouse 3 is null tgfbl ^
mouse 4 is heterozygous tgfbl*^
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Figure 3.6
Average age of death of Tgfpl null mice
No. of 
mice
10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44
Age of death
Graph shows the spread of ages of death of Tgfpl null mice.
The mice have a mixed genetic background: 50% NIH, 37.5% C57B16, 12.5% 129SV
Total no. of Tgfpl null mice examined =35
Mean age of death: 23.3 days
Median age of death: 20.5 days
85
Table 3.2
Incorporation of BrdU into proliferating cells of the interfoliicular epidermis in 
21-day old Tgfpi-null mice and their wild-type littermates
Mixed Genetic Background (50% NIH, 37.5% C57B16,12.5% 129SV)
Wild-type tgfpl null
Litter 1 3.6
1.7 
2.3 
2.0
1.25
1.3
Litter 2 0.8
1.9
1.3
Litter 3 1.65
0.8
3.25
2.25
Litter 4 3.3 2.6
2.1
0.8
Median 2.2 2.0
Mean +/- S.D. 2.0 +/- 0.9 1.9+/- 0.8
93% NIH Genetic Background
Wild-type tgfpl null
Litter 1 0.66 0.4
0.42 0.6
Litter 2 0.9 1.1
1.1
Litter 3 0.9 1.0
0.75 0.4
Median 0.76 0.75
Mean +/- S.D. 0.8 +/- 0.2 0.7 +/- 0.3
Each number represents the labelling index of a single mouse. Labelling index shown is the number of 
BrdU-positive cells per 100 basal cells of interfoliicular epidermis. A minimum of 1000 cells were 
counted for each skin section and two sections were assayed from each mouse.
86
Figure 3.7
Incorporation of BrdU into proliferating cells of the interfoliicular epidermis 
in Tg/pl-null mice and their wild-type littermates
Mixed Genetic Background
Wild-type
TGFb-null
Litter 1 Litter 2 Litter 3 Litter 4
1.5-,
NIH Genetic Background
I Wild-type 
iTGFb-null
Litter 1 Litter 2 Litter 3
3 -,
3  2 -
Ü
3
Combined BrdU Counts
W ild -ty p e
TGFb-null
Mixed Total NiH Total
Genetic Background
Each bar represents the average BrdU labelling index of all the wild-typeb or Tgfpl-null mice in each litter 
shown in Table 3.2. Combined BrdU counts represents the pooled data of the litters within each genetic 
background.
TGFb-null = Jg/pl-null
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analysed by Glick et al, two were 5 weeks old and one was 3 weeks old whereas mice 
in this study were all analysed at precisely 21 days, and when the mice were not in a 
hair-growing phase of the hair cycle.
3.5 Suprabasal Tgfpi Increases keratinoeyte proliferation in both wild-type and 
Tgfpi null mice
To further investigate the action of the KlO-Jg/pl transgene, it was decided to cross 
the transgenics onto a 7g/pl-null background. It was a possibility that epidermally 
targetted Tgfpl from the transgenic mice could act in an endocrine manner to rescue 
2g/pr^' mice from their lethal phenotypes. This cross would also be interesting in 
assessing the epidermal proliferation phenotype of the K10-7g/pl transgene on a 
Tgfpl-null background.
Two generations of breeding were necessary to produce animals with the full range 
of genotypes for littermate comparisons. Firstly, an animal heterozygote for the Tgf^l 
knockout allele was crossed with a female which was homozygous for the K10-7g/pl 
transgene. Offspring were screened for the presence of the 7g/pl knockout allele (as 
shown in figure 3.5B) and males heterozygous for both the knockout and the KIO- 
7g/pl alleles were crossed with females of the same genotype (see figure 3.8 A).
This cross produced animals with a range of genotypes (see figure 3.8A). In this F2 
generation, the K10-7g/pl allele was screened by Southern blotting in an attempt to 
distinguish homozygote K10-7g/pl from heterozygote. An SV40 poly A probe and a 
probe specific for the cystic fibrosis transmembrane regulator {Cftr) gene (Tata et al, 
1991) were hybridised at the same time to a nylon membrane containing the F2 
generation mouse genomic DNAs which had been digested with BglH. Zygosity was 
estimated by comparing intensity of SV40 polyA bands using the Cftr bands as an 
internal control (see figure 3.8B).
As before, these mice were injected with BrdU and dorsal skins were harvested. 
Skin sections were labelled with an anti-BrdU antibody and labelled cells in the 
interfoliicular epidermis were counted. The counts are shown in table 3.3.
The first observation was that there was no obvious rescue of lethality of Tg/pF^' 
mice. Due to small numbers of Tg/pl null mice reaching weaning age, it proved 
impossible to generate sufficient numbers of all genotypes to achieve statistical
Figure 3.8
Generation and genotyping of Tgf^ X knockout X K10-7g/pl mice
A. Outline of breeeding scheme to generate 7g/pl knockout mice carrying the 
K10-7jg/pl (H) transgene
tgfbC'- X H/H
tgfbl*'  ^ tglbV X tgfbl ' tgfbr"
H/+ H/+ I H/+ H/+
tgfbl tgfbl '^- tgfbl'
H/H H/+ +/+ H/H H/+ +/+ H/H H/+ +/+
1/16 1/8 1/16 1/8 1/4 1/8 1/16 1/8 1/16
tgfbl""represents a mouse which is homozygous for the 7g/Pl knockout allele 
tgfbF^^ represents a mouse which is wild-type with respect to its 7g/pl status.
H/H represents a mouse which is homozygous for the KlO-Tg/pl transgene 
+/+ represents a mouse with no KlO-Tg/pl transgene.
B. Example of southern blot used to screen for K10-7g/pl transgene
1 2 3 4 5
Cftr -------  # #  # 0  « M t  M  "— 5 kb
KIO-  3.1 kb«  “L ' ■  M
or.   <■» W '  # »  M
Southern blot analysis o f genomic DNA from various 7g/pl knockout x H-line mice using the SV40- 
specific hybridisation probe to detect the transgene and the mCftr probe (Tata et al 1991) as an internal 
loading control
Lanes 1 and 4: Wild-type (+/+)
Lanes 3 and 5: Heterozygous for K I0-7g/pl transgene (H/+)
Lane 2: Homozygous for K10-7g/pi transgene (H/H)
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Table 3.3
Suprabasal Tgf^l expression increases BrdU labelling index in KlO-Tg/pl 
transgenic mouse epidermis on both a wild-type and Tg/pl-null background
GENOTYPE BRDU LABELLING INDEX
tg fb U 'U + /+ 1.1
2.1
1.8
tgfbU^^, H/+ 1.7
1.2
tgfbU^U H/H 3.5
4.9
tgfbU^-, +/+ 1.4
1.6
tgfbU^-, H/+ 2.1
tgfbU ' , H/H 4.1
tgfb l  ^ , +/+ 1.3
1.8
tgfb l '- , H/+ 2.5
1.1
1.0
tg fb l ' , H/H 3.6
Each number represents the labelling index o f  a single mouse. Labelling index shown is the number o f  
BrdU-positive cells per 100 basal cells o f  interfoliicular epidermis. A minimum o f 1000 cells was 
counted for each skin section and two sections were assayed from each mouse.
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significance; even assuming no prenatal lethality, only one in sixteen mice born from 
the cross would be both null for 7g/pl and homozygote for the K10-7g/pl transgene. 
However, from the mouse skins that were analysed, some observations were made. 
BrdU labelling indices from this cross suggest that the K10-7g/pl transgene enhances 
basal cell proliferation even in the complete absence of endogenous Tgfpl. One 
possible explanation for this is that the transgene effect is not solely due to a general 
over expression of Tgfpl. Instead, the increased basal cell proliferation may be ascribed 
to the perturbed Tgfpi production in the particular cellular compartment of transgene 
expression. An alternative explanation is that endogenous Tgfpl levels are near to zero 
in the epidermis. Hence, in terms of the epidermis, Tg/pT^’ mice are not much different 
than wild-type mice. However, clearly, increasing Tgfpl does have an effect, therefore 
there must be Tgfp receptors present.
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3.6 Characterisation of K10-J7CZ-2 Transgenic Mice
3.6.1 Introduction
BCL-2 is a central player in research on apoptosis (for review see Hockenbery, 
1995; Korsmeyer, 1999). It has been shown to be an inhibitor of apoptosis in various 
systems, although its relevance in skin is still being determined. Two lines of Bcl~2 
transgenic mice that had not yet been analysed in terms of expression of their 
transgenes became available by collaboration with Dr D. Fowlis at the Centre for 
Genome Research, Edinburgh. The same transgene was utilised to generate both lines 
and consisted of a bovine KIO promoter, a rabbit beta-globin intron (for efficient RNA 
processing and nuclear export), a human BCL-2 cDNA with some V  non-coding 
sequence and a human growth hormone poly-adenylation signal (see figure 3.9). 
Therefore, BCL-2 was targeted to the suprabasal compartment of the epidermis. 
Previous reports suggested that endogenous Bcl-2 expression was restricted to the 
basal layer of the epidermis (Hockenbery et al, 1991), and so these mice could provide 
an in vivo model to investigate the consequences of perturbed Bcl-2 expression in the 
epidermis.
3.6.2 Screening KlO-BCL-2 transgenic mice
The two transgenic lines originally received were named the B-line and C-line. The 
genetic background of the mice was [C57B16 x CBA]. A set of primers was designed to 
screen the mice. One primer annealed to the KIO promoter (KBCl), the other to the 
BCL-2 cDNA (KBC2) which together amplified a recombinant fragment of 830bp (see 
figure 3.9). Using this pair of primers ruled out the possibility of a false positive 
reaction occurring through human contamination.
This PCR was used to screen some of the original offspring of the B-line founder 
mouse sent from Edinburgh (figure 3.10A) This revealed a much higher proportion of 
mice carrying the K10-5CZ-2 transgene than expected. Therefore, the mice were re­
screened by Southern blot using the human BCL-2 cDNA fragment of the transgene as 
a probe. This revealed that some of the B-line offspring contained a low-copy number 
transgene insert (probably 2-3 copies) and some contained a higher-copy number insert 
(see figure 3.1 OB) i.e. the B-line founder had a double insert of the transgene. The high-
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Figure 3.9
Structure of KlO-BCL-2 transgene
KIO Promoter Intron
K Bg
BCL-2 polyA
K l iC I
RI B
KIÎC2
lîCI BC2
Bg K
KIO promoter: 5.5kb
Intron:
BCL-2:
polyA:
Promoter region of bovine cytokeratin VI gene 
Targets suprabasal cells of epidermis
650 bp
Intron fragment from rabbit beta-globin gene 
1.9 kb
760 bp of human BCL-2 cDNA followed by 1.1 kb 3’ non­
coding sequence
630 bp
Polyadenylation cassette from human growth hormone gene
Restriction sites: B: BamWl, Bg: BglW, E: £coRI, K: Kpn\
KBCl, 2: Primers used in PCR reaction shown in figure 3.10 
BCI, BC2: Primers used in PCR reaction described in figure 3.12
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Figure 3.10
Transgene status and screening of KlO-BCL-2 transgenic mice
A. PCR reaction to screen K10-RCZ.-2 transgenic mice
L 1 2 3 4 5 6 7
830bp
Analysis of PCR on tail DNAs using primers KBCl and KBC2 (see figure 3.9). 
L: Ikb DNA ladder
Lanes 1,2,5,7: Mice that are wild-type with respect to KlO-RCL-2 transgene 
Lanes 3,4,6: Mice carrying the K10-BCZ,-2 transgene
B. Southern blot analysis of transgenic KlO-BCL-2 and wild-type littermate 
DNAs probed with a human BCL-2 cDNA probe
Hi Hi -ve Lo Hi -ve
^ ___1.5kb (endogenous bcl-2)
1 ^ -----1.2kb ( transgene K10-BCL-2)
B-line mouse genomic DNAs were digested with BamHl and probed with the human 
BCL-2 cDNA. The probe hybridised as expected to a 1.2 kb fragment in the transgenic 
DNAs. It also hybridised to a 1.5 kb DNA fragment which corresponds to a BamWl 
fragment of endogenous mouse bcl-2.
Hi: Transgenic (high-copy) DNA 
Lo: Transgenic (low-copy) DNA 
-ve: Wild-type DNA
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copy insert appeared to have at least 50 copies of the transgene. The B-line was 
subsequently bred out to produce a new line: BL (low-copy). Attempts were made to 
differentiate between the mice with both the high copy and the low-copy integration 
and those with just the high-copy: the human growth hormone poly A fragment of the 
transgene was used as a probe on the Southern blot to check for different BamVÜ end 
fragments but this was uninformative. Also, Bglll and EcdBl were used in the initial 
genomic DNA digestion of other Southern blots in the hope of distinguishing different­
sized end fragments of the integrated transgenes. However, it was not possible to 
distinguish high-copy insert DNAs from those with both inserts.
The third line (C-line) had just one insert which contained multiple (>50) copies of 
the transgene. This was estimated by comparing the relative densities of the 
endogenous mouse Bcl-2 band (2 copies) with the transgene band.
3,6.3 RNA expression analysis of KlO-BCX-2 transgenic mice
To test for expression of the transgene, RNA was extracted from dorsal skin 
epidermis, tail skin epidermis and whole ear as described in Materials and Methods. 
Reverse transcriptase PCR (RT-PCR) was performed using a pair of Bcl-2 primers 
(BCI and BC2), designed to amplify a 300bp fragment of the human BCL-2 cDNA. 
This pair of primers was not species-specific and also amplified the equivalent 
endogenous mouse Bcl-2, The PCR products from the two species are the same size 
and veiy similar in sequence, but the mouse product contains a Sail site which the 
human does not (see figure 3.11 A). RNA extractions from the ears of the three 
transgenic lines and wild-type mice were reverse-transcribed; the resulting cDNA 
products were amplified with the BC1/BC2 primers (see figure 3.1 IB) and the 
products were then gel-purified (Geneclean^^) and digested with SaB. All three 
transgenic lines retained undigested PCR product whereas RNA from wild-type lines 
did not (figure 3.11C). Therefore all three transgenic lines seemed to be expressing 
transgenic RNA. A PCR using the KBCl and KBC2 primers on the cDNA products 
ruled out the possibility of contamination of the RNA preparations by genomic DNA.
Northern blot analysis was performed with independent RNA preparations. The 
strongest signal was seen with C-line ear RNA. The B and BL transgenic lines showed 
wealcer bands of the same size (see figure 3.12). The transgenic transcript is 
approximately 1.8kb, which is consistent with the size of the human BCL-2 insert
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Figure 3.11
Detection of human BCL-2 mRNA from the KlO-BCL-2 transgene through RT- 
PCR
A.PCR products of a reaction using primers BCI and BC2 yield products for 
both transgenic and non-transgenic cDNAs
Ear RNA preparations from wild-type and KlO-BCL-2 transgenic were reverse 
transcribed as described in Materials and Methods. The resulting cDNAs, as well as 
transgenic and wild-type genomic DNAs, were subjected to PCR with primers BCI 
and BC2 (see figure 3.9).
Genomic DNAs produce a PCR product as the binding sites for primers BCI and BC2 
lie within the same exon.
Contamination of cDNAs with genomic DNA was ruled out by demonstrating the lack 
of a PCR product sing primers KBCl and KBC2 (see figures 3.9 and 3.10).
Marker: Ikb DNA ladder
Lane T. PCR product of genomic C-line DNA
Lane 2: PCR product of genomic wild-type DNA
Lane 3: PCR product of cDNAs from wild-type ear RNA
Lane 4: PCR product of cDNAs from C-line ear RNA
B. Comparison of mouse and human sequences of the BCL-2 gene showing SaB 
site
The pair of primers BCI and BC2 amplifies both human and mouse BCL-2 cDNAs, 
The resulting PCR products are the same size and very similar in sequence except for 
certain single-base differences shown in red. One of these differences results in the 
presence of a Sail site in the mouse bcl-2 sequence which is absent in the human 
version.
C. Digestion of cDNAs with SaB yields cleaved mouse bcl-2 cDNA and uncleaved 
human BCL-2 cDNA
PCR products from A were cleaned, digested with SaB, and digests were run out on a 
1.8% agarose gel. PCR product of cDNAs from C-line ear RNA remain uncut, while 
that of wild-type ear RNA is digested. The same result is obtained with B and BL 
lines.
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500bp
298bp
Genomic DNAr cDNA
# 300bp
B
Sal\
murine bcl-l\ ...GGCCACAAGTGAGGTCGACAAACCT. 
human 5CI-2:...GGCCACAAGTGAAGTCAACATGCCT..
Genomic DINAr cDNA
300bp S'a/I-resistant 
human cDNA
190bp 1
r  5ûf/l-cleaved 
1 lObp J mouse cDNA
97
Figure 3.12
Northern blot showing expression of transgenic human BCL-2 mRNA in KIO- 
BCL-2 transgenic mouse skins
Wild-type B-iine BL-iine C-line
/ \  / \  \  / ------
Lane: E D T E D  T E D T  E O T
I
human 
BCL-2 
— 1.8 kb
B
I Gapdh
Northern blot analysis of wild-type and transgenic K\0-BCL-2 mice using 15pg total 
RNA per lane, probed with human BCL-2 DNA and a Gapdh (glyceraldehyde phopho- 
dehyrogenase) probe to determine loading.
E: RNA from whole ear
D: RNA from dorsal skin epidermis
T : RNA from tail epidermis
All three transgenic lines show expression of transgenic mRNA with the strongest 
being C-line.
RNA extracted from tail epidermis was degraded.
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without transcription of the downstream poly A fragment. This is not surprising, since 
the transgenic BCL-2 fragment contains a long 3’ untranslated sequence (1.1 kb) which 
probably contains sufficient processing signals for efficient mRNA production.
The probe used for the blot was the human BCL-2 cDNA fragment of the transgene. 
This fragment has 95% sequence similarity to its mouse equivalent but the probe did 
not pick up any endogenous mouse Bd-2 mRNA (expect 7.5kb and 2.4kb transcripts 
(Negrini et al, 1987)). This may indicate a relatively low endogenous Bcl-2 expression 
in the skin. The blot was also probed with Gapdh to check loading.
3.6.4 Human BCL-2 protein expression in KlO-BCZ-2 transgenic mice
Having shown RNA expression in all three transgenic lines, the next step was to 
determine whether the transcript was producing protein. Protein was extracted from 
ear, dorsal skin epidermis and tail epidermis as described in Materials and Methods. A 
Western blot was carried out with the skin protein extracts from the three lines. An 
antibody specific for human BCL-2 (i.e. which does not cross-react with mouse Bcl-2) 
picked up protein expression in the C-line (see figure 3.13). The size of the protein 
was as expected - approximately 26kDa.
3.6.5 KlO-BCL-2 transgene RNA expression and localisation by in situ 
hybridisation
To further qualify mRNA expression of the transgene in the C-line, various skin 
sections were subjected to in situ hybridisation. Using this technique it should be 
possible to identify individual cells which possess the RNA transcript under 
investigation. A combination of in situ hybridisation and immunohistochemistry can 
also, in certain cases, show differences between the site of mRNA synthesis and 
localisation of the final protein.
In the case of BCL-2, previous reports claimed that it was endogenously expressed 
in the basal layer of the epidermis (Hockenbery et al, 1991; Krajewski et al, 1994)). 
The KIO promoter should direct expression of the transgenic BCL-2 to the suprabasal 
layer. Since adult mice have a relatively thin epidermis in which it can be sometimes 
difficult to distinguish a suprabasal layer of cells, the skins of transgenic and control 
neonatal mice were also collected for analysis by in situ hybridisation. The skins of
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Figure 3.13
Expression of transgenic human BCL-2 protein by C-line transgenic mice
EAR SKIN
M NIH C57 B BL C
46
kDa
30
kDa
26kDa
human
BCL-2
21.5
kDa
The antibody used w as a hum an-specific BCL-2 antibody (sc509 , Santa Cruz).
50p g  total protein w as loaded in each lane except the positive control lane (500ng).
Human BCL-2 protein was detected in protein preparations from both ear and skin epiderm is 
o f  C -line m ice. The antibody appears to cross-react with a 50kD a protein -  possibly an 
abundant keratin.
M: Positive control fusion protein (bcl2A 21, Santa Cruz)
NIH: W ild-type NIH m ouse 
C57: W ild-type C57/B16 m ouse 
B, BL, C: K10-5CZ--2 transgenic lines
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these pups (2-5 days old) have a thicker epidermis, making identification of different 
layers of cells more apparent (see figure 3.14),
A 561 bp BamHI fragment of the human BCL-2 cDNA was subcloned into the 
pBluescriptll SK^ plasmid. Antisense and sense templates were generated using 
appropriate enzymes and polymerases. The templates were used to make probes 
labelled with ^^S-UTP and skin sections of C-line mice were then treated and probed as 
described in Materials and Methods. Following autoradiogaphy and development of 
the emulsion, the sections were stained with Harris’s Haematoxylin.
Strong but relatively patchy signal was observed in transgenic pup skin with no 
signal apparent in the negative littermates (see figure 3.15). [Under a high power (x40), 
the signal appears to be in mainly suprabasal cells of the epidermis (figure 3.15D)]. 
The signal Is not uniform with some cells showing strong mRNA signal and others very 
little or none. Adult transgenic epidermis also shows expression of the transgene 
transcript although the signal is weaker than that of neonatal skin.
A comparison of transgenic mice with their negative littermates shows that the C- 
line mice obviously express the human BCL-2 mRNA in the epidermis. The data from 
the neonate mice suggests that expression is suprabasal as expected. A surprising 
finding perhaps is the lack of any endogenous mouse Bcl-2 signal. The human BCL-2 
cDNA fragment used for the probe has 98% sequence homology with the equivalent 
mouse fragment and so if their was sufficient mouse Bcl-2 mRNA present it is 
reasonable to assume that the probe would have picked it up. As mentioned 
previously, several studies report BCL-2 protein expression in the epidermis. One 
possible explanation is that the protein may have a long half-life, and so relatively little 
RNA transcript is needed.
3.6.6 Localisation of transgenic human BCL-2 protein in suprabasal cells of the 
epidermis by immunohistochemistry
Having established that transgenic protein was being produced in the skin it was 
decided to investigate protein localisation in the epidermis with a BCL-2 antibody. 
Despite many variations of the labelling technique, it was not possible to detect 
transgenic protein in paraffin sections of C-line skin with the human-specific BCL-2 
antibody that had been used in the Western blot (section 3.2.4). Therefore, a second
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Figure 3.14
Epidermis of a neonatal mouse pup is thicker and contains more suprabasal 
layers than adult mouse epidermis
keratin
 ^ suprabasal
6pm paraffin sections of skin from adult mouse (A) and 4-day old mouse pup (B) were 
stained with haematoxylin and eosin. Neonatal epidermis has more pronounced 
suprabasal and granular layers than adult epidermis.
Bar: 50pm
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Figure 3.15
Localisation of BCL-2 transgene mRNA to the suprabasal kératinocytes of C-line 
neonatal mice by in situ hybridisation
Six-micron paraffin sections of C-line neonatal dorsal skin were subjected to in situ 
hybridisation using -labelled antisense human BCL-2 cDNA riboprobe.
Dark-field (A) and bright-field (B) images of the same section are shown. 
Staining of skin of a negative littermate (C) shows no positive staining.
(D) Higher magnification of B showing suprabasal signal of the transgene mRNA. 
In (D) the basement membrane is outlined to show the epidermis:dermis boundary.
Bars: 400pm (A,B,C) or 50pm (D)
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BCL-2 antibody (Bcl-2(N19)) was tried -  an antibody, according to the manufacturers, 
that should detect both human and mouse Bcl-2.
6pm sections of dorsal skin from both adult and neonate C-line mice (both 
transgenic and wild-type) were cut from paraffin blocks. Sections were labelled with 
BCL-2(N19) antibody as described in Materials and Methods. Slides were 
counterstained with Harris’s haematoxylin.
The BCL-2(N-19) antibody detected differences between the transgenic and non- 
transgenic skins in both adult and neonate mice. In adult mice, transgenics showed a 
distinct staining pattern compared to negatives and this tended to be suprabasal when 
different epidermal layers were distinguishable (see figure 3.16). Transgenic neonates 
also had suprabasal staining. With these skins, there was a more noticeable patchy 
expression of the transgenic protein with some individual cells heavily stained (see 
figure 3.17)
As mentioned, this antibody should pick up both human and mouse BCL-2 (in this 
case, transgenic and endogenous). In negative skins there was weak staining of the 
epidermis, and this tended to be uniform throughout the different layers (figure 3.17B). 
This disagrees with earlier reports of basal-restricted expression of BCL-2 
(Hockenbery et al, 1991). More recently however, some studies have detected BCL-2 
in suprabasal and granular layers also (Krajewski et al, 1994; Stenn et al, 1994). The 
staining reported here would agree with the latter studies.
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Figure 3.16
Expression of transgenic human BCL-2 in KlO-BCL-2 mouse adult epidermis
« • •
Skins of adult C-line mice were stained with a BCL-2 antibody (BCL-2 N19, Santa 
Cruz) which should detect both human and mouse BCL-2.
A transgenic mice (A) and negative littermate (B) are shown.
Transgenic skins have patchy staining whoch appears suprabasal when the skin is 
thick enough to notice, while negative littermates have very little positive staining. 
Bar: 100pm
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Figure 3.17
Expression of transgenic human BCL-2 in KlO-BCL-2 mouse neonatal epidermis
keratin
j- suprabasal 
^n)asal
B
Skins of neonatal C-line mice were stained with a BCL-2 antibody (BCL-2 N19, Santa 
Cruz) which should detect both human and mouse BCL-2.
A transgenic pup (A) and negative littermate (B) are shown.
Transgenic skins have a patchy suprabasal staining pattern while negative littermates 
have a weaker, more uniform pattern.
Bar: 100pm
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3.7 Functional Analysis of KlO-BCL-2 Transgenic Mice
3.7.1 Introduction
Following confirmation of expression of the K10-5CZ-2 transgene, the next stage 
involved an investigation of the phenotypic consequences of BCL-2 overexpression in 
the epidermis. ¥^\0-BCL-2 transgenic mice appeared grossly phenotypically normal. 
There was no obvious skin or hair abnormalities. Haemotoxylin and eosin staining of 
adult and neonatal skins also showed no histological differences between transgenic and 
wild-type skins. Therefore, if functional BCL-2 was being expressed in the epidermis, 
its presence did not produce any noticeable changes in skin morphology. A number of 
experiments were carried out to assess any effects that recombinant BCL-2 might have 
on cell proliferation or growth.
3.7.2 Epidermal cell proliferation rates are not affected in K10-.BCL-2 transgenic 
mice
BCL-2 has been reported to play a role in growth control in some systems (Vairo et 
al, 1996) and to act as a suppressor of apoptosis. It may thus disrupt cell turnover. 
Cellular proliferation in the epidermis of K10-.5CZ-2 transgenic mice was therefore 
investigated. Three transgenic and three wild-type mice were injected with BrdU one 
hour before sacrifice. Both adult (12 weeks old) and neonatal pups were analysed in 
this way. Dorsal skins of these mice were stained with an anti-BrdU antibody as 
described in Materials and Methods and the labelled cells of interfollicular epidermis 
were counted.
No difference in labelling indices was found between K10-5CL-2 transgenic mice 
and their wild-type littermates (see table 3.4A). Therefore aberrant expression of 
human BCL-2 in mouse skin epidermis did not induce a proliferative change. It was 
therefore not surprising that no hyperplasia or hypoplasia was observed either in 
neonate or adult transgenic mice.
3.7.3 Immunohistochemical Bax expression is not disrupted in K10-.BCL-2 mice
BCL-2 is known to interact with a number of proteins as discussed in Chapter 1. 
BAX is one protein with which it forms a heteromer during the regulation of
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Table 3.4 A
Proliferation rates in the interfollicular epidermis of KlO-BCL-2 transgenic mice 
are similar to that of wild-type littermates
KlO-BCL-2
Transgenic
W ild-type
2.21 1.48
Adult 1.77 2.0
mouse 1.92 2.11
Mean: 1.97 Mean: 1.86
2.97 3.72
Neonatal 3.16 3.82
pup 3.78 3.06
M ean: 3.30 M ean 3.52
Each number is the BrdU labelling index of an individual mouse and represents the average number of 
BrdU+ve cells per 100 interfollicular basal epidermal cells.
Table 3.4B
Proliferation rates in the interfollicular epidermis of K10-5CL-2 transgenic mice 
are similar to that of wild-type littermates following chronic TPA treatment
KlO-^CE-2 W ild-type
Transgenic
32.3 38.4
25.3 24.4
26.8 33.1
Mean: 28.1 Mean: 31.9
Each number is the BrdU labelling index of an individual mouse and represents the average number of 
BrdU+ve interfollicular cells per 500pm skin epidermis.
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apoptosis. Transgenic and wild-type skins were stained with a Bax antibody as 
described in Materials and Methods.
Bax staining was observed throughout the epidermis as had previously been shown 
for wild-type mice (figure 3.8). However, no difference in staining was evident between 
K10-5CZ-2 transgenics and wild-type littermates. Therefore overproduction of BCL-2 
protein in the epidermis did not affect endogenous Bax expression as assessed by 
immunohi stochemistry.
3.7.4 Response to treatment of skin with a tumour promoter is not altered in 
K10-J5CL-2 transgenic mice
The tumour promoter TPA ( 12-0-tetradecanoylphorbol-13 acetate) perturbs the 
homeostasis of the skin and induces hyperplasia of the epidermis. To investigate the 
effects of aberrant Bcl-2 expression during such a chemical insult to the skin, KIO- 
BCL-2 transgenic mice were treated with TPA. Female mice between 10 and 12 weeks 
old were used for the TPA treatments. Two different types of TPA treatment (chronic 
and acute) were carried out.
3.7.4.1 Chronic TPA treatment
Firstly, the effects of a chronic application of TPA were examined. Three female 
transgenic mice and three wild-type female littermates had their dorsal skins treated 
with 200pl of 10"^M TPA solution (0.02moles). The mice were treated a further three 
times at three days, six days and nine days after the initial application. Twelve days 
after the first treatment, mice were injected with BrdU and dorsal skin was collected.
Chronic treatment with TPA caused the skins of both transgenic and wild-type 
mice to undergo hyperplasia and the epidermis became markedly thickened (see figure 
3.18). There was no noticeable morphological difference in skins of transgenic and 
wild-type littermates following the treatment.
Expression of the KlO-BCL-2 transgene following chronic TPA treatment was 
examined both by in situ hybridisation and immunohistochemistry. Human BCL-2 
RNA and protein were both strongly induced (see figure 3.19). This might be due to 
individual cells expressing higher levels of transgene mRNA and protein and/or the fact 
that there are more suprabasal-like cells in the epidermis of TPA-treated skin. This 
TPA treatment did not appear to induce endogenous Bcl-2 mRNA or protein
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Figure 3.18
Epidermal hyperplasia and hyperproliferation following topical application of TPA 
to mouse dorsal skin
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Mouse adult skin was either untreated (A, C) or treated (B, D) with the the phorbol ester 
TPA 4 times over a period of 10 days. 12 days after the initial treatment, mice were 
injected with BrdU and dorsal skin was harvested 1 hour later. Tissue was fixed in 4% 
paraformaldhyde and 6pm paraffin sections were made. Sections were either stained with 
haematoxylin and eosin (A, B) or labelled with an anti-BrdU antibody (C, D).
TPA treatment resulted in hyperproliferation and hyperplasia of the epidermis including 
the appearance of proliferating cells in suparabasal layers.
Bars: 100pm (A, C), 50pm (B, D)
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Figure 3.19
Tumour promoter TPA causes induction of the KlO-BCL-2 transgene
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Following chronic TPA treatment, 6pm paraffin sections of KlO-BCL-2 transgenic 
mice or their wild-type littermates were subjected to in situ hybridisation with a 
^^S-labelled human BCL-2 cDNA riboprobe (A and B) or stained with a Santa Cruz 
N19 BCL-2 antibody (C, D, E and F).
A and B are bright-field and dark-field images respectively of the same section of 
a KlO-BCL-2 transgenic skin following TPA treatment.
C and E are untreated adult skins: C is transgenic and E is non-transgenic.
D and F are TPA-treated skins: D is transgenic and F is non-transgenic.
Bars: 200pm (A,B) or 60pm (C, D, E, F).
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expression. Staining with an anti-BrdU antibody showed that there was no difference 
in cellular proliferation between transgenic and wild-type mice. Counts of BrdU- 
positive cells are shown in Table 3.4B.
3.7.4.2 Acute TPA Treatment
Acute TPA treatment consisted of one application of 200pl of 10’^ M^ TPA solution 
(0.02moles) followed by analysis of the treated mice at various timepoints after the 
initial application. Animals were 8 - 1 4  weeks old females. At each of 7 timepoints 
post-TP A, three transgenic and two wild-type littermate mice were injected with BrdU 
one hour before sacrifice and their dorsal skins fixed in 4%PFA. Treated mice were 
analysed at 0 hours, 6 hours, 12 hours, 24 hours, 48 hours, 4 days, 7 days and 10 days 
post-TP A treatment.
Expression of the transgene was examined by in situ hybridisation and 
immunohistochemistry at 24 hours post-TPA. As with the chronic TPA treatment, 
both the transgenic mRNA and protein expression were induced.
Skins were labelled with an anti-BrdU antibody and numbers of proliferating cells at 
all timepoints were counted (see figure 3.20). There was a peak in basal cell 
proliferation at 48 hours post-TPA in both transgenics and controls and there was no 
significant difference in the number of S-phase cells throughout the rest of the time 
course. The final timepoint examined was 10 days post-TPA at which point one would 
expect the skin to have returned to its quiescent state. This timepoint was looked at to 
determine whether the presence of excess Bcl-2 would delay the process of the 
epidermis returning to quiescence from the hyperplastic state. As can be seen from 
figure 3.20, and from histological appearance of the skins, this process was not 
affected.
It can be seen from these two TPA experiments that the presence of human BCL-2 
in the epidermis did not alter the response of the skin to the phorbol ester, TPA. The 
increased cellular proliferation and profile of hyperplastic responses was similar in 
both transgenics and controls.
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Figure 3.20
Profile of BrdU labelling indices in interfolicular epidermis following acute TPA 
treatment is similar in both KlO-BCL-2 transgenics and wild-type mice
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KlO-BCL-2 transgenic mice and wild-type littermates were applied with 10“M TPA 
and skins were harvested at 0, 6, 12, 24, 48 hours and 4, 7 and 9 days after TPA 
treatment. One hour before sacrifice, mice were injected with BrdU. Three mice of 
each genotype were collected at each timepoint and the epidermal labelling indices 
were estimated. The BrdU labelling index is the number of interfollicular BrdU+ve 
cells per mm.
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3.8 Transgenic Model of Skin Carcinogenesis
3.8.1 Introduction
TGppi is a potent inhibitor of cell growth but various reports have shown that it 
can act as a stimulator or suppressor of tumour growth and progression (Cui and 
Akhurst, 1996 and references therein). A previous study in our lab had demonstrated 
this biphasic action of exogenous Tgfpl in skin (Cui et al, 1996). Transgenic mice 
overexpressing Tgfpl in the suprabasal layer of the epidermis were subjected to long­
term chemical carcinogenesis. The transgenics were more resistant to induction of 
benign skin tumours than control mice, but the malignant conversion rate was vastly 
increased. The 7g/p transgenics utilised in the study included H-line (K10-7g/pl) 
transgenics, which have been discussed previously, and the M2-line (K6-7g/pl). Lilce 
the H-line, the M2-line drives expression of activated Tg/pl in suprabasal 
kératinocytes, but the K6 gene promoter is inducible and is only switched on in the 
hyperplastic state.
The aim of the next experiments was to assess whether Tgfp was predominantly 
tumour suppressing or tumour progressing in a different model of mouse skin 
carcinogenesis, namely in K.5-Æ/l  ^transgenic mice (see Materials and Methods figure 
2.1C). These mice have been previously characterised (Brown et al, 1998) and express 
mutant Harvey RAS (Ha-iM5) in basal kératinocytes. To assess the effect of exogenous 
Tgfpl expression on tumorigenesis in this system, the )L5-RAS transgenic mice were 
bred with KIO- and K6-7g/pl transgenic mice to produce mice expressing both active 
mutant RAS and Tgfpl in skin epidermis. Tumour development and progression were 
followed on the various crosses.
3.8.2 Genetic background affects the phenotype of K5-ÆH5 mice
The K5-Æ4^ mice were originally received from Dr K. Brown on C57B1/6J and FVB 
genetic backgrounds. Both strains were observed over a period of 2-3 months. It was 
noticeable that K5-7M6' mice on the FVB background had a much more severe 
phenotype than C57B1/6J KS-iMiS mice i.e. the expressivity was greater on the FVB 
background. FVB K5-iM/S' mice tended to develop acanthotic lesions as pups (figure 
3.21) and keratoacanthomas as young adults (figure 3.22). On the other hand, C57B1/6J
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Figure 3.21
K5-RAS transgenic neonates and pups develop acanthotic lesions
A. A region of acanthosis of the skin of a K5-RAS transgenic 2-week old mouse
B. Haematoxylin and eosin staining of an acanthotic lesion
Region o f  acanthotic skin from a 6-day old mouse. The skin has become hyperplastic forming folds o f  
epithelium Note the absence o f  hair follicles.
Bar: 200|im
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Figure 3.22
Keratoacanthomas develop spontaneously on the skins of K5-RAS transgenic 
adult mice
A and B. Keratoacanthomas on the heads of adult K5-RAS transgenic mice
C. Haematoxylin and eosin staining of a keratoacanthoma from a KS-iMiS' 
transgenic mouse
A 6p,m section of a keratoacanthoma was stained with haematoxylin and eosin. 
Skin (S) enapsulates the tumour forming a cup-shaped mass which consists of 
epithelial cells (E) and an abundance of keratin (K).
Bar: 300pm
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K5-7MS' mice rarely developed skin lesions as pups and developed keratoacanthomas 
later than mice on the FVB background.
There was also a difference in penetrance of a skin phenotype between the two 
genetic strains. Within 8 weeks of birth, 16 out of 24 K5-iMiS transgenic mice on a 
FVB background had developed a skin lesion of some sort, while 2 out of 22 C57B1/6J 
K5-7MS mice displayed a phenotype over the same period. Within each particular 
genetic strain there was also incomplete penetrance of the transgene and considerable 
variation in expressivity, making a quantitative analysis of characteristics such as 
tumour formation difficult.
To ensure that the genetic background was consistent, and since the Tgf^l transgenic 
mice were on a NIH background, the FVB KS-TMiS mice were firstly bred on to a NIH 
background. The KS-iMiS mice were backcrossed three times onto stock NIH mice. 
Ensuing crosses with other transgenic lines on the NIH background thus resulted in 
93% NIH offspring. As with the C57/B16 and FVB genetic backgrounds, the NIH 
background displayed variable penetrance. It had been thought that on a NIH 
background there would be a phenotype as least as severe as that of FVB: previous 
chemical carcinogenesis studies had shown NIH to be one of the most susceptible to 
tumour formation (Balmain et al, unpublished observations). Surprisingly, K5-7L45 
mice on a NIH background had a less severe phenotype than those on the FVB 
background. The main difference was that NIH transgenics tended to get single tumours 
as opposed to the multiple tumours of FVB transgenics.
3.8.3 NIH KS-iLd/S mice develop spontaneous follicle-derived tumours
On a NIH background the main type of tumour was a keratoacanthoma - this is a 
benign lesion which grows quite rapidly, spreading outwards beneath the epidermis and 
projecting above the surface of the skin as a cup-shaped mass which undergoes 
kératinisation in the centre. A buttress of tissue encircles the keratin-filled centre (see 
figure 3.22). In terms of position of the keratoacanthomas, there was great variability: 
the skin of the back, abdomen, ears, face/snout, genitals, limbs and even tail (see figure 
3.23) all gave rise to keratoacanthomas on various mice.
The NIH KS-TMS" mice developed other types of tumours too. Other skin tumours 
include papilloma-like lesions on the ears and regions of acanthosis on snout, limbs or
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Figure 3.23
Haematoxylin and eosin staining of a cross-section of a keratoacanthoma on the 
tail of a K5-RAS transgenic mouse
Kerato­
acanthoma
Mouse
tail
A 6fim paraffin section of a keratoacanthoma on a transgenic mouse tail was stained 
with haematoxylin and eosin.
Bar: 1mm
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tail. Non-skin tumours noted include salivary gland tumours, teratomas and in one case 
hyperplasia of the Vas Deferens tubules.
There was tremendous variation in the age of mice when tumours/acantho sis first 
appeared. A small number of pups developed acanthotic lesions between 2 days and 2 
weeks of age. This acanthosis tended to spread very rapidly, often covering 50% of the 
dorsal skin area by 48 hours after onset. The animal would then be culled complying 
with Home Office regulations. However, mice developing skin tumours beyond 2 
weeks of age tended to develop more localised keratoacanthomas which expanded more 
slowly, usually reaching an endpoint (>10mm in diameter) within 2 weeks of 
appearance.
Injection with BrdU before sacrifice, and subsequent labelling with an anti-BrdU 
antibody revealed a high BrdU labelling index within the keratoacanthomas. There was 
also evidence of proliferating cells in suprabasal layers of the tumours (figure 3.24). 
This is reflected by the speed with which these tumours grew.
3.8.4 Transgene expression in tumours
In order to examine the expression pattern of the transgene in the
tumours, in situ hybridisation was carried out on sections of normal skin and tumours 
from transgenic mice using a probe specific to the SV40 intron and poly adénylation 
sequences of the transgene construct. A strong signal was observed in basal
and basal-like cells of tumours including keratoacanthomas and regions of acanthosis 
(see figure 3.25). Expression was not uniform throughout these cells, but was patchy. 
No expression of the transgene was observed in normal skin of K5-ÆT5' transgenic mice 
showing that the transgene is induced in dysplastic tissue.
3.8.5 Exogenous suprabasal Tgf(3l expression does not affect tumour formation 
in K5-RAS transgenic mice
K5-7M5' transgenic mice were crossed with the 7g/pl transgenic lines: line H (KIO- 
Tg/pl) and line M2 (K6-7g/pl). The breeding scheme and consequent lines that were 
produced are shown in figure 3.26. Lines RH and RHC are half-littermates, as are RHH 
and RHN, RM and RMC, RMM and RMN. This means that each pair of lines share 
one parent (the father in all these cases).
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Figure 3.24
Spontaneous acanthotic lesions in K5-/L45 transgenic mice exhibit a high BrdU 
labelling index and contain proliferating cells in suprabasal layers
A,
ré
' C ,
Mice were injected with BrdU 1 hour before sacrifice and tumours were fixed in 
4%PFA before being stained with an anti-BrdU antibody.
The arrow indicates a proliferating cell in a suprabasal layer of the lesion.
Bar: 100pm
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Figure 3.25
In situ hybridisation analysis shows that tumours from K5-RAS mice express the 
K5-RAS transgene
A kerataoacanthoma was removed for the skin of a K5-RAS transgenic mouse and 
probed with a ^^S-labelled PolyA cDNA fragment.
Low-power views of dark-field (A) and bright-field (B) images are shown. A higher 
magnification of a section of the tumour (C) shows localisation of transgene in basal- 
like epithelial cells of the tumour.
Expression of the transgene in normal skin of K5-RAS transgenic mice is undetectable. 
Bars: A and B, 500pm; C, 100pm
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Figure 3.26
Schematic outlining breeding protocols for crossing K5-RAS transgenic line with 
KlO-Tg/pl (H line) and K 6 -T ^ \  (M2 line)
NIH X ras(+/-) X H/H
ras(-/-)
+/+
ras(+/-)
+/+
RHC
ras(-/-)
H/+
ras(+/-)
H/+
RH
NIH
ras(+/-)
H/+ H/H
ras(-/-)
H/+
ras(-/-)
+/+
ras(+/-)
+/+
ras(+/-)
H/+
ras(-/-)
H/H
ras(-/-)
H/+
RHN
ras(+/-)
H/+
ras(+/-)
H/H
RHH
ras(+/-) mouse negative for H-line K10-7g/pl transgene 
ras(+/-) mouse positive for H-line K10-7g/pl transgene
The K5-/M5 cross with the M2 line (K6-7g/pl) was set up in the same way.
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Mice were screened for the RAS transgene using primers specific for the human Ha- 
RAS cDNA (see figure 3.27). Previously, H-line and M2-line mice had been screened 
using a probe or primers specific to the SV40 poly A fragment. However, since the K5- 
RAS mice also contained the SV40 polyA fragment, a new pair of primers was designed 
to screen for the presence of the 7g/pl transgene (S4-SR5, see Materials and 
Methods).
Offspring from the above crosses were observed daily and examined for evidence of 
skin abnormalities or tumours. Notes were made of age at appearance of tumours, 
types of tumours, location of tumours, how quickly the tumours progressed and when 
and why the mice were culled (see appendices 1 and 2). Table 3.5 shows numbers of 
mice generated by the crosses and the proportions of K5-iM5' mice that consequently 
developed a skin phenotype.
Mice with tumours were generally culled when the tumours either reached the 
maximum size permissible by Home Office regulations (>10mm in diameter) or because 
the tumour caused the mouse to become sick.
Occurrence of skin tumours in single (K5-iM5) and double (KS-RAS/Tg/^l) 
transgenic mice is portrayed in figure 3.28. 187 mice were analysed in the K5-7M»S'/H- 
line cross and 86 mice were analysed in the K5-iM*S'/M2-line cross. No significant 
differences were found between single and double transgenics in terms of latency of 
tumour formation. Unlike the study by Cui et al, 1996, where exogenous Tgfpl had a 
major effect on both tumour suppression and malignant conversion, the presence of 
exogenous Tgfpl did not inhibit tumour formation by prolonging latency.
It was impossible to assess whether the presence of the K10-7g/pl transgene 
influenced the malignant conversion rate of K5-/L4.S' tumours. This was because these 
tumours tended to grow quite large relatively quickly, and before they had a chance to 
progress to carcinomas. Under Home Office regulations a mouse must be culled if a 
tumour reaches more than 10mm in diameter and because of the nature of growth of 
keratoacanthomas, most mice under this regime had to be sacificed before malignant 
conversions.
Not all positive mice developed skin tumours. In this study, approximately
50% of mice developed a skin phenotype of some sort over a period of 55 weeks. 
Occurrence of other tumour types such as teratomas and salivary gland tumours had no 
correlation with 7g/pi transgenic status.
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Figure 3.27
K5-RAS transgenic mice were screened by PCR using primers tcrl and tcr2
M 1 2 3  4 5 6 7
TshP (386 bp) 
(257 bp)
Primers tcrl and tcr2 (see figure 2.ID) are specific for human Ha-TM  ^cDNA and 
produce a 257 bp fragment. Primers for thyroxine stimulating hormone P (Tshp) 
produce a fragment of 386 bp that acts as an internal control.
M: Ikb DNA ladder (Gibco BRL)
Lanes 2,3,5,  and 7 contain K5-7M5positive DNAs
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Table 3.5
Genotype and Phenotype Status of Mice from the K5~RAS/TgJÿl Transgenic 
Crosses
LINE
Number of 
mice
Number of mice 
with skin 
phenotype
Percentage of mice 
that developed a 
skin phenotype
Statisistical 
significance of 
difference between 
the two groups
K5~RAS+\e
KlO-Tgfpl-ve
61 28 46% p = 0.239
K 5-R A S+ \e
KlO-Tgfpl+ve
126 53 42% p = 0.239
KS-'RAS+ve
K6-Tgfpl-ve
32 18 56% p = 0.591
K5~RAS+\e
K6-Tgfpl+ve
54 27 50% p = 0.591
The table shows the numbers of mice from each transgenic group that developed skin 
tumours. Kaplan Meier survival curves were drawn for each group with the endpoint 
being age at onset of tumour and these are shown in Figure 3.28. The p value is 
gennerated from the log-rank test and represents the chance that random sampling of 
subjects would lead to as big a difference in tumour onset as was observed.
The p values show that there is no difference between K5-i?A5+ve KlO-Tgfpl-ve vs 
K5-RAS+WQ KlO-Tgfpi+ve mice (p = 0.239) or between K5-RAS+\q K6-Tgfpl-ve vs 
K5-i?A5+ve K6-Tgfpi+ve mice (p = 0.591).
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Figure 3.28
Rate of tumour appearance in K5-RAS transgenic mice which have been crossed 
with K10-7g/pl (H) or K6-7g/pl (M2) transgenic lines
Tumour Progression In mice from a 
K5RAS X K10TGFP1 CfOSS
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Graphical portrayal (Kaplan-Meier survival curve) of tumours accumulated in mice 
generated from crosses of K5-RAS transgenics with either KlO-Tgfpi or K6-Tgfpi 
lines. Numbers of mice observed are depicted in Table 3.5 and individual mice with 
types of tumours and transgenic status are listed in Appendices 1 and 2.
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The results presented show that there is no major effect on tumour formation. Cui 
et al (1996) saw up to a 6-fold decrease in chemically-induced tumour formation due to 
the presence of the KlO-Tg/pi transgene after a period of 26 weeks. The tumours 
which develop in }L5-RAS mice are derived from the hair follicle while those which arise 
due to chemical treatment of the skin tend to be derived from interfollicular 
kératinocytes. The suprabasal site of exogenous 7g/pl expression may account for the 
difference in action on the two different tumour models.
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Chapter 4 
DISCUSSION
An imbalance between the rates of cell proliferation and cell death is considered to be 
important during the pathogenesis of many human tumours. This imbalance may be 
reflected in an enhanced rate of proliferation and/or a decreased susceptibility to 
undergo apoptotic cell death or terminal differentiation. In fact, the most common 
malignancies, including low grade lymphomas, skin cancer, and prostate cancer are 
characterised, initially, by a period where the rate of cell division does not exceed that 
of the normal tissue of origin, thus implicating abnormalities in the cell death pathway 
that lead to tumour growth. It is relevant, therefore, to determine the molecules and 
pathways that control the homeostasis in normal tissue and whose perturbations result 
in tumorigenesis.
4.1 Proliferation rate in KlO-Tg/pl transgenic skins is not altered by p53 
deficiency
Absence of p53 failed to alter the heightened epidermal proliferative index 
phenotype of KlO-Tg/pl transgenic mice. Even though the difference between KIO- 
Tgfpi transgenics and those wild-type for the transgene on a p53-null background was 
not significant, the p value was just outside the standard cut-off for significance, and 
analysis of the raw data suggests the difference is real. Therefore, whether or not Tgfpi 
induces apoptosis or terminal differentiation in K10-7g/pl transgenic mouse skin, the 
mechanism must be p53-independent.
Whether P53 is involved in the response to TGppi has been investigated in a number 
of cell types. Gerwin et al (1992) found that when a mutant TP53 cDNA was expressed 
in bronchial epithelial cells, the growth inhibitory response and induction of terminal 
differentiation response to TGppi were decreased. This study suggested that the action 
of wild-type P53 could facilitate the effects of TGPpl on these cells. Similarly, 
introduction of mutant TP53 into epidermal kératinocytes reduced sensitivity of these 
cells to TGppi (Reiss et al, 1993). One possibility was that TGPpl might signal 
through P53 via MYC. TGPpl has been shown to induce a decrease in c-MYC 
expression that correlates with growth inhibition and this effect is blocked by 
expression of HPV-16 E7, or SV40 T Ag. Since the Tp53 promoter region contains a
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MYC/MYOD consensus binding site (Ronen et al, 1991), a shift in the various binding 
interactions of the MYC protein might constitute an area of intersection between P53 
and TGppi in control of cellular growth.
Wyllie et al (1991) looked at epithelial thyroid cells which had lost wild-type P53 
function. As with the above studies, TGPP responsiveness was shown to be lost in 
correlation with loss of wild-type p53. However, in a more comprehensive study, the 
same group found that P53 function was not necessary for TGppi response -  the result 
suggesting that P53 and TGPp generate separate but interacting inhibitory signals 
(Blaydes et al, 1995). This agrees with a study on HaCaT cells which found that TGPp 
could induce the CDK inhibitor p21^^^^ in a P53-independent manner (Datto et al,
1995). Pinally, Ewen et al, (1995) showed that, in mink lung epithelial cells, TGppi 
down-regulates the translation of CDK4 in a pathway leading to G1 arrest and this 
pathway is dependent on the presence of wild-type p53. Therefore it appears that 
involvement of P53 in the growth responsiveness of cells to TGPpl probably depends 
on factors such as cell type and the specific signalling pathway activated by TGPpl.
TGppi has been shown to be able to induce apoptosis in a number of cell types and 
many apoptotic pathways have been shown to be P53-dependent. However, the 
literature suggests that the induction of apoptosis by TGppi may also vary between cell 
or tissue types in terms of whether P53 is involved in mediating the signal. p53 was 
shown to be up-regulated during TGppi-induced apoptosis of rat liver epithelial cells 
(Teramoto et al, 1998). However, a number of reports have found that apoptosis 
triggered by TGppi can occur in cells expressing no functional P53 (Yamamoto et al, 
1996; Hipp et al, 1997; Christensen et al, 1998).
A further consideration is the role of p53 in normal skin growth control. p53 null 
mice develop spontaneous sarcomas and lymphomas, but exhibit no skin abnormalities 
(Donehower et al, 1992) and it seems likely that there may be differences in 
susceptibility of different cell types to p53 loss. Furthermore, p53 null mouse epidermis 
has a surprising resistance to early-stage carcinogenesis after topical exposure to a 
chemical carcinogenesis protocol (Kemp et al, 1993b) or by breeding with transgenic 
mice expressing epidermally targeted oncogenes (Greenhalgh et al, 1996). Thus, it 
appears that the epidermis, which is frequently exposed to environmental carcinogens, 
has a strong defence system to compensate for p53 loss. One possibility is that 
expression of p73, a putative tumour suppressor gene with significant homology to 
Tp53 in the DNA-binding, transactivation, and oligomerisation domains (Kaghad et al, 
1997; Jost et al, 1997), may compensate for the loss of p53.
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4.2 Immunohistochemical bax staining is no different between wild-type, KIO- 
Tg/pl transgenic or rp53-null skins
Bax protein expression in the skins of mice from a KlO-Tgj^VTpSS knockout cross 
were examined by imunohistochemistry. Staining for Bax protein was similar in all 
skins of K10-7g/pl transgenics and their wild-type littermates whether the background 
was p53 wild-type or p53 null.
In the skins of mice of all genotypes, Bax staining was present in all layers of the 
epidermis as has been reported previously (Krajewski et al, 1994). However, this is the 
first report of Bax staining in skins of p53 null mice. Miyashita et al (1994) observed 
lower levels of Bax protein by either intensity of immunohistochemical staining or 
Western blot levels in several tissues of p53-deficient mice compared to wild-type 
littermates. Several neuronal populations as well as cells of the small intestine, thymus, 
lungs and liver showed reduced levels of Bax. If loss of p53 in skin affects Bax protein 
induction, it is not detectable by immunohistochemistry.
It is not known if BAX plays a direct role in TGPpi-induced apoptosis. In a myeloid 
leukaemia cell line, Selvakumaran et al (1994) found that BAX expression was up- 
regulated during p53-mediated apoptosis but not in an apoptotic pathway induced by 
TGPpi. More recently, however, TGppi has been shown to induce Bax during 
apoptosis of rat liver epithelial cells (Teramoto et al, 1998). There are no reports though 
of an association in skin between TGppi signalling and Bax induction and, if the 
increased cell turnover in the epidermis of KlO-Tg/pl is due to an increase in apoptosis, 
perturbation of Bax protein is not an associated feature.
4.3 Lack of altered proliferation in Tgf^l null mice
In this lab, it has been reported that when Tgfpi is overexpressed in suprabasal cells 
of the epidermis, there is an increase in proliferation in epidermal basal cells (Cui et al,
1996). Glick et al (1993) had found an increased BrdU labelling index in the epidermis 
of Tgfpl null mice. The fact that a relatively small number of mice of disparate ages 
and undefined genetic background had been used in the latter study led us to repeat this 
experiment with our colony of Tgf^l knockout mice. In contrast to this study no 
difference was found between Tgfpi null mice and their wild-type littermates either on 
a mixed or inbred genetic background.
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It should be noted that there was larger variation in the BrdU counts of mixed 
genetic background mouse skins than in those of an inbred (NIH) background. This is 
perhaps not surprising based on the variation in survival rates of Tgfpi null mice on 
different genetic backgrounds observed by Bonyadi et al (1997). It seems reasonable to 
assume that one or more genetic modifiers might affect factors such as proliferation 
index of epidermis. Alleles of these genetic modifiers might vary in their modifying 
capacities depending on the genetic background of the mouse from which they 
originated. Consequently, a litter of mice on a mixed genetic background would 
harbour more versions of the modifying alleles than those of an almost pure inbred 
background.
This interpretation might also provide an explanation for the conflicting results of 
Glick et al (1993). The genetic background of the mice analysed in their study is not 
defined but appears to be mixed. They examined two wild-type, four heterozygote, and 
3 homozygote knockout Tg/pl mice from three different litters, two of which were 5 
weeks old and one of which was 3 weeks. Even among their controls, there was a five­
fold difference in BrdU labelling index between the largest and smallest indices. This 
large variation (probably due to genetic background) combined with the small number 
of mice examined and the differences in their ages means that the possibility that their 
findings are artefactual must be considered. Examination of Tg/pl knockout epidermal 
labelling indices of significant numbers of mice with various inbred genetic 
backgrounds and a range of ages might help explain the variation.
It is perhaps not surprising that loss of Tgfpl in the epidermis does not cause a 
proliferation defect. One possible explanation is that other proteins compensate for the 
loss of Tgfpi. There is evidence that there may be cross-regulation between the three 
Tgfp isoforms, Tgfpl, p2, and P3. Signalling through Tgfp2 and Tgfp3 is still present 
in Tgfpi null mice and may compensate for loss of Tgfpi. Tgfp2 is expressed in the 
epidermis (Glick et al, 1991) and Tgfp3 is probably dermally-expressed, but may still 
affect epidermal proliferation as it is a secreted protein and can probably diffuse from 
dermis to epidermis (Escherick et al, 1993).
Two recent studies involving expression of a dominant-negative type II Tgfp 
receptor (pRII-DN) in skin epidermis provide further insight into the role of Tgfp in the 
control of epidermal homeostasis (Wang et al, 1997; Amendt et al, 1998). Expression 
of the PRII-DN only in basal cells of the epidermis resulted in no change in 
proliferation of the skin (Amendt et al, 1998), but when expressed in both basal and
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suprabasal cells, the labelling index of the skin was doubled (Wang et al, 1997). There 
are a number of possible explanations for the difference in these two studies. One 
possibility is that there is a quantitative difference in expression levels of the pRII-DN. 
The loricrin promoter of Wang et al may have more efficient basal expression than the 
K14 promoter of Amendt et a l In fact, the latter study reports not only a more severe 
phenotype in homozygote transgenics than heterozygotes, but also a reduction in the 
phenotype of heterozygote mice as the adult matures. Difference in phenotype due to 
different expression levels of a transgene is illustrated by two studies describing the 
control of 7g/pl by suprabasal promoters in the epidermis (Sellheyer et al, 1993; 
Fowlis et al, 1996).
An alternative explanation is one suggested by Amendt et al implying that Tgfpl's 
prime function in normal homeostasis is in regulation within the suprabasal layer and 
this impacts on the basal layer. This would agree with reports of the localisation of 
Tgfpi in the suprabasal layer of the epidermis (Akhurst et al, 1988) and would also be 
consistent with the phenotype of K lO -T ^ l transgenic mice described above and in the 
following section.
4.4 Proliferation rates in K10-7g/pl transgenic skin in the absence of endogenous 
Tgfpi
In order to further assess the importance of Tgfpl signalling in the epidermis, KIO- 
7g/pl transgenic mice were crossed with the Tg/pl knockout line. Due to the small 
number of Tgfpl null mice which reach 3 weeks of age, and the fact that the 
proliferation phenotype of K10-7g/pl mice is more pronounced in homozygote 
transgenics than heterozygotes, it was not possible to generate sufficient numbers of 
KlO-Tg/pl homozygote mice on a Tgfpi null background in order to make a 
statistically significant observation. However, of the mice that were analysed, the KIO- 
Tg/pl transgene induced the increase in basal cell proliferation on a Tgfpi null 
background just as it does in the presence of endogenous Tgfpi. Therefore, the 
epidermis can cope with a loss of endogenous Tgfpi in terms of homeostasis, yet 
expression of transgenic Tgfpl in the suprabasal layer disrupts the balance. Perhaps 
Tgfpl is only a differentiation-inducing factor in the epidermis and not a growth- 
inhibitoiy factor.
135
4.5 Expression of transgenic and endogenous BCL-2 in skin epidermis
Characterisation of a BCL-2 transgenic line under the control of a KIO promoter 
determined the presence of a 26 kDa human BCL-2 protein expressed in suprabasal 
cells of transgenic epidermis. The size of this protein agrees with previously published 
results (Allsopp et al, 1993) although it can not be ruled out that the protein is slightly 
truncated. The strong but relatively patchy expression of the transgene as demonstrated 
by immunohistochemistry agrees with reports of expression of other transgenes driven 
by the KIO promoter (Bailleul et al, 1990; Cui et al, 1995).
Endogenous mouse Bcl-2 mRNA was demonstrated by RT-PCR but was not 
detected by either Northern blot or the more sensitive radioactive in situ hybridisation. 
A previous study demonstrated that, in mouse, the Bcl-2 gene generates two mRNA 
species (7.5kb and 2.4kb) (Negrini et al, 1987). However, levels of Bcl-2 mRNA in 
skin have not been previously reported and the lack of murine Bcl-2 signal may indicate 
a relatively low endogenous Bcl-2 expression in the skin.
BCL-2 protein expression in skin has been demonstrated by both Western blotting 
and immunohistochemistry (Hockenbery et al, 1991; Rodriguez-Villanueva et al, 
1998). Immunohistochemistry is less quantatative than Western blotting, but, since the 
antibody used detected both human and mouse BCL-2, a comparison between relative 
expression of endogenous and transgenic BCL-2 could be made. Transgenic BCL-2 
expression was stronger and patchier than the endogenous Bcl-2 which was weaker and 
more uniformly spread throughout the cellular layers of the epidermis. Previous reports 
of BCL-2 immunohistochemical staining have been ambiguous. The staining data 
presented here agrees with Krajewski et al (1994) and Stenn et al (1994) who saw 
BCL-2 protein in both basal and suprabasal layers of the epidermis, whereas others 
reported staining in just the basal compartment of the epidermis (Hockenbery et al, 
1991; Verheagh et al, 1995). On the basis of the Western blot analysis and 
immunohistochemistry it may be stated that the KlO-BCL-2 transgene results in the 
deregulated expression of BCL-2 in terms of absolute amounts of BCL-2 protein and 
the distribution of BCL-2 protein within the epidermis.
4.6 Consequences of exogenous BCL-2 expression in transgenic epidermis
None of the experiments carried out on the KlO-BCL-2 transgenic mice 
demonstrated any functional potential for transgenic BCL-2 protein targeted to
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suprabasal cells of the epidermis. Indeed, several concurrent studies from other labs 
have now been published which come to the same conclusion. Other transgenic lines 
which consist of aberrant BCL-2 expression in the epidermis show a similar resilience 
in terms of disruption of normal homeostasis or response following chemical insult. 
Firstly, another KlO-BCL-2 transgenic mouse line, similar to the lines characterised 
here, has been recently generated independently in another laboratory (Rodriguez et al, 
1997b). As with the lines characterised here, they observed no histological or 
proliferative defects. Marthinuss et al (1995) generated K5-BCL-2 transgenic mice so 
that BCL-2 was overexpressed in the basal layer of the epidermis but, again, there was 
no apparent phenotype. In fact, the only report in which aberrant expression of BCL-2 
in the epidermis has resulted in any noticeable growth alterations is from a recent study 
by Rodriguez-Villanueva et al (1998).
They generated transgenic mice expressing BCL-2 in the epidermis driven by a K1 
promoter. Newborn pups carrying the transgene developed multifocal areas of 
hyperplasia. Apart from these scattered sites, the skin was normal and, in fact, in older 
pups and adult transgenics, this phenotype disappeared. The K1 promoter is a strong 
promoter and directs expression to both basal and suprabasal layers of the epidermis. 
The multifocal nature of the hyperplasia in these young mice is unusual as the transgene 
is expressed uniformly throughout the epidermis. But, as the authors suggest, it may 
indicate that compensatory, homeostatic mechanisms are operative which, in general, 
restore the normal rate of keratinocyte turnover (Rodriguez-Villanueva et al, 1998). It is 
worth noting that there is no change in BrdU labelling indices in these transgenic mice, 
even in the areas of hyperplasia. However, the K1-BCL-2 transgene did confer 
resistance to cell death induction by UV-B in vitro, and papillomas developed at a 
greater frequency in the K1-BCL-2 mice compared to control littermates following 
chemical carcinogenesis (Rodriguez-Villanueva et al, 1998).
In the KlO-BCL-2 mice examined here, the histomorphology of the epidermis was 
not altered. If BCL-2 plays a role in controlling apoptosis in the epidermis it might be 
reasonable to anticipate that the high levels of BCL-2 protein produced in the epidermis 
of KlO-BCL-2 would result in hyperplasia. The lack of dysplasia may be indicative of 
compensatory devices in the skin working to balance hoeostasis. It might therefore be 
predicted that the proliferative rate within the epidermis of the transgenics would be 
lower than that of control littermate mice. However, steady-state levels of proliferation, 
as assessed by incorporation of BrdU were comparable in KlO-BCL-2 mice and control 
mice. It is conceivable that the mechanism of cell death induction in the normal 
epidermis proceeds via a Bcl-2-independent mechanism.
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Chemical insult to the skins of KlO-BCL-2 transgenic mice, in the form of tumour 
promoter treatment, revealed no role for the transgenic BCL-2 in affecting 
histomorphology or epidermal proliferation rate. TP A (in both chronic and acute 
treatments) induced hyperplasia in the skins of both transgenic and wild-type littermate 
mice to a similar extent. The profile of cell proliferation rate following TP A treatment 
was also similar in KlO-BCL-2 transgenic skin and control skins with a peak in 
proliferation at 48 hours. Treatment of mouse skin with TPA induces many of the 
molecules involved in cell cycle and proliferation control including c-myc, cyclins D l, 
E and A, p21^'^\ Tgfpi, and Rb phosphorylation. However, exogenous BCL-2 
expression (which was also induced) did not appear to interfere with the process by 
which these factors respond to chemical insult and restore normal homeostasis to the 
skin.
The lack of demonstration of functionality of the KlO-BCL-2 transgene begs the 
question as to whether functional BCL-2 is actually being produced in these mice. 
However, it has been shown here that full-length protein is produced, expressed in the 
cellular compartment that it’s meant to be, and is produced at a detectable level. 
Furthermore, the human BCL-2 fragment used to generate the KlO-BCL-2 transgenic 
mice has been shown to possess functionality when expressed in vitro (Allsopp et al, 
1993). The lack of any phenotype in either quiescent or growth-perturbed transgenic 
skins may represent the relevance of the involvement of BCL-2 in apoptosis or cellular 
proliferation in the epidermis. Bcl-2 null mice show loss of melanocytes in skin but 
show no defect in development or homeostasis of the epidermis (Veis et al, 1993). 
Therefore, this organ appears to be relatively refractile to alterations in levels of Bcl-2.
The resistance to disruption of homeostasis in skin, of course, does not rule out a 
critical role for apoptosis in the epidermis. For example, in some tissues considered to 
undergo extensive apoptosis in relation with cell renewal such as the small intestine, 
even a very high expression of transgenic BCL-2 in enterocytes does not lead to tissue 
changes, nor protects enterocytes against apoptotic stimuli (Rodriguez et al, 1997a). 
Apoptosis has been shown to be a response to damage incurred by sunlight in the form 
of UV irradiation (Kraemer, 1997) and it has also been suggested that apoptosis may 
contribute to the process of skin aging (Haake et al, 1998).
Other transgenic lines have demonstrated the resistance of skin to disruption of 
homeostasis. Mice overexpressing the BCL-2 related gene BCL-x in the epidermis have 
been created (Pena et al, 1997). BCL-Xi^ or BCL-Xs was expressed in the basal 
compartment of the epidermis driven by the K14 promoter. Like the KlO-BCL-2 
transgenics, there was no effect on normal proliferation or terminal differentiation. The
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oncogene o-MYC is thought to be coupled with BCL-2 in the regulation of cell growth. 
Recently it's been shown that mice overexpressing a c-myc transgene in the epidermis 
do not display increased apoptosis in vivo despite undergoing hyperplasia (Pelengaris et 
al, 1999). However, when kératinocytes from these mice were cultured in appropriate 
serum conditions, the transgene was able to induce apoptosis. It would seem that in vivo 
survival signals act to suppress myc-induced apoptosis. Similarly, other homeostatic 
mechanisms may work to counteract over-expression of BCL-2.
4.7 Genetic background and penetrance effects on the K5-RAS transgene
The role of Tgf|3l in tumorigenesis has been investigated in a number of tissues 
using both transgenic and non-transgenic mice, and conflicting and sometimes 
seemingly irreconcilable results have been observed. In this lab, Tgf^l transgenic mice, 
overexpressing the growth factor in skin epidermis were subjected to long term 
chemical carcinogenesis. It was found that the transgenics were more resistant to the 
induction of benign skin tumours than control mice, and that the malignant conversion 
rate of papillomas to carcinomas was increased in the 7g/pl transgenics. To further 
characterise the effects of Tgfpi during skin tumorigenesis, these transgenic mice were 
crossed with a Ka-RAS transgenic line that devlops spontaneous skin tumours.
It was observed that K5-RAS transgenic mice on a FVB background had a phenotype 
more severe than those on a C57B1/6J background in terms of age of onset of 
acanthosis or keratoacnthomas and numbers of tumours appearing. This observation 
correlates with previous chemical carcinogenesis studies which demonstrated 
differences in susceptibility to skin tumorigenesis by mice of different genetic 
background (Balmain et al, pers.comm.; Balmain et al, 1998). C57B1/6J strain tended 
to be more resistant to carcinogenesis than FVB mice. Differences in tumour 
prevalences and severities between mouse strains have also been observed in other 
transgenic and tumour-suppressor knockout animal models (Threadgill et al, 1995; 
Donehower et al, 1995b).
The chemical carcinogenesis studies mentioned above had shown the NIH genetic 
background to be one which was relatively susceptible to skin tumorigenesis, and in 
fact, at least as susceptible as the FVB background (Balmain et al, unpublished 
observations). Therefore it was surprising to find a reduced tumour load with K5-/?A5 
mice on the NIH background compared to FVB. Differences in tumour susceptibility of
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mice on different genetic backgrounds following chemical carcinogenesis have been 
shown to be due to the presence or absence of modifying loci (Balmain et al, 1998). 
The greater resistance of K5-/L45' mice on a NIH background to formation of skin 
tumours than the resistance of NTH mice to chemically-induced tumours may be due to 
the differential effects that genetic modifying loci have on different tumour types. Skin 
tumours arising from mice undergoing chemical carcinogenesis arise from both 
interfollicular and follicular epidermal subpopulations whereas tumours due to the K5- 
RAS transgene are all follicular in origin. Different NIH modifier loci may influence 
susceptibility to follicularly-derived tumours and those arising from interfollicular 
epidermal compartments.
4.8 Effects of transgenic Tg/pl on tumorigenesis in K5-RAS mice
It was found that neither KlO-Tg/pl nor K6-7g/pl transgenic mice when crossed on 
to the K5-RAS mice caused a significant change in tumour development compared to 
K5-RAS single transgenic mice. This is in contrast to the findings of Cui et al (1996) 
who showed that the presence of either of the Tg/pl transgenes could reduce papilloma 
formation and also increase malignant progression during chemical carcinogenesis.
The lack of inhibition of tumour development might be explained by the cellular 
compartments in which transgenic Tgfpi acts. K10-7g/pl and K6-Tg/pl transgenic 
mice express exogenous 2g/pl in suprabasal layers of the epidermis. It is not known 
though if the overexpressed Tgfpl acts in a paracrine or autocrine manner. Papillomas 
arising through chemical carcinogenesis originate from thickened skin with a large 
population of suprabasal-like, KlO-expressing kératinocytes. Expression of transgenic 
Tgfpi in these cells inhibits the outgrowth of these papillomas and this might be due to 
quite a localised autocrine effect of the exogenous protein.
In contrast, tumours arising in K5-RAS transgenic mice are follicular in origin. Cells 
expressing the K5-BA5 transgene are restricted to the outer root sheath of the hair 
follicle where there is no KIO expression and to small patches of interfollicular cells 
(Brown et al, 1998). Therefore, the initial clonal expansion preceding tumour 
outgrowth is from a cell or cells that are not in immediate contact with cells expressing 
transgenic Tgfpl. And so, the growth inhibitory effects of the exogenous Tgfpi are not 
encountered by the developing keratoacanthomas. The differences between autocrine.
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paracrine and juxtacrine effects of Tgfp have been demonstrated before in other 
systems. Glick et al (1994) used a skin grafting model to show that autocrine Tgfpl 
could inhibit malignant progression of tumours derived from initiated kératinocytes and 
that autocrine and paracrine Tgfpi could have opposite effects on the labelling index of 
the tumours.
The relationship between TGpp and RAS is still being elucidated but there is some 
evidence that RAS may play a role in TGFP signalling events. It has been shown that 
RAS transformation of intestinal and other epithelial cell lines inhibits the 
antiproliferative effects of TGFP (Filmus et al, 1993; Schwarz et al, 1988; Valverius et 
al, 1989; Houck et al, 1989). Mink lung epithelial cells are normally growth arrested by 
TGFpl. When transfected or microinjected with Ha-RAS however, they acquire a 
complete resistance to growth inhibition by TGFpl (Longstreet et al, 1992; Howe et al, 
1993). Furthermore, in these cells, TGFpl has been shown to decrease the levels of 
active GTP-bound RAS, suggesting that TGFp controls proliferation by modulating the 
activity of RAS (Howe et al, 1993).
Further evidence of the role of RAS in TGFp growth-inhibition came from Yan et al 
(1994). In two sublines of the same colon carcinoma cell line, which respond in 
opposite ways to TGpp (proliferation or growth inhibition), RAS has been shown to 
play role in the response leading to growth inhibition. In U9 cells where TGFpl acts as 
a mitogen, the activity of the myelin basic proteins was increased without any 
detectable activation of RAS. On the other hand, when TGppi inhibited the growth of 
HD3 cells, RAS was activated.
Elucidation of the downstream signalling pathway of TGpp has revealed more about 
the interactions of RAS with this pathway. As discussed in Introduction, TGpp 
signalling causes phosphorylation of SMAD2 and/or SMAD3. These SMADs associate 
with SMAD4, move into the nucleus and assemble transcriptional complexes. 
Kretzschmar et al (1999) have shown that oncogenically activated RAS inhibits TGFp- 
induced nuclear accumulation of SMAD2 and SMAD3 and SMAD-dependent 
transcription in mammary and lung epithelial cells. This inhibitory effect is strong 
enough to significantly limit the activity of the TGpp/SMAD pathway.
Hartsough et al (1996) showed that RAS activation was necessary and sufficient for 
TGFp-mediated ERKl activation in intestinal epithelial cells. The same group later 
showed that inactivation of RAS, either by expression of a dominant-negative mutant or 
addition of a MAP and ERK kinase inhibitor decreased the ability of TGFp to induce
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phoshorylation of SMADl in the same cells. Recently, Calonge & Massague (1999) 
were able to restore TGFP-responsiveness to a colon cancer cell line by co-transfection 
of SMAD4 and a RAS phosphorylation-resistant SMADS. The result suggested that loss 
of SMAD4 function and inhibition of SMAD2/3 function by a hyperactive RAS 
pathway jointly prevent TGFp antiproliferative responses in this cell line.
TGFpl and RAS have also been shown to collaborate in bringing about changes in 
the invasive properties of epithelial cells. When grown in collagen gels, both normal 
and BA5-transformed mammary epithelial cells maintain their epithelial characteristics. 
However, when treated with TGppi, the normal cells undergo growth arrest while RAS- 
transformed cells become fibroblastoid, invasive and resistant to growth inhibition by 
TGFP {Oft etal, 1996).
In the current study, any effect on malignant progression of the tumours arising in K5- 
RAS mice was difficult to assess as there were very few carcinomas observed. This was 
probably because many of the K5-RAS transgenic mice bearing tumours had to be 
sacrificed after a certain period of tumour progression due to the size of the tumour. 
Some of these mice may have gone on to develop carcinomas. A much larger number of 
mice under study would be needed to assess whether Tgfpl could influence malignant 
progression in the same way as it did during chemical carcinogenesis.
4.9 Summary and future directions
A major factor in the generation of results throughout this project has been the 
breeding strategies employed to cross various transgenic and/or knockout mouse 
models. In general, as a rule, all crosses were performed so that comparisons could be 
made directly between either littermates or half-littermates (mice sharing one parent) to 
try to minimise any variation due to differences in genetic background of the mice. The 
workload could have been reduced by not having this as a requirement. For example, in 
the analysis of the KlO-Tgfpi transgene on various p53 knockout backgrounds, the 
parents were heterozygous for both the KlO-Tgfpi transgene and the p53 knockout 
allele. This meant that mice carrying both homozygous transgene and knockout alleles 
were represented by one-sixteenth of the offspring. To produce sufficient numbers of 
mice carrying the various relevant combinations of transgene and knockout allele
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genotypes, many mice had to be generated and genotyped which were not actually used 
in the final analysis of proliferation rates in the epidermis. Two separate crosses, with 
both parents either homozygous for the KlO-Tgfpl allele or both parents wild-type at 
this locus would have reduced the numbers of mice used and subsequently the 
workload.
There is still much to be learned about how homeostatic mechanisms work in the 
skin in order to preserve the balance between proliferation, cell death and 
differentiation. It is clear that Tgfp does play some role in skin epidermis and mice such 
as KlO-Tg/pl transgenic mice will be extremely useful in defining that role. Perhaps 
Tgfpi is solely a differentiation-inducing factor in the epidermis. Examination of the 
expression of differentiation-specific markers such as K6 and loricrin in the epidermis 
of these mice may help answer that question. On the other hand, Kl-Tg/pl transgenic 
mice have the opposite phenotype (lack of proliferation) and why two seemingly similar 
transgenic lines can have such different phenotypes is interesting in itself.
The generation of KlO-Tg/pl transgenic kératinocytes in vitro may make them more 
amenable to experiments such as examination of their response to treatment with 
exogenous growth factors or chemicals, however even the action of culturing 
kératinocytes can switch on genes such as K6 which are normally off in vivo. Therefore, 
a better approach may be to carry out other in vivo crosses with mice such as the myc 
transgenic mice described by Pelengaris et al (1999) where inducible expression of c- 
myc in the suprabasal epidermis triggers proliferation and disrupts differentiation.
Similarly, crosses with the KlO-BCL-2 transgenic mice described here would be 
very useful tools in analysing why transgenic 7g/pl or c-myc expression in the 
epidermis perturbs proliferation or differentiation. Initial crosses were carried out 
between KlO-Tg/pl mice and KlO-BCL-2 mice during this study but unfortunately 
there was not enough time to complete them satisfactorily. In hindsight, it may have 
been advantageous to immediately set up a long-term chemical carcinogenesis 
experiment when mice were initially received to determine whether exogenous BCL-2 
affects tumour formation or malignancy. Other obvious experiments to carry out on the 
KlO-BCL-2 mice would be an analysis of the cell death response following UV 
irradiation both in vivo and on kératinocytes in vitro. It has been shown more recently 
that phenotypes of similar transgenic mice might be easier to establish in primary 
kératinocytes from such animals, especially following a UV insult. However, caution 
must be observed about the relevance of in vitro studies before applying them back to 
an in vivo model.
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The reason why overexpression of Tgfpl leads to an increase in proliferation in 
K10-7g/pl epidermis has still not been determined. Newer technologies may help 
unravel the mechanism of action of the overexpressed growth factor. For example, a 
comparison of RNA expression profiles of wild-type and transgenic epidermal RNA 
using cDNA arrays might give some clue as to which other genes are induced or down- 
regulated by expression of the recombinant Tgfpi. This may lead to some idea as to 
which, if any, pathway is triggered in the transgenic mice.
The actions of Tgfp and related molecules during multistage carcinogenesis are 
obviously very important both scientifically and clinically. The precise mechanisms as 
to how Tgfp can act as a suppressor of tumorigenesis at some stages of multistage 
carcinogenesis and in some tissue types, and yet can promote malignant progression at 
other stages, must be determined. This is especially relevant in terms of the therapeutic 
consequences of using TGFp antibodies, the cytokine itself, or drugs targeted to block 
or enhance its activity or activity of a TGFP pathway.
The difference of action of transgenic TgfP on two similar mouse cancer models 
(chemical carcinogenesis and K5-RAS transgenic) illustrates how differences such as 
the particular cell compartment from which a tumour develops can determine the 
progression of tumours arising in the same tissue. This study has also emphasised the 
pitfalls of transgenic breeding experiments for example when a transgene is not fully 
penetrant, or a change in genetic background affects the penetrance. However, crossing 
the K10-7g/pl mice with other transgenic models of skin tumorigenesis such as KIO- 
RAS mice would help clarify exactly how TGFpi acts when suppressing tumour 
formation for example, whether the effect is due to a paracrine or autocrine action.
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